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CHAPTER 1 
INTRODUCTION 
1.1 G-Protein Coupled Receptors 
Receptors linked to second messenger generation through guanine-nucleotide- 
binding regulatory proteins (G-proteins) have become the most important receptor 
system studied. Despite incredible diversity of the ligands which bind to these receptors 
and the equally diverse nature of the cellular effects that these ligands elicit there is a 
surprisingly high degree of sequence homology in the receptors themselves, especially 





Figure 1.1. Schematic representation of a signal transduction pathway. The location of the components 
involved in signal transduction mediated by G-protein coupled receptors is indicated relative to the 
membrane bilayer [from ref. 21. 
The schematic representation of a signal transduction pathway is shown in Fig. 
1.1. The first step in the signalling pathway of the interaction of an extracellular 
message with a receptor, which spans the membrane, leads to the formation of a high- 
affinity complex between the ligand-bound receptor and one of a family of related G- 
proteins. The formation of this ternary hormone-receptor-G-protein complex results in 
the exchange of GDP from the guanine nucleotide binding site of the G-protein, by 
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GTP. The GTP-bound form of the G-protein is the activated form, which dissociates 
from the receptor and interacts with specific effector enzymes, modulating the levels of 
intracellular second messengers. At least 50 different G-protein-coupled receptor sys- 
tems have been identified so far. The signal transduction pathway involving G-protein- 
coupled receptors represents one of the major mechanisms of transmembrane signalling 
[for reviews, see ref. 1,2]. 
1.1.1 Structure of GProtein Coupled Receptors. 
The recent cloning of the genes encoding many of these receptors, G-proteins, 
and the effector enzymes has revealed structural similarities within each of these classes 
of proteins, presumably reflecting common elements in their mechanism of action [3]. 
All of the G-protein coupled receptors, the primary sequences of which hzve been 
determined are characterised by the appearance of 7 regions of 20-25 hydro-phobic 
amino acid residues, which, based on the structure of bacteriorhodopsin, are predicted 
to form transmembranal (TM) a-helices, separated by 8, more divergent, hydrophilic 
regions, envisaged to form alternating extracellular and intracellular loops. 
Figure 1.2. Proposed transmembranal topology of the human Dl receptor [adopted from ref. 16,231 
The greatest degree of amino acid similarity among the receptors is in the trans- 
membrane helices. The sequence homology varies from 20 to 90% with the greatest 
conservation observed between the different subtypes of a particular receptor class 
[4,5,6,7]. In contrast, very little homology is found in the loops, connecting the 
transmembrane helices. A model of for the transmembrane orientation of the Dl recep- 
-- 
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tor is shown in Fig. 1.2. 
Several other interesting structural features are conserved among the receptor 
proteins. All of the proteins contain between one and four sites, capable of N-linked 
sugar addition. Only the sites present at the N-terminal are glycosylated in bacteriorho- 
dopsin and the O-adrenoceptor (BAR). All of the receptors contain proline residues at 
conserved positions within the transmembrane regions. These residues have been 
postulated to be involved in distorting the helical structure to allow the binding of 
ligands [8,9]. A number of charged residues, which are conserved among the various 
proteins and may be involved in the binding of ligands to the receptor, are present 
within the hydrophobic regions [lo, 1 11. 
Figure 1.3. Schematic diagram of Gs and Gi coupled receptor structures 
The major structural differences between the receptors are the different sizes of 
the third intracellular loop and the C-terminal domain p i g  1.3). The sizes of these 
regions seem to be similar for those receptors which interact with the same G-protein 
and different for those interacting with other G-proteins. The receptors that couple to 
Gs (stirnulatory G-protein) have a relatively small third intracellular loop and a long C- 
terminal domain. Those that couple to Gi (inhibitory G-protein) have large third 
intracellular loops and short C-terminal domains. These observations suggest that these 
internal regions may determine the specificity of the receptor1G-protein interaction. 
1.1.2. Structure-Function Relationships of GProtein Coupled Receptors. 
A combination of biochemical and genetic analysis has suggested the identifica- 
tion of the ligand binding site, the sites of G-protein interaction, and the regulatory sites 
on several of the G-protein linked receptors. The l3-adrenoceptor (BAR) is one of the 
best studied receptors of this class. A systematic replacement of charged residues within 
the transmembranal helices revealed that aspartic acid 113 in the third helix was 
critically important for ligand binding, whereas aspartic acid 79 in the second helix was 
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important only for the binding of agonists [l 11. Replacement of residues in the seventh 
helix also affected agonist and antagonist binding. No single amino acid substitution 
outside the transmembrane helices have been found which effect the ligand binding 
ability of the BAR. These data, support a model were the transmembranal helices not 
only provide a structural framework for the receptor, but are, in fact, the ligand binding 
domain of the receptor. As the transmembranal helices are also the portions of the 
receptors where the highest degree of sequence homolgy is observed, it is proposed that 
this model will hold true for all the receptors in this class. Not surprisingly, the highest 
similarity scores were found within receptor subtypes, with the exception of the 5- 
H T ~ A  serotonin receptor. This receptor has greater identity with the dopaminergic and 
adrenergic receptors than with the other 5-HT subtypes. Ligand selectivity would then 
be determined by the limited sequence divergence among the receptors and by 
conformational differences found within the transmembrane regions. 
Figure 1.4. Schematic representation of the interaction of several recognition sites of the D2 receptor 
with the neurotransmitter dopamine [adopted from ref. 141. 
The substitution of aspartic acid residue (1 13) of the BAR with a variety of other 
residues dramatically alters the affinity for the BAR for both agonists and antagonists. 
Therefore it was proposed that the carboxylate group of the aspartic acid side chain 
interacts directly with the protonated amine group of the ligand [12]. Several groups 
have proposed a three-dimensional model for the ligand binding domain of G-binding- 
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protein. coupled receptors [12,13,14,15]. The model of Hibert and co-workers is 
detailed and very illustrative. A schematic representation of the D2 dopamine receptor 
is shown in figure 1.4. The proposed ionic interaction between the carboxylate group of 
the aspartic acid side chain of transmembrane region 3 (TM 3) with the protonated 
amine group of dopamine is indicated. The ligand is proposed to lie within a bundle of 
the seven helices in the plane of the membrane, interacting directly with residues in 
several of the helices. All those receptors the genes of which have been cloned, and 
which bind cationic amine ligands, contain this aspartic acid residue. In the model, three 
highly conserved aromatic residues form a hydrophobic cluster around the aspartate- 
ammonium ion pair, and thus strongly stabilize the complex. The two serine residues in 
TM 5 are only found within catecholamine receptors and probably play a role in the 
binding of the catechol moiety. The residues defining the hydrophobic area interacting 
with the nonbasic part are also highly conserved and consist for the D2 receptor of 
phenylalanine (TMg and TMg). 
This use of molecular modeling techniques to describe the receptor-ligand 
complex could prove usel l  for the rational design of new receptor ligands. 
1.2 Dopamine Receptors 
Dopamine is a predominant catecholamine neurotransmitter in the mammalian 
brain and it is involved in the regulation of a number of physiological activities, these 
being predominantly movement, emotional stability and prolactin secretion. These acti- 
vities are associated with three principal dopaminergic pathways: (1) The nigrostriatal 
pathway controls movements; partial degeneration of this system contributes to the 
pathogenesis of Parkinson's disease. (2) The mesocorticolimbic pathway is involved in 
emotional stability; imbalance in this pathway is thought to contribute to the aetiology 
of schizophrenia. (3) The tuberoinfundibular pathway regulates prolactin secretion from 
the pituitary and influences lactation and fertility [16]. 
1.2.1 Biosynthesis and Catabolism of Dopamine 
Dopamine is formed from L-tyrosine. The rate-limiting step in the biosynthesis 
of DA is the conversion of tyrosine to 3,4-dihydroxyphenylalanine (DOPA) by the 
enzyme tyrosine hydroxylase (TH). The final step is the decarboxylation by the enzyme 
called aromatic L-amino acid decarboxylase. The newly synthesized DA is then taken 
up into the vesicles located in the nerve endings, where it is stored in a complex with 
chromogranins, divalent ions, i.e. magnesium and calcium, and ATP. The release of DA 
from the nerve endings occurs via exocytosis and is calcium dependent. 
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The main pathways involved in its metabolism are shown in Scheme 1.1. The 
two enzymes monoamine oxidase (MAO) and cathechol 0-methyltransferase (COMT) 
convert DA to the compounds 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic 
acid (HVA) and 3-methoxytyramine (3-MT), which are the main products of DA 
metabolism in the brain [17]. MA0 is associated with the outer layer of mitochondria 
and occurs in two forms (A and B), which have different substrate specificities. Many 
psychotic drugs have been shown to affect the accumulation of DOPAC, HVA and 3- 
MT in brain tissue. DA agonists decrease DOPAC and HVA levels, whilst in general, 
DA levels are not significantly affected. DA antagonists, the neuroleptics, produce the 




M A 0  1 ADH 
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Scheme 1.1. The metabolism of dopamine by COMT (catecho1 0-methyltransferase); MA0 (monoamine 
oxidase) and ADH (aldehyde dehydrogenase) 
1.2.2 The Classification of Dopamine Receptors: State of the Art 
Around 1980, only two different doparnine receptor subtypes were defmitively 
known to exist: the Dl receptor, linked to the stimulation of adenylyl cyclase, and the 
D2 receptor, which either inhibited adenylyl cyclase or was unlinked to this enzyme 
[IS]. D2 receptors have now been suggested to be linked to additional second 
messenger systems, including inhibition of phosphatidylinositol (PI) turnover, activation 
of K+ channels and inhibition of ~ a 2 +  channel activity [19]. 
Recent investigations within a variety of disciplines have demonstrated, however, that 
the Dill32 classification scheme is no longer adequate to account for all experimental 
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findings regarding the actions of dopamine. Five pharmacologically distinct receptors 
have now been defined through molecular cloning techniques, and identification of 
additional family members is a likely event. 
D2 receptor. The rat D2 receptor gene cloned by Bunzow and co-workers (Fig. 
1.5) [20] was actually the first dopamine receptor subtype to be isolated and sequenced. 
The D2 receptor has subsequently been determined to exist as two protein isoforms that 
differ in length by 29 amino acids, 415 and 444 respectively, and are derived from the 
same gene by alternative RNA splicing. Hydropathy analysis of this protein predicts the 
presence of seven transmembranal domains. However, biochemical evidence supporting 
this model has been generated for only two members of this family, namely 
bacteriorhodopsin and the B2-adrenoceptor. The location of the splice variation occurs 
in the third cytoplasmic loop, a region of the receptor believed to be involved in G- 
protein coupling. Although this might suggest that the two isoforms differ functionally 
in some fashion, no pharmacological differences have been observed between them. 
Both isoforms have been shown to inhibit adenylyl cyclase, to activate K+ channels, to 
potentiate arachidonic acid release, and undergo agonist-induced desensitisation with 
Figure 1.5. Topology of the dopamine D2 receptor [adopted from 16,201 
Dl-receptor. The human and rat Dl receptor gene (Fig 1.2) has recently been 
cloned [22,23]. This receptor is 446 amino acids in length and has seven putative mem- 
brane spanning domains typical of the G-protein-linked receptor family. It also exhibits 
the expected pharmacological and functional characteristics. In contrast to the D2- 
receptor subfamily the Dl-receptor has a small third cytoplasmic loop and a long C- 
terminus. This seems to be a characteristic of receptors that are coupled to Gs and 
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activate adenylyl cyclase. The areas of highest expression are the caudate-putamen, 
nucleus accumbens and olfactory tubercle. 
D3-receptor. Sokoloff et al. have isolated a new receptor, named D3, from rat 
cDNA and genomic libraries [7]. The Dg receptor structure is 52% homologous with 
the D2 receptor and this homology increases to about 75% if only the transmembrane 
regions are considered (Table 1.1). It contains a large third cytoplasmic loop of similar 
size as the long form of the D2 receptor and a short C-terminal. This is similar to the 5- 
H T ~ A  and a2-adrenoceptors which, like the D2 receptor, are linked to adenylyl cyclase 
inhibition. Altogether, the structure of the Dg receptor suggested a close relationship 
with the D2 receptor which, has been confirmed by pharmacological analysis. It binds 
D2 and not Dl or other cathecholamine-ligands although its amity to most 
neuroleptics was 10-100 fold less than that of the D2 receptor. On the other hand, the 
D3 receptor was found to bind two atypical antagonists, (+)-AJ 76 and (+)-UH 232 with 
3 to 5 times higher amity than the D2 receptor. These antagonists are thought to have 
a preferential antagonism for the presynaptic dopamine receptors. Regional distribution 
of D3 receptor mRNA has indicated that it is less abundant and more narrowly distribu- 
ted than that of the D2 receptor [7]. Dg receptor mRNA is predominantly located in the 
ventral striatum, nucleus accumbens and other 'limbic' areas. This has led to the 
hypothesis of an important association of the Dg receptor with cognitive and emotional 
CNS functions and thus may be relevant to anti-psychotic therapy involving dopamine 
antagonists. Because the D3 receptor also appears to be expressed in the substantia 
nigra, indicating that it may serve an autoreceptor function, presynaptic agonists 
likewise can be interesting for such a therapy. 
Dq receptors. Van To1 et al. [24] have found another D2 related dopamine 
receptor, named the Dq receptor. The Dq receptor amino acid sequence appears to 
comprise a protein of 387 residues in length with seven putative membrane spanning 
domains. In its transmembrane domains, the homology between the Dq receptor with 
the D2 and the Dg receptor is about 56% in both cases (Table 1.1) and contains residues 
necessary for catecholamine recognition. Most of the agonists and antagonists tested 
displayed amities for the Dq receptor which were similar or lower than those for the 
D2 receptor. However, the Dq receptor binds the atypical antipsychotic, clozapine, with 
an Smity 10-fold higher than the D2 or D3 receptors. Clozapine is a particularly 
interesting antipsychotic agent, the action of which is not associated with the 
extrapyrimidal side effects which are present in all other neuroleptics. A preliminary 
analysis of the Dq receptor tissue location indicated that this receptor is expressed in the 
mesocorticolimbic system rather than in the nigrostriatal system. This distribution 
system may partly explain the lack of extrapyrimidal side effects observed with 
clozapine treatment. 
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Dg receptor. Sunahara et al.[25] have recently cloned a second member of the 
Dl receptor subfamily termed the Dg receptor, a protein of 477 residues in length. 
Hydrophobicity analysis again suggests the presence of seven transmembrane regions. 
The homology within the transmembranal spanning regions between the Dl and Dg 
receptors is about 80% (Table 1.1). The Dg receptor is linked to stimulation of adenylyl 
cyclase. Dopamine is tenfold more potent at Dg than at Dl receptors. This has led to 
the hypothesis that the D5 receptor may be important in maintaining dopaminergic tone 
and arousal. The highest expression of the Dg receptor is seen in the hippocampus and 
hypothalamus, with lower amounts in the striaturn and frontal cortex. The level of 
expression is, however, much lower than that for the Dl receptor. 
Table 1.1 Properties of cloned dopamine receptors. 
receptors Dl D2 D3 Dq Dg 
Alternative nomenclature D1A D2As D ~ B  D ~ c  D ~ B  
receptors D 2 ~ 1  
No. of amino acids 446 415- 446 387 477 
444 
Sequence identity (%) Dl 100 44 41 41 80 
in transmembrane domains "2 100 75 52 36 
D3 100 51 35 
"4 100 33 
"5 100 
Sibley and Monsma [26] have proposed a similar hierarchical system of 
nomenclature for the dopamine receptors as applied presently for the adrenoceptor 
family. The basis for this nomenclature would be the well defined Dl and D2 receptor 
subtypes. Additional receptor subtypes that have been identified and cloned should be 
compared both structurally and pharmacologically with Dl and D2 receptors. If the 
pharmacology is similar and the transmembrane sequence homology is greater than 
50% compared to a previously cloned subtype, then it should be designated as a 
member of that subfamily using an A,B,C nomenclature. Using this method the 
receptors would be designated as shown in Table 1.1. 
The complexity of the dopamine receptor family is not surprising in view of that 
observed for other receptor families that are part of the G-protein-receptor supergene 
family. There is already evidence for additional 'Dl- and D~l ike '  receptors. How many 
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dopamine receptors will be found is unknown. What is important is to note that, as 
presently understood, there are two widespread and qualitatively predominant doparnine 
receptors, the classical Dl  and D2 receptors. The others are present in significantly 
lower amounts in restricted localizations. 
Many drugs used in the treatment of psychiatric, neurologic and endocrinic 
disorders gave side effects, which may be due to multiple receptor interaction. 
Hopefully, the recent cloning of the individual receptor subtypes will assist in the 
developing of subtype-selective agonists and antagonists, likely with fewer side-effects. 
The dopamine autoreceptor concept. Carlsson introduced a theory [27] that the 
responsiveness of pre- and postsynaptic D2 receptors to agonists, although they both 
belong to the same receptor population, depends on previous agonist (dopamine) 
occupation of the receptor. According to this theory, under physiological conditions in 
vivo the endogenous dopaminergic tone at postsynaptic D2 receptors is much higher 
than at dopamine autoreceptors. This is assumed to be caused by the localization of 
post-synaptic receptors inside the synaptic cleft, whereas doparnine autoreceptors are 
largely or entirely located outside the synaptic cleft. Pharmacological studies with 
selective DA Dl  and D2 receptor agonists by Wolf and Roth [28] indicate that the DA 
autoreceptor is of the D2 type. 
A related theory has been presented by Meller and co-workers [29,30]. This 
theory focuses on the receptor effector coupling efficiency, i.e. the difference in 
receptor reserve at pre- and postsynaptic receptors, to clarify the enhanced in vivo 
potency of D2 agonists at DA autoreceptors. Autoreceptors involved in the control of 
dopamine synthesis and release display a large receptor reserve implicating a very 
efficient coupling between receptor and effector mechanisms in terms of receptor 
occupancy. In contrast, postsynaptic receptors that mediate an increase of nigrostriatal 
acetylcholine content show no receptor reserve. 
Highly selective agonists of the autoreceptor type are of considerable interest 
since they should be able to reduce dopaminergic transmission in the central nervous 
system by inhibiting DA release via activation of terminal andlor somatodendritic D2 
receptors. According to the 'dopamine hypothesis' of schizophrenia, which postulates 
that abnormally high dopaminergic transmission is involved in major aspects of the 
disease, lack of postsynaptic stirnulatory effects is therefore critical for the realisation of 
this novel therapeutic concept [3 11. 
1.3 Serotonin Receptors 
The existence of a pressor substance in the circulation was supposed fiom the 
beginning of the century. This pressor factor, named serotonin, was purified fiom serum 
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in 1948 [32]. The structure was later found to be 5-hydroxy&yptamine (5-HT). The 
identification of this amine in the central nervous system in 1953 by Twarog and Page 
[33] triggered an intensive research on the influence of 5-HT on different regions of the 
nervous system and Marrazi and Hart [34] and Brodie [35] suggested its role as a cen- 
trally active neurotransmitter. The physiological role of the central 5-HT neurons is still 
far fiom clear. Different testing models often give contradictory results. Nevertheless, 
5-HT is thought to play an important role in various functions, such as motor activity, 
feeding, stress, nociception, regulation of sleep and body temperature, aggressive 









4 ~-hydroxVbVPtOPhd H I 5-hydroxy-lndole acetic acid 
Scheme 1.2. Biosynthesis and catabolism of serotonin, TH (tryptophan-5-hydroxylase), AAC (aromatic- 
L-amino acid decarboxylase), MA0 (monoatnine oxidase), ADH (aldehyde dehydrogenase), AR 
(aldehyde reductase). 
- - - 
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1.3.1 Biosynthesis and Catabolism of Serotonin 
The biosynthesis and metabolic pathways of 5-HT are outlined in Scheme 1.2. 
The essential amino acid L-tryptophan is the starting material for the biosynthesis of 5- 
HT. Inside the neuron it is converted to L-5-hydroxytryptophan (5-HTP), which is 
enzymatically decarboxylated to 5-HT. The formation of 5-HTP is the rate-limiting step 
in this sequence. Inactivation is achieved by removal of 5-HT from the cleft by a 
membrane uptake carrier present on the 5-HT nerve terminals. Once back within the 
neuron, 5-HT is degraded by different metabolic pathways. Oxidation by MAO-A 
constitutes the major route of elimination. The 5-hydroxy-1H-indole-3-acetaldehyde 
formed is rapidly oxidized to 5-hydroxy-lH-indole-3-acetic acid (5-HIAA) by a 
reaction catalyzed by the enzyme aldehyde dehydrogenase. 
1.3.2 Classification of 5-HT Receptors 
Extensive pharmacological studies have led to the discovery of multiple types of 
receptors for this transmitter, thus providing a molecular basis for the diversity of its 
actions. The 'D' and 'M' nomenclature, adopted by Gaddum and Picarelli [39], is still 
relevant but does not take into account the results of radioligand binding studies, which 
have indicated the existence of other 5-HT receptors. Bradley et al. [40] have thus 
propdsed to use the classification into 5-HT1-like, 5-HT2 and 5-HT3 main classes. The 
5-HT sites can be further subdivided in at least distinct subsets that differ in their 
regional distribution and function. They are at present termed ~ - H T ~ A ,  ~ - H T ~ B ,  5- 
HTlc  and ~ - H T ~ D  sites [41]. Among the 5-HT receptors subtypes cloned today (5- 
HTIA, 5-HTlc, ~ - H T ~ D  and 5-HT2), we find very close sequence homology between 
the ~ H T ~ c ,  ~ - H T ~ D  and 5-HT2 receptors; the ~ - H T ~ A  is a more distant cousin of 
these two subtypes. 
Table 1.2 Cloned serotonin receptors 
Sequence identity ~ - H T ~ A  100 40 5 5 4 1 
in transmembrane 5-HT1 c 100 33 78 
domains (%) ~ - H T ~ D  100 3 1 
5-HT2 100 
All four cloned receptors are members of the seven transmembrane domain 
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family whose responses are mediated via G-proteins. The ~ - H T ~ A  receptor is a single 
subunit protein containing approximately 450 amino acids probably arranged as seven 
interconnected helical transmembranal segments [42]. The ~ - H T ~ A  receptor appears to 
be negatively coupled to adenylyl cyclase in certain brain regions, although some 
laboratories have reported positive coupling. Hartig [43] deduced, by comparison of 
amino acid sequence data of related proteins, that aspartic acid residues in transmem- 
brane segments 2 and 3, and an asparagine residue in segment 7, may be of importance 
for ligand binding. The model proposed by Hibert et al. [14] for the D2 receptor (Fig 
1.4) is also useful for the ~ - H T ~ A  receptor (Fig 1.6). However, only one threonine 
residue is found in TM region 3, supporting the concept that only two serine or 
threonine residues are necessary when the ligand caries a catechol moiety. 
Figure 1.6. Schematic representation of the interaction of the neurotransmitter serotonin and recognition 
sites of the proposed 5-1-1~ receptor (adopted from Hibert [14]). 
The 5-HT receptors in the hippocampus and also other parts of the limbic system are 
primarily of the ~ - H T ~ A  type. It is therefore tempting to speculate that drugs that 
display a high degree of selectivity for these receptor sites may selectively affect 
anxiety states [43]. A breakthrough in that direction was the finding that buspirone, a 
drug with anxiolytic activity in humans also displays a high affinity for the ~ - H T ~ A  
binding sites. 
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In intact animals, selective ~ - H T ~ A  agonists produce h y p e r p b a  and hypother- 
mia, and stimulate sexual behaviour. Moreover, they elicit the 5-HT behavioural 
syndrome. 
1.4 Scope of the present investigation. 
This investigation is part of a research project aimed at developing compounds 
with selectivity for central dopaminergic and serotonergic receptor subtypes. 
It has become clear that those receptors that interact with G-proteins share a 
variety of structural and functional similarities. In particular, there appears to be a 
common motive for the ligand binding domains of the receptors that involve critical 
residues within the transmembranal regions. In a not too distant future it should be 
possible to identify all points of interaction between the receptor and its ligands, and to 
use this knowledge to design better ligands for that receptor. Because of these sirnilari- 
ties it is not surprising that the ligands possess structural similarities. Thls thesis will 
describe the synthesis and pharmacological evaluation of some putative dopamine D2 
receptor agonists and also indicate that small modifications within these molecules yield 
compounds that show &hities for other G-protein coupled receptors (e.g. the 5- 
HT~A). 
By use of the potent 2-di-n-propylaminotetralins as lead compounds, the effects 
of bioisosteric replacement of the C4 methylene group by an oxygen atom yielding 
chromamines has been studied. 
To circumvent difficulties involved in the preparation of the active trans isomers 
of the octahydrobenzo[fJquinolines, the isosteric ring systems containing an oxygen 
atom, i.e hexahydronaphth[l,2b][1,4]oxazines, have been prepared. The 6-oxy analo- 
gues of these compounds have also been synthesized. Due to their low dopaminergic 
activity the physico-chemical properties were monitored. With the interestingly low 
affinity and activity of these compounds, the influence of the pKa values on the 
dopaminergic activity and pre- and postsynaptic selectivity has been studied. 
In chapter 3 and 4 the combination of respectively, dopamine- and serotonine 
agonistic properties and monoamine oxidase inhibiting properties within one and the 
same molecule is treated. 
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When the structure of the molecular target is unknown, predictions of the activity 
of different molecules have to rely on indirect models. The development of such a 
model may be based on the recognition of key features common to sets of active 
molecules, the pharmacophore. The identification of a pharmacophore may provide 
insight into the mechanism of the drug-receptor interaction. 
Drug-receptor interactions can be divided into two different events. The recogni- 
tion by the receptor of the ligand, agonist or antagonist, is expressed in its affinity for 
the receptor. The binding of an agonist induces a change in the drug-receptor complex 
that eventually leads to a measurable response. The inability of antagonist to induce a 
response may be related to different receptor interactions as compared to those of the 
agonists and thus, the use of both agonists and antagonists when developing a model, 
i.e. by using only amity data, may be misleading. 
Several attempts to correlate structural features of dopaminergic and serotonergic 
agents with their activity have been made [1,2,3,4]. However, the lack of comparable 
pharmacological data and the limited access to enantiomerically pure test compounds 
have in some cases resulted in less relevent models [5,6]. 
2.2 Structure-Activity Relationships of Dopamine Agonists 
Drug design is, in spite of the recent developments in molecular biology, up to 
now an empirical exercise. The true design of new active structures is still virtually 
impossible at the present state of the art. Thus, one finds that all dopamine agonists 
which have been developed as a result of design processes originated in one of two 
ways. They represent either structural dissection effforts, or they attempt to incorporate 
the structure of dopamine into a rigid framework. 
Typical of the former approach would be the dissection of the semi-natural 
product apomorphine 1 (Scheme 2.1) to yield first, linear benzo[g]quinolines (2), and 
with further dissection 2-amino-5,6-dihydroxytetrahydronaphthalenes (3). 
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Scheme 2.1. Dissection of the semi-natural product apomorphine (1). 
Incorporation of the dopamine moiety into a rigid fiamework essentially repre- 
sents the converse process. 
Scheme 2.2. Incorporation of the doparnine moiety in a variety of ring systems. 
One of the great challenges in dopaminergic structure-activity relationship studies 
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(SAR's) is that the elements of the dopamine molecule can be incorporated within the 
matrix of a variety of ring systems, with retention of a high degree of potency and 
activity itself. Scheme 2.2 illustrates some representative ring systems that have been 
studied [1,2,3,7]. 
There have been many studies of the structure-activity relationships (SAR) of 
central and peripheral DA receptor agonists [l- 3,7,8]. 
The purpose of this section is to give a brief summary of the structure-activity 
relationships of dopaminergic Zaminotetralins and related compounds. 
In addition to the apomorphine and ergot analogues, the 2-aminotetralin derivati- 
ves have been one of the most important groups of compounds which have increased 
our understanding of the neurobiology of dopaminergic systems. Interest in the dopami- 
nergic activity of this class of compounds arose as a result of the report of Woodruff et 
al. [9] on the pharmacological profile of 6,7-ADTN (5). In the aminotetralins, the 
dopamine moiety can be incorporated in two ways, the so-called a- and B-rotameric 
form (Fig. 2.1) [2]. In the 2-aminotetralins, both the a-conformer and 8-conformer of 
the dopamine moiety retain at least a portion of the spectrum of dopaminergic agonism. 
Figure 2.1. Chemical structures of the rotamen of dopamine and its aminotetralin analogues. 
In the 2-aminotetralins, differences in metabolic pathways and in rates of 
metabolism seem at least as important as structural parameters in determining spectrum 
and sites of dopaminergic effects. One of the main problems with 5 is its very limited 
ability to pass the blood-brain barrier. Improved permeation and prolonged duration of 
action by ester formation of the catechol OH groups in aminotetralins [lo] has facilita- 
ted and controlled absorption and distribution of these dopaminergic agonists. The 
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resorcinolic 5,7-dihydroxy substitution pattern led to compounds that were, in general, 




Figure 2.2. Dibenzoyl ester of 6,7-ADTN (6). 
A catechol group is not necessary for activity. The discovery of the high potency 
of 5-hydroxy-2-dipropylaminotetralin (7) was particularly interesting. As compared to 
the catechols, this compound could be expected to have a higher chemical and 
metabolic stability and consequently a longer duration of action. Since the chemotrigger 
zone of the emetic centre is considered to be located outside of the blood brain barrier, 
there is also a possibility that a more lipophilic compound, i.e. with large N- 
substituents, could be relatively less emitic. Based on these considerations we and other 
groups have synthesized and tested a large number of N-alkyl-5-hydroxyaminotetralins 
[ll-141. 
Tertiary amines are generally more potent than the secondary amines. Potency and 
activity in phenylethylamines, certain Zaminotetralins, apomorphine, chromanamines 
and the octahydrobenzo[fjquinolines are maximal with n-propyl or di-n-propyl substitu- 
tion on the nitrogen. Higher alkyl substitution results in complete or almost complete 
loss of activity [2]. The n-propyl group seems to have a special effect at the receptor 
side, not exclusively due to its lipophilic character. The observations regarding the 
structural specificity for the N-substituents of DA-agonists seem to indicate that at least 
one of the N-substituents must fit into a cavity, which because of its size, can 
maximally accommodate an n-propyl group. Smaller groups like methyl or ethyl can 
also fit this pocket although these groups probably give less efficient binding. The se- 
cond N-substituent is allowed to vary within wide limits. The only restriction that is 
found is that this substituent should not be branched at the carbon next to the nitrogen. 
In fig 2.3 some potent agonists of the 2-aminotetralin group are shown. 
When the hydroxyl group is moved from C5 to the other positions, interesting effects 
are observed. 6-OH-DPAT (8) has lost most of its dopaminergic potency whereas 7- 
OH-DPAT (9) is a potent DA receptor ligand. 8-OH-DPAT (10) is not a DA receptor 
agonist but rather a potent and selective ~ - H T ~ A  receptor agonist (see also section 2.3). 
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Figure 2.3 . Chemical structures of some potent dopaminergic Z-aminotetralins. 5-OH-DPAT (7), 6- 
OH-DPAT (8), 7-OH-DPAT (9), 8-OH-DPAT (lo), N-0437 (ll), N-0434 (12). 
The potent selective D2 receptor agonist 2-(N-n-propyl-N-2-thienylethyl- 
amino)-5-hydroxytetralin ((*)-N-0437, 11) is of special interest, because it is the first 
example of a 2-ATN derivative, which has reached the stage of clinical evaluation for 
the treatment of Parkinson's disease. The enantiomers of this potent and D2 selective 
agonist have been extensivily tested for their pharmacological action on D2 
autoreceptors, in vivo, by measuring DA release by microdialysis during local 
administration of both drugs and in vitro, by measuring their effects on the electrically 
stimulated release of [ ~ H I D A  from striatal slices [15]. In both experiments (-)-N-0437 
acted as agonist on receptors controlling the DA release. The (+)-enantiomer of N-0437 
displayed partial agonistic activity at DA D2 receptors. (+)-N-0437 showed agonistic 
activity in a DA synthesis model (GBL-model), while in the microdialysis release 
model it showed antagonistic activity. The (+)-enantiomer also acted as a weak 
antagonist at postsynaptic receptors in the in vitro  HI-acetylcholine release model and 
in some behavioural models [16,17] . This spectrum of activity is similar to that of (-)- 
3-(3-hydroxyphenyl-N-n-propylpiperidine ((-)-3-PPP, 13), which indicates that (+)-N- 
0437 may have potential antipsychotic activity [18]. 
In a series of ring-halogenated mono and di-OH-ATN analogues, Weinstock and 
associates have found that the 8-chloro and 8-fluoro-6,7-dihydroxy aminotetralins 14 
were selective Dl agonists [19]. However, this is in contrast to findings of Murray and 
Waddington [20], who found no selectivity for a receptor subtype. Replacement of the 
6- or 7-OH group by a halogen reduced the dopaminergic activity. 
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Figure 2.4. Structures of (-)-S-3-PPP (13) and 8-halo-6,7-dihydroxyaminotetralin (14) (X = C1, F) 
Introduction of a methyl group in the 1-position has produced some interesting 
compounds [2 11. The putative DA autoreceptor antagonist cis-(1 S,2R)-5-methoxy- 1- 
methyl-2-(n-propy1amino)tetralin ((+)AJ76, 15a) and its dipropyl analogue (+)-UH 232 
(15b) have about 4 times higher a m i t y  for Dj than for D2 receptors [22]. The C1- 
methylated phenolic compounds were less active as antagonists at central DA receptors 
as compared with the non-methylated analogues. However, cis-(+)-(lS,2R)-5-OH-1- 
CH3-DPAT ((+)-UH242, 16) was the DA receptor antagonist with preferential action 
on DA autoreceptors that was first discovered [23]. 
Figure 2.5. Structures of (+)-AJ 76 (15a) (R = H), (+)-UH 232 (15b) (R = n-propyl) and (+)-UH 242 
(16). 
2.2.2 The McDermed Receptor Concept 
A key discovery was that the stereoisomers of 5-hydroxy and 7-hydroxy ATN 
derivatives, which have high affinity D2 receptor binding, and which show 
pharmacological activity in functional assays of dopaminergic activity, have the 
opposite absolute configuration. The active enantiomer of 5-hydroxy-2-(di-n-pro- 
py1)aminotetralin has the (2s) configuration. This enantiomer is more potent than its 
antipode in a number of dopaminergic test systems. In sharp contrast, 7-hydroxy-2-(di- 
n-propy1amino)tetralin and 7,8-dihydroxy-2-(di-n-propy1amino)-tetralin exhibit the 
opposite stereochemical requirement; their (2R)-(+) enantiomers are more potent then 
their optical antipodes. These stereochemical differences have been elegantly rationali- 
zed in a simple manner by McDermed et al. [24]. They suggested that the two most 
important binding sites in the DA receptor interact with the amino nitrogen and the 
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hydroxyl group meta to the ethylamine side chain (Fig 2.6). Thus, although the (2s)-(-)- 
5-OH-DPAT and (6aS)-(-)-apomorphine both bind in a similar way to the receptor, 
(2R)-(+)-7-OH-DPAT and (2R)-(+)-6,7-OH-DPAT must be rotated with respect to the 
other two compounds in order to fit this model. 
Figure 2.6. Orientation of (2.9)-5-OH-ATN (7) and (2R)-7-OH-ATN (9) towards the two proposed 
major binding sites of the D2 receptor. 
McDermed has also included a boundary in the receptor preventing the interaction with 
compounds having steric bulk in this region (Fig 2.7). 
Figure 2.7. Interaction of (2s)-SOH-ATN with conceptual receptor model of McDermed 
Thus, this model not only rationalizes the activity of many DA receptor agonists, but it 
is also of predictive value. Although it is conceivable that the exact receptor preferred 
conformation of DA might be different at Dl and D2 receptors, it is possible to reach 
some general conclusions which can be applicable for both receptors. 
This so-called "McDermed flip" has been the start of several hypothetical 
dopamine receptor models, some of whch will be discussed in this chapter. 
In an extension of this model by Wikstrijm et al. [25,26], applied to the 
dopaminergic monohydroxylated 3-phenylpiperidines 13 and the octahydro- 
benzo[fJquinolines 17 and 18, they have found that there is a relationship between the 
absolute configuration, the ring position of the hydroxyl group and the size of the N- 
alkyl substiuent. There are now two different directions possible for the N-alkyl 
Structure-Activity Relationships 23 
substituents, namely upwards- and downwards (Fig 2.8). An assumption they made is 
that, due to the different directions in which the N-substituents point, the space 
17 18 
Figure 2.8. Wikstrom's modification of McDermed's model. The structures of 7- and 9-OHB[f3Q's 
superimposed. 
available for the N-substituent of compound 18 might be more restricted than for the 
corresponding isomer 17. And indeed, they have found that the N-substituent 
downwards is sterically restricted to maximally a propyl group, whereas the upwards 
direction has less restricted demands. 
lipophilic cavity 7 
Figure 2.9 Topographical model for dopamine receptors: Grol's model [27,28]. 
Grol et a1 [27,28] have postulated two binding sites, P and M, complementary to 
the p-OH and m-OH groups of agonists; X and Y are putative electronegative sites 
complementary to different amino binding sites for a- and 13-rotameric compounds (Fig 
2.9). The two sites have been proposed to rationalize the activity of agonists in which 
the m-OH to N distance varies between 5.5 and 7.44. In their view, these two nitrogen- 
binding sites correspond with the distance (- 2.4 A) between the two oxygen atoms of 
the carboxylate anion of likely the aspartic acid (Grol, personal communication). xl is 
an interaction place for an aromatic ring and n2 is an accessory site for the 1-aryl group 
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of 3-benzazepines. This model was developed from a different approach, using 
molecular orbital calculations as the basis. 
The graphic representation of a dopamine receptor proposed by McDermed [24] and 
modified by Liljefors and Wkstr6m [25,26] (Fig 2.8), as well as similar models propo- 
sed by Grol and Rollema [27,28] (Fig 2.9), Seeman [29], Kaiser and Jain [1,30] and by 
Seiler and Markstein [3 11, have provided some insights into structural requirements for 
dopaminergic agonism, and have permitted rationalization of the activity of some 
molecules and of the inactivity of other molecules; but this work has been largely retro- 
spective. 
No extant receptor model seems to explain adequately the agonist actions of all 
categories of dopaminergic agents and to rationalize the observed inactivity of all the 
molecules for which dopaminergic agonism may have predicted. None of the proposed 
models take into consideration all the subpopulations of DA receptors currently under 
discussion in the literature. 
2.2.3 Chromanamines 
Isosteric replacement of the C4 in the aminotetralins by an oxygen atom yields 
the 3-chromanamines. 6,7-Dihydroxy-3-chromanamine (19) was found to have in vivo 
activity similar to that of the parent compound, but its in vitro activity was much less 
pronounced [32]. We and other groups have demonstrated that the 6- and 8- 
monohydroxylated chromanamines are potent agonists at the DA receptor [33-371. The 
behavioural effects on locomotion in naive and reserpine pretreated rats suggest that 
these compounds do have selectivity for autoreceptor sites [35]. 8-Hydroxy-N,N-di-n- 
propylchromanamine (21), which contains the DA pharmacophore in an a- 
conformation was more potent than the 6-OH analogue 20, which exists in the P- 
conformation. Comparing the general structure of an aminotetralin and an 
aminochroman in their preferred conformations according to MMP2 calculations, the 
compounds appear very similar in size and shape [37] and the Merence between the 
two structures, when tested in biological assays, should therefore be related to 
electronic factors. An additional oxygen will have an electronically donating effect and, 
therefore an enhanched electron density over the aromatic ring. And indeed, Thorberg 
[37] and we (Chapter 6) have shown that the phenolic group is less acidic (- 1 pKa 
unit), as compared to that of the aminotetralins. It also displays a weakened electron 
density over the aliphatic nitrogen. Maybe these differences are the reasons for the 
better CNS penetration. The 5-hydroxy isomer 22 showed, by analogy to the 2- 
aminotetralins, ~ H T ~ A  activity. 
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Fig 2.10. Structures of 6,7-dihydroxy-3-chroma~mine (19); 6-OH (20) , 8-OH (21) and 5-OH-3-(di-n- 
propy1amino)-2H- 1 -benmpymns (22). 
This group of DA-agonists can be looked upon as aminotetralin analogues with 
one propyl group fixed on the non-aromatic ring of the tetralin. The trans-fused 
monophenolic 7- and 9-OH-octahydrobenzo[flquinolines (OHB[fJQs) have been found 
to possess potent dopaminergic activity. The nitrogen must be properly substituted. For 
trans-9-OH in the 'downwards' direction the substituent must be 5 n-propyl and any size 
in 'upwards' direction for trans-7-OH-OHB[flQ (see also section 2.2.2) [25]. By 
analogy to the 2-aminotetralins, the 10-OH showed ~ - H T ~ A  receptor activity (Fig 
2.11). 
Figure 2.11. Structures of OHB[fJQ's (17 and 18), naphthoxazines (23), bemopyranopyridines (24) and 
the benzopyranoxaZmes (25). 
2.2.5 Hexahydronaphthoxazines 
Due to difficulties involved in the preparation of the active trans-isomers of these 
compounds, the isosteric ring system containing an oxygen, the trans-hexahydro-4H- 
[1,2b][l,4]oxazines (23) have been prepared (see Chapter 5). The 9-hydroxy trans-N- 
propyl analogue (23) (N-0500) was found to be a very potent and selective D2 agonist 
[38,39]. The (+)-enantiomer (PHNO) has been found to be active in cases of 
Parkinson's disease [40]. The absolute configuration of the (+)-enantiomer has been 
shown to be R for C4a, thus, the absolute configuration of (+)-PHNO and (+)-7-OH- 
DPAT are comparable. 
-- 
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2.2.6 Tetrahydrobenzopyranoxazines and Hexahydrobenzopyranop3;ridines 
Replacement of a methylene group in the naphthoxazines by oxygen produced 
compound 25, which was much less active in both in vitro and in vivo tests of DA 
receptor activation (see Chapter 6). This low activity, compared with hexahydro- 
naphthoxazines (23), may result from inadequate protonation of the compound at 
physiological pH due to its low pKa value. Previous work, employing both dopamine 
agonists and antagonists, suggests that it is the charged species of the dopaminergic 
ligand which actually binds to the DA D2 receptor [41]. CGS 15855A (24) (R = n- 
propyl) a rigid trans-hexahydrobenzopyranopyridin-9-01 was reported as an auto-recep- 
tor agonist which produces a dose dependent decrease in 3-methoxytyramine levels in 
both mouse and the rat. Weak behavioural stereotypies have been observed with 25 only 
at doses 20 times the ED50 for activity in the GBL model. The behavioural effects 
appear to be confined to the (+)-enantiomer [42,43,44]. 
2.2.7 The Significance of the Charge on the Nitrogen Atom of Dopamine 
Agonists. 
Although catecholamines can exist in a variety of forms at physiological pH, a 
basic question arises as to which of these species islare involved in the binding and 
activation of dopamine receptors. 
Figure 2.12 Possible charged and uncharged species of dopamine that could interact with dopamine 
receptors. 
Some reports indicate that an uncharged nitrogen atom is required for the 
activation of the DA receptor [45,46], whereas others have reported that the charged 
form of the nitrogen atom is a prerequisite for activity [41,47]. Nichols [48] has 
suggested that the real importance of this atom lies in the orientation of its unshared 
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electron pair, whether free or protonated. However, the introduction of a second oxygen 
atom at the 6-position in the hexahydronaphthoxazines led to compounds which are 
only protonated to an extent of 2% under physiological conditions (pH - 7.4), and 
which are very weak DA agonists. This decrease in activity has led to the hypothesis 
that DA agonists probably bind to their receptors through the charged rather than the 
non-protonated nitrogen atom (chapter 6). Further evidence for this assumption is 
afforded by Miller and Uretsky [49,50,51], who have synthesized analogues of 
dopamine and ADTN in which the amine group was replaced with either a neutral 
methylsulfide, a methylselenide or a sulfoxide group. 
Figure 2.13. Some permantly uncharged (26, 29) and charged (27, 28, 30) sulfide, sulfoxide and 
sulfonium analogues of doparnine and 6,7-dihydroxy-2-aminoMin (28), and uncharged 31 and charged 
32 sulfur analogues of DA antagonist sulpiride. 
These analogues were tested for D2 activity. None of these permanently 
uncharged analogues activated the DA D2 receptor regulating the depolarization- 
induced release of [3~]acet~lcholine. However, the permanently charged 
dimethylsulfonium, dimethylselenonium and trimethylammonium analogues of 
dopamine exert D2 receptor activity. They have also synthesized and examined the 
biological activity of permanently uncharged and permanently charged analogues of the 
dopamine antagonist sulpiride. And again, only the permanently charged compounds 
have shown to be active as dopamine antagonists [52]. 
In all cases, the activity of these compounds is less than that of the parent 
compounds. The lower activity of the permanently charged compounds may be due to 
- -- 
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their lack of hydrogen at the charged center. Without a hydrogen atom these analogues 
are not capable of forming a reinforced ionic bond with the receptor, but are only 
capable of forming an ionic bond. Since an ionic bond has approximately one half the 
bond strength of a reinforced ionic bond (5 kcallmol vs. 10 kcallmol) and since the 
interaction of the amine nitrogen with the dopamine receptor is thought to be a major 
contributor to the binding of agonists and antagonists to the dopamine receptor, the 
lower activity of the permanently charged analogues may be due the inability of these 
compounds to form a reinforced ionic bond with an anionic site on the dopamine 
receptor [53,54]. 
2 3  Structure-Activitivity Relationships of Serotonin Agonists 
2.3.1 The SAR of 2-Aminotetralins at the ~ - H T ~ A  Binding Sites. 
The ergoline skeleton contains, in its rigid structural framework the key elements 
of both dopamine and 5-HT. It has been exploited by medicinal chemists, who have 
designed and synthesized potent and selective rigid dopamine analogues belonging to 
the aminotetralin class. The 8-hydroxy-2-N,N-di-n-propylaminotetralin (8-OH-DPAT, 
10) was independently synthesized by Feenstra et al. [55] and Arvidsson et al. [56]. 
According to both groups, the compound did not have any effect on dopamine 
receptors. In 1980, Arvidsson [56], showed that 8-OH-DPAT possessed very potent 5- 
HT receptor stimulant properties both in behavioral and biochemical tests. As 
mentioned above, 8-OH-DPAT became a very important pharmacological tool to 
characterize 5-HT receptor subtypes. The compound possesses a very high affinity for 
the ~ - H T ~ A  sites and a low affinty for the 5-HTlb, 5HTlC and 5-HT2 sites. 
Extensive structure-activity relationship studies of the aminotetralins have been 
performed [56,57]. The main conclusions are the following: 
- (R)-(+)-8-OH-DPAT is the most potent compound in the series, the (S)-(-) 
enantiomer being two times less active. The 8-methoxy analogue is six times less 
active compared to its parent compound. 
- The 5-, 6- and 7-hydroxy analogues of 8-OH-DPAT are practically inactive at 
~ - H T ~ A  receptor sites [58,59]. 
- The N-substituents are important for ~ - H T ~ A  activity. The N,N-diethyl and 
N,N-di-n-propyl-substituted aminotetralins are equipotent, whereas longer 
branched chains reduced the potency. However, one of the N-propyl groups may 
be exchanged for a considerable larger substituent. 
- By introducing methyl groups in the non-aromatic ring of the tetralin skeleton, 
steric and bulk conformational requirements of the receptors can be examined. 
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Hjorth et al. [60] have found that the activity of the cis 1-methylated 8-OH- 
DPAT analogue (+)-ALK-3 was comparable to the parent compound in reducing 
the 5-HT output from rat ventral hippocampus. In comparison, both the (-)-ALK- 
3 and the trans diasteromers were inactive, whereas the two enantiomers of 8- 
OH-DPAT strongly reduced 5-HT release. ALK-3 is highly stereoselective and 
may therefore represent a useful probe in further characterization of the 5-HT 1~ 
receptor mediated mechanisms and functions. This study defines some of the 
sterochemical requirements for ~ - H T ~ A  receptor interaction, emphasizing the 
importance of the receptor region complementary to C 1 and C2 carbons of the 8- 
OH-DPAT molecule. 
"CaH7 R = CONH, 
F 
34 36 
Fig 2.14. Chemical structures of serotonin (5-HT), LSD (33), 8-OH-DPAT (lo), UH301 (34) 
and the amide and thiomethyl derivatives of 8-OH DPAT (36). 
Introduction of fluorine in the aromatic ring in the selective ~-HT~A-receptor 
agonist 8-OH-DPAT (10) has been shown to alter dramatically the pharmacological 
profile. 5-F-8-OH-DPAT (UH 301, 34) is stereoselective whereas 8-OH-DPAT is not. 
The enantiomers of 5-fluoro-8-hydroxy-2-(dipropy1amino)tetralin have opposite 
activities, and the Renantiomer is a ~ - H T ~ A  agonist, although of slightly lower 
potency than &OH-DPAT, whereas the S-enantiomer behaves as a ~ - H T ~ A  antagonist 
[61,62]. Fluorine differs only little in size from hydrogen, and its effect on the acidity 
should be minimal. The NMR experiments and molecular mechanics calculations 
indicate that the fluorine does not induce any conformational change. Thus, the major 
difference between 10 and 34 may be related to their electronic distribution. 
Consequently, these results indicate that the eff~cacy may be further modified by 
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changing the the electronic properties of the aromatic ring. 
Compounds 36 showed high ~ - H T ~ A  receptor binding aff i ty ,  indicating that 8- 
methoxy or 8-hydroxy substituents are not necessary for efficient binding [63,64]. 
Glennon et al. [65] have demonstrated that the introduction of the large N- 
(phthalimidobutyl) group is not only tolerated but can result in simcantly enhanced 
affinities at the ~ - H T ~ A  sites. This group is also tolerated by members of every major 
class of agents known to display significant a f f i t y  for 5-HT 1~ sites . 
8-OH-DPAT has been used as a template to construct a photoaffinity label for 5- 
H T ~ A  receptors. The label 37 binds with high affinity to ~ - H T ~ A  sites in rat 
hippocampus. In addition to its importance as a biological tool, this agent demonstrates 
that, just like by the dopaminergic 2-aminotetraliis, one of the propyl groups may be 




The chromane analogue of 8-OH-DPAT, where an oxygen atom replaces the 
carbon C-4 of the aminotetralin skeleton, has been described [67,68]. This agent, 5- 
hydroxy-3-N,N-di-n-propylaminochromane (5-OH-DPAC, 38), possesses an affinity 
comparable to &OH-DPAT for the 5-HT site, but is claimed to be 10 to 20 times less 
active at the presynaptic sites in the striatum. The 5-MeO-DPAC also acts in the nM 
range on ~ - H T ~ A  sites, but in contrast to 8-OH-DPAT did it scarcely binds to 
presynaptic striatal slices. These presynaptic sites are possibly associated with 5-HT 
reuptake in serotonergic terminals [69]. The electronic enrichment which results from 
isosteric 0-substitution mimics that created by a double bond in two other preferential 
~ - H T ~ A  ligands such as LSD and BAY R 1531. Boyer et al. [70] described a selective 
tricyclic ~ - H T ~ A  ligand in which electronic enrichment in the same position of the 
molecule is provided by an oxygen as in 5-MeO-DPAC. So, comparison of the chemical 
structures of 5-MeO-DPAC and other ~ - H T ~ A  ligands suggests that electronic 
enrichment due to isosteric displacement of carbon by an oxygen may play an important 
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role in the selective recognition of the ~ - H T ~ A  receptor by these drugs. 
2.3.3Tricyclic 2-Aminotetralin Congeners 
Figure 2.16 Structures of tricyclic S-I-IT~A agonists. 10-OH OHB[fjQ (39), CGS 18102A (40) and the 
tetrahydro-benzopyranopyridine (41) 
Analogously to the 2-aminotetralins, the 10-hydroxy octahydrobenzo[fl- 
quinoline showed 5-HT-like activity. The relatively low potency has been explained on 
conformational grounds [71]. Potent and selective ligands for ~ - H T ~ A  receptors may be 
obtained by appropriate modification, from compounds related to the 3-amino- 
chromanes, namely the hexahydro-benzopyranopyridines 40 and the tetrahydro- 
benzopyranopyridines 41 [78]. Compound 40 (GCS18102A) is relative selective for 5- 
H T ~ A  and 5-HT2 receptors. Compunds 40 and 41 may be viewed as tricyclic analogues 
of lysergic acid (33) in which the pyrrole ring has been eliminated and an oxygen has 
been introduced at the former 3-position of the indole moiety. 
2.3.4 Receptor Model 
X-ray analysis and conformational studies of 5-HT do not provide conclusive 
information regarding the receptor-bound conformer of 5-HT, since numerous side 
chain conformations are separated only by low energy barriers. Consequently, scientists 
have turned to rigid active molecules to investigate receptors. In this respect, (+)-LSD 
proved to be an important compound. Models based on the structure of (+)-LSD have 
been proposed and it has been claimed that the A-ring and the aliphatic nitrogen atom 
are essential for the binding to the receptor. In addition, it has been suggested that the 
pyrrole function and the C9-C10 double bond in (+)-LSD are of importance for an 
electrostatic interaction, and that the phenol group on 5-HT and &OH-DPAT should 
correspond to the double bond in terms of electronic properties. The importance of the 
phenolic group for serotonergic activity was supported by the fact that 2-aminotetralins 
with hydroxy substituents in other positions of the aromatic ring apparently lack 5-HT 
activity and instead show dopaminergic properties. According to Hibert [58], the 
minimal structural parameters necessary for 5-HT~A-receptor stimulation is one 
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aromatic ring and one amino group and its lone pair of electrons in the relative position 
shown in Fig 2.17a. The mean distance between the center of the common aromatic ring 
and the nitrogen atom is 5.3-5.6 A, and the nitrogen lies at 0.2 A above the plane 
defined by the reference ring and the electron lone pair is almost perpendicular to the 
plane of the aromatic ring. Nevertheless, these two primary points of binding are 
probably not always sufficient and additional binding groups are presumably required to 
stabilize the receptor-ligand complex. It seems reasonable to assume that the 8-hydroxy 
or 8-methoxy and the N-di-n-propyl substituents of the aminotetralin moiety seems to 
be required to offset the lack of the indole nucleus and to obtain compounds with high 
affinity and selectivity for the ~ - H T ~ A  recognition site [58]. According to this model, 
the stereochemical requirements of the ~ - H T ~ A  and a-adrenoceptor are identical. Inte- 
restingly, the height of the nitrogen atom above the plane defined by the aromatic ring, 
as well as the directions in which the nitrogen lone pair of electrons point are different 
in the model for antagonistic and agonistic activity, respectively [58]. This may allow 
comparison of the active and inactive conformation of the ~ - H T ~ A  receptor induced 
during the fitting process by agonists and antagonists. 
X 
a. b. 
Figure 2.17. Pharmacophore of the 5-I- lTl~ agonist recognition site as proposed by a) Hibert et al. [58], 
and b) Mellin et al. [76]. All the distances in the models are in A: y = 2.1 - 2.6; x = 5.2 - 5.7; a = (-) 28' 
- (+)-28' ; j3 = (-)-4' - (+) 0.4' 
Because it was not possible to obtain a reasonable fit with conformationally 
restrained, but active derivatives of 8-OH DPAT, a second model has been proposed by 
the group of Hacksell [76]. This model describes the minimal structural parameters 
necessary for agonists at the ~ - H T ~ A  receptor. Since the non-phenolic 2- 
(propy1amino)tetralin possesses fairly high affinity for the ~ - H T ~ A  receptor [77], the 
phenol group is omitted in this model. The pharmacophore model consists of two 
elements 1) an aromatic site; 2) a dummy atom-nitrogen site. This dummy atom, located 
2.6 A from the nitrogen and aligned with the N+-H bond vector, was supposed to mimic 
a cation binding site (most likely, a carboxylate) at the receptor. The model defrnes 
limits within which the relative position of an aromatic nucleus and a nitrogen-dummy 
atom vector may vary (Fig 2.1%). It also defines a partial 5-HT~A-receptor-excluded 
volume. Just as the model of Hibert et al., this model also does not take into account the 
electronic properties of the aromatic moiety. 
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Because a large N-(phthalimidobutyl) group is tolerated and also seems to enhance 
aflinity, Glennon [65] postulated that these agents probably utilize a common aryl, 
terminal amine and a phthalimido site. 
An extensive study of the molecular electrostatic potential of ligands with other substi- 
tuents which may contribute to the ligand-receptor complex stability by interacting 
directly with electropositive or hydrogen bond donor residues of the recognition site 
remains to be performed (see chapter 9). 
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CHAPTER 3 
SYNTHESIS OF A SERIES OF 2-(N-METHYL-N-PROPAR- 
GYLAMIN0)TETRALINS: DOPAMINE AGONISTS WITH 
MONOAMINE OXIDASE INHIBITING PROPERTIES. 
Summary: A series of non-, mono and dihydroxylated 2-(N-methyl-N-propargyho)ains 
were synthesized and studied with respect to their dopamine agonist and monoamine oxidase inhibitory 
activities. It was concluded that the mono and dihydroxylated compounds have MA0 inhibiting and 
dopamine receptor stimulating activities. The MA0 inhibitory activity predominated in the monohydroxy 
structures, whereas the dopamine agonistic effect was predominant for the catecholic compounds. 
3.1 Introduction 
The important study by Blaschko et al. [l] on the inactivation of epinephrine (E) 
led to the concept of amine oxidase, an enzyme system which catalyzes the oxidation of 
a large number of amines. Zeller [2] proposed the name 'monoamine oxidase' (MAO) 
for the class of enzymes responsible for the oxidative deamination of the monoamine 
neurotransmitters. 
Mitochondria1 MAO, a spherical protein with a density of 1.4 and a molecular 
weight of about 100 000 D, is widely distributed in different types of neurones, glia 
cells, liver, kidney, heart, intestine, lung, salivary gland, gonads and various kinds of 
smooth muscle. It is bound to the outer mitochondria1 membrane and plays an important 
role in the inactivation of both exogenously and endogenously formed amines. 
Monoarnine oxidase is a flavine-containing enzyme [12]. 
The concept that mitochondrial MA0 plays a physiological role in the biological 
inactivation of transmitters like norepinephrine (NE), dopamine (DA) and serotonin (5- 
HT) is well established by much experimental evidence [3,4,5]. Inhibition of MA0 
leads to an increase in concentration of NE, DA and 5-HT in the brain to new steady- 
state levels and increases the stores of these transmitters in reserpinized animals. 
Clinically useful inhibitors of MA0 have a long history. It began with clinical 
observations of central mood-elavating effects of iproniazid [6]. One early report on this 
drug in the treatment of sanatorium patients with tuberculosis described patients as 
"dancing in the halls and it wasn't because they had seen their X-ray pictures". The 
subsequent association of these effects with the inhibition of MA0 initiated the 
development of numerous inhibitors that were enthusiastically proclaimed for the 
treatment of depression. However, this popularity was short-lived through the 
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appearance of serious side effects, especially the well documented 'cheese reaction', a 
blood pressure response to tyramine found in certain foodstuffs after the inhibition of 
MAO. This has led to severe hypertensive crises and even death in some cases [7,8]. 
It is now accepted that monoamine oxidase exists in two forms, MAO-A and 
MAO-B, with different distribution amongst organs and across species and with diffe- 
rent sensitivity to inhibitors. The enzyme form that preferentially oxidizes 5-hydroxy- 
tryptamine and noradrenaline and is inhibited by low concentrations of clorgyline is 
designated type A and the form that preferentially deaminates phenethyl-amine and 
benzylamine and which is sensitive to low concentrations of L-deprenyl is called type B 
[9,10]. The neurotransmitter dopamine (DA) is a substrate for both forms of the enzyme 
[ l  11. The proteins, however, are closely related having 70% sequence homology [12]. 
Both forms of MA0 are present in human brain, but the relative concentration of MAO- 
B is higher than that of MAO-A, which is the reverse as compared to rat brain. 
The deamination of monoamines by MA0 can be described as follows [13,14]: 
RCH2NH2 + 0 2  + H20 + RCHO + Hz02 + NH3 
The aldehyde formed is then further metabolized to the correspondmg alcohol and acid 
by aldehyde reductases and dehydrogenases, respectively. 
3.2 Pharmacology and Therapeutic Potential of MAO-B Inhibitors in 
Parkinson's Disease 
When L-deprenyl was reported by Knoll and Magyar [lo] to inhibit selectively 
the B form of MAO, the therapeutic potential of such a compound appeared somewhat 
limited because the two monoamines most likely to be implicated in depression, nor- 
adrenaline and serotonin, were believed to be preferentially degraded by MAO-A [15]. 
Subsequently, it was shown that dopamine is predominantly metabolized by MAO-B in 
humans [16,17], a finding that rationalized the use of a selective MAO-B inhibitor in 
the dopamine deficiency syndrome, Parkinson's disease. However, the consequences of 
the 80-90% reduction in the dopamine content of the basal ganglia of Parkinsonian 
patients are not amenable to improvement by L-deprenyl therapy alone. When 
combined with L-DOPA and carbidopa, there is a beneficial effect on the 
pharmacokinetics of the dopamine formed from L-dopa [18]. 
The aetiological events that ultimately result in Parkinson's disease have not yet 
been unraveled. In this context, the finding that 1-methyl-1,2,3,6-tetrahydropyridine 
(MPTP, 3), a contaminant of a pethidine-related 'designer drug', is transformed by 
MAO-B in a neurotoxin that selectively destroys nigrostriatal dopamine neurons, has 
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attracted considerable attention [19]. This selective damage results in clinical signs that 
are indistinguishable from Parkinson's disease. The MAO-B selective inhibitors L- 
deprenyl and pargyline have been used to block the metabolic activation of MPTP in 
animals. The interest generated by the biochemical and pathological effects of MPTP 
has resurrected the dormant hypothesis that neuronal degeneration seen in Parkinson's 
disease is due to environmental factors [20]. 
Scheme 3.1. Structures of pethdine (1); its 'designer drug' analogue 1-methyl-4-propionoxypiperidine 
(MPPP, 2); MPTP (3), and the oxidation of MPTP to 1-methyl-4-phenylpiperidinium (MPP+,~) 
The discovery that the selective h4AO-B inhibitor selegiline@ (L-deprenyl, 5) is 
fiee of the tyramine effect and is able to prevent the toxicity of MPTP (3) in animals led 
to the reassessment of selegiline@ in the treatment of "de novo" Parkinson's disease. 
selegiline@ is now widely used in the early management of Parkinson's disease. 
3.3 Irreversible and Selective Inhibitors of MAO. 
Many of the selective inhibitors of MA0 are not reversible, they inhibit the 
enzyme in a time dependent manner. Some representative irreversible inhibitors of 
MA0 are shown in Fig 3.1. These inhibitors can be divided into four classes, namely 
the acetylenic inhibitors, the cyclopropylamines, the fluorallylamines, and the hydrazi- 
nes. The group that has been studied most is the acetylenic type of inhibitor. From 
structure-activity relationship studies, it has been shown that irreversible inhibition is 
found only when the acetylenic group is fi to the amino group in the inhibitor molecule. 
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Figure 3.1. Structures of  various irreversible MAO-inhibitors 
The acetylenic, cyclopropyl, and hydrazinic inhibitors have been shown to 
inhibit MA0 by acting as 'suicide' inhibitors [21,22]. In such a reaction, a reversible 
enzyme-inhibitor complex is formed and subsequent reaction within this complex 
involves the generation (as a result of enzyme action) of a reactive inhibitor molecule 
which then forms a stable enzyme-inhibitor adduct, thus inhibiting irreversibly the 
enzyme. The reaction can be described as follows: 
E + I El - El* 
where E = enzyme, I = inlubitor, EI = reversible enzyme-inhibitor complex and EI* = 
irreversible enzyme-inhibitor adduct. 
Thorough investigations, including the characterization of the flavine adduct, 
have allowed Abeles et al. [21] to propose the following reaction for inhibition of MA0 
by a tertiary propargylamine (Scheme 3.2). 
Reasonable radical mechanisms have been proposed for the inhibition reactions of the 
monoamine oxidases. Krantz et al., for example, have formulated a single electron 
transfer (SET) mechanism for the inhibition reactions of propargylic (e.g. pargyline) 
and related allenylmethylamines with MA0 based upon the close similarity between the 
adducts formed in the enzyme inhibition reactions and model flavin-amine 
photochemical processes [40]. 




Scheme 3.2. Formation of the flavin adduct by reaction of a N-methyl-N-propargylamine with the 
enzym-bound flavin [2 11 
One of the prototypes of the MAO-B selective inhibitors, L-deprenyl 5, has been taken 
as a starting point for an extensive structure-activity relationship study by Knoll and his 
group 1211 ; their results are summerized in Fig 3.2. 
(H, CH3 7 )  
2-carbon chain 1 





Figure 3.2. Some structure activity relationships of the propargylamines. 
3.4 Topic of this Study 
The combination of dopamine agonistic activity and MA0 inhibiting activity in 
one and the same molecule was the topic of this study. Z(N-methyl-N- 
propargy1amino)tetralin [24] has shown to be a potent MA0 inhibitor. It was therefore 
of interest to synthesize a series of non-, mono- and dihydroxylated 2-(N-methyl-N- 
propargy1amino)tetralins and investigate the biochemical, behavioural and neuroche- 
mical effects of these compounds. The MA0 inhibitory effect of the compounds was 
studied in in vitro and ex vivo experiments using rat brain homogenates as the enzyme 
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source. We studied the affinity of the various compounds through their ability to 
displace the dopamine agonist [3~]-~-n-prop~l-nora~omorphine from rat striatal 
homogenates. Effects on DA receptors in the central nervous system were evaluated in 
test models which are generally used for studying pre- and postsynaptic actions of DA 
agonists. Thus, the gamma-butyrolactone (GBL) model [25], which involves the rever- 
sal of the GBL-induced increase in L-DOPA accumulation in rat striatum, was chosen 
as the presynaptic test model. The induction of stereotyped behaviour in rats [26] and 
the reversal of reserpine induced hypomotility in mice [27] were both used for 
investigating postsynaptic DA receptor stimulation. In addition, the potency of the com- 
pounds to decrease DA turnover in rat striatum, another indication of presynaptic DA 
receptor activation, was determined by measuring the levels of the DA metabolites 
DOPAC and HVA. It is known that striatal levels of the DA metabolite 3-met- 
hoxytyramine (3-MT) are decreased by DA agonists but increased by MA0 inhibitors. 
This DA metabolite was therefore investigated as a measure for the balance of both 
activities in our compounds. 
3.5 Chemistry 
Scheme 3.3. Synthetic route to the 2~-rnethyl-N-propargylamino)tetralins. R = H, OCH3; n = 1,2; 
Reagents (a) N-methyl-N-propargylamine; (b) NaBH3CN, H+; (c) BBr3, 
The 2-(N-methyl-N-propargy1amino)tetralins were prepared as shown in Scheme 3.3. 
The tertiary amines were synthesized fiom the correspondmg Ztetralones by use of 
literature procedures. Thus, compound 11 was allowed to react with N-methyl-N- 
propargylamine, and the resulting enamine 12 was rapidly reduced by sodium 
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cyanoborohydride at an initial pH of 5 in a 15: 1 tetrahydrofuran/methanol mixture [28] 
to afford 13. The enamine group itself is resistant to reduction, but rapid and reversible 
protonation on carbon generates a readily reducible iminium salt. Treatment of 13 with 
boron tribromide at a low temperature yielded the phenols and the catechols 14 in good 
yields. 
CH, 
13a. R' = R2 = R3 = H 
14b. R' = O H ,  R2 = R 3 =  H 
14c. R' = RZ = H, R' = OH 
14d. R' = R2 = OH, R' = H 
Figure 3.3 Structures of the 2-(N-methyl-N-propargy1amino)tetralins used in this study. 
3.6 Results and Discussion 
All the compounds proved to be in vitro MA0 inhibitors. Comparison of the 
IC50 values for this series (Table 3.1) showed that the nonhydroxylated analogue 13a 
Table 3.1. Effects of 2-(N-methyl-N-propargy1amino)tetralins and some standard drugs on in vitro 
MAO-A and MAO-B inhibition in rat brain homogenates. Substrate concentrations in the MA0 assay 
were 100 pM 5-HT (type A) and 10 pM PEA (type B). IC50 values represent mean values of determina- 
tions in triplicate at inhibitor concentrations over the range 10-lo to M. 
Compound Ic50 
MAO-A MAO-B Ratio All3 
13a (N-0425) 
14b (5-OH) 
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(N-0425) was the most potent within the series. Substitution of the aromatic ring led to 
a decrease in enzyme inhibitory activity. The monohydroxylated compounds were 
slightly more potent than the dihydroxylated analogues. The 7-OH derivative was found 
to be the most potent inhibitor of MAO-B within the monohydroxylated structures. 
Replacement of the N-methyl function by a N-n-propyl group resulted in a marked 
decrease in potency (results not shown). 
Table 3.2 shows that in ex vivo experiments the order of potency of the various 
compounds for inhibiting MA0 corresponds reasonably well with the results of the in 
vitro experiments. Feenstra et al. [29] have reported on the MAO-A inhibitory activities 
of 5,6- and 6,7-di-propyl-ADTN. They estimated the IC50 values of these compounds 
to be > 10-4 M. Thus, we conclude fiom our experiments that MA0 inhibition is 
increased about 100 times by the introduction of a methyl and a propargyl function on 
the nitrogen atom. 
Table 3.2. Effects of mono- and dihydroxylated 2-(N-methyl-N-propargy1amino~alins on ex vivo 
MAO-A and MAO-B inhibition in rat striatal homogenates. Compounds were administered i.p. at a dose 
of 10 mgkg, excepting 13a which was tested at 5 mg/kg, and the animals (n = 4 per dose) were 
terminated 4 h later. MA0 activity was assayed after a 20 min incubation period with substrates. Data 
are expressed as percentages of enzyme activity of striatal homogenates of controls (vehicle treatment) 
determined in triplicate. 
Compound % Inhibition versus controls 
MAO-A MAO-B 
To study the affiity for dopamine receptors in vitro, the compounds were 
compared with apomorphine for their ability to displace [~HINPA fiom its binding sites 
(Table 3.3). The catechols had a potency similar to that of apornorphine whereas, the 7- 
and the 5-OH analogues were found to be 3 to 7 times less potent. The nonhydroxylated 
analogue was the weakest compound in the series. 
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Table 3.3. Potency of various compounds to displace [ 3 ~ - ~ ~ ~  from binding sites in rat striatal 
homogenates. Biding assays were run at 25 OC in 1.0 mL TrislEDTA buffer, including 0.01% ascorbic 
acid, 0.25 nM [ 3 ~ - ~ ~ ~  and 2.5 mg tissue (wet weight). Nonspecific binding was determined in the 
presence of 1 pM d-butaclamol. IC50 values were estimated graphically from displacements curves made 
with data obtained from 3 independent experiments, each analyzed in triplicate over the concentration 
range 10-1 1 to 10-5 M. 
Compound Ic50 
13a (N-0425) 3000 
14b (5-OH) 120 
1 4 ~  (7-OH) 3 5 
14d (5,6-OH) 16 
14e (6,7-OH) 13 
apomorphine 18 
Table 3.4. Effects of various compounds on y-butyrolactone-induced increase in DOPA 
accumulation in rat striatum following decarboxylase inhibition (NSD 1015). Compounds were 
administered i.p. 40 min before termination whereas GBL (750 mgkg, i.p.) and NSD 1015 were 
administered 35 and 40 rnin before termination, respectively. ED50 values represent the dose in mgikg 
i.p. producing 50% reversal of DOPA accumulation and were determined graphically from log dose 
effect curves each point representing the mean DOPA content of 8 striata. a Data from Van Oene et al. 
[301. 
Compound ED50 ( ~ u n o n g  i . ~ . )  
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Stimulation of presynaptic DA receptors (autoreceptors) was investigated using 
the gammabutyrolactone (GBL) model of Walters and Roth [25]. In this model an 
increase in DOPA levels can be antagonized by selective stimulation of presynaptic DA 
receptors. All the hydroxylated compounds were effective in reversing the GBL- 
induced rise in DOPA content in rat striatum following decarboxylase inhibition with 
the aromatic amino acid decarboxylase inhibitor NSD 1015. The ED50 values shown in 
Table 3.4 express the dose at which 50% reversal of the induced DOPA accumulation 
was achieved. 
Comparing the effectiveness of the various compounds showed that, of the 
monohydroxylated derivatives, the 7-OH analogue was twice as active as the 5-OH 
compound. The dihydroxylated analogues were shown to have a potency similar to that 
of apomorphine. N-0425, the most potent MA0 inhibitor, produced only a 40% 
reversal at a dose of 42.5 p o l k g  i.p.. One would expect, however, and as a 
consequence of MA0 inhibition, that the DA levels in the striatum should increase 
resulting in the inhibition of tyrosine hydroxylase activity, as was reported by Roth 
[31]. In addition to apomorphine, the selective DA autoreceptor agonist (k)-3-PPP was 
also used as a reference compound. 
All of the hydroxylated compounds produced a dose-dependent decrease in HVA 
levels in rat striatum (Fig 3.4). The 7-OH analogue was the most potent 
Figure 3.4. Dose-dependent effects of mono- and dihydroxylated 2-m-methyl-N- 
propargy1amino)tetralins on HVA concentrations in rat striatum. Effects were measured 60 min after an 
i.p. injection of the test compound. Animals were terminated by focussed microwave irridation. Values 
are given as % of controls (0.54 f 0.05 ( I S )  pglg ; mean r. SEM, number of animals). Each point is the 
mean of 4-5 determinations. * P < 0.05; ** P < 0.01 vs. controls (Dunnett's test). 
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compound of the series, reducing striatal HVA concentrations by about 60% following 
a dose of 5 mgkg i.p. This effect is an indication of presynaptic DA receptor stimu- 
lation and/or MA0 inhibition; both types of activity lead to a decrease in the levels of 
this metabolite. In addition, striatal 3-MT levels were measured as a marker for 
agonistic activity (decrease in 3-MT concentrations) and/or MA0 inhibiting activity 
(increase in 3-MT concentrations). The effect of the 3-MT levels are shown in Fig 3.5. 
The 5-OH analogue increased the 3-MT levels significantly to 195 f 25 % (mean f 
SEM) at 20 mgkg i.p. (P < 0.05 vs. controls, Dunnett's test) suggesting a possible 
domination of MA0 inhibitory activity at relative high doses of this compound. In 
contrast, the dihydroxylated derivatives tended to reduce 3-MT levels, suggesting a 
more pronounced agonistic activity of these structural analogues. The latter effect was 
to be expected for the dihydroxy compounds in view of the results found in the GBL 




Figure 3.5 Dose-response relation of mono-and dihydroxyated 2-(N-methyl-N-propargy1amino)tetralins 
on 3-MT concentrations in rat striaturn. Effects were measured 60 min after an i.p. injection of test 
compound. Animals were terminated by focussed microwave irridation. Values are given as % of controls 
(34.9 f 5.1 nglg (15); mean f SEM, number of animals). Each point is the mean of 4-5 determinations. 
The dihydroxylated analogues produced a more pronounced stereotyped 
behaviour than did the monohydroxy compounds although they were less active than 
the reference drug apomorphine (Table 3.5). 
Dopamine Agonists with M O  Inhibiting Properties 49 
Table 3.5. Induction of stereotyped behaviours in rats by various compounds. The animals were placed 
in individual cages and obsewed for a 60 min period. Stereotyped behavioun were scored according to 
Costall [32], i.e. 0 = no stereotypy; 1 = periodic sniffing andlor r e t i v e  head and limb movements; 2 = 
continuous sniffing andlor repetitive head and limb movements; 3 = periodic gnawing, biting or licking; 4 
= continuous gnawing, biting or licking. Each dose was investigated in 4 rats in separate experiments. 
Compound Dose Stereotypy Duration Other behavioural 
(povkg)  score (min) effects 
13a (N-0425) 42.5 - sedation 
(0-20 min) 
14b (5-OH) 40 1-2 0-20 
1 4 ~  (7-OH) 40 1 0-45 
14d (5,6-OH) 37 3 -2 20-45 sedation 
(0-15 min) 
14e (6,7-OH) 37 2-3 20-45 sedation 
(0-20 min) 
Deprenyl 45 - locomotor stim. 
Apomorphine 6.6 4 0-30 
3 30-35 
2 35-40 
Methamphetamine 20 4 10-60 locomotor stim. 
(0-10 min) 
Following treatment with the 5,6- and 6,7-OH compounds there was a phase of 
hypomotility that preceded the stereotyped behaviour. This phenomenon might be 
explained by a more dominant stimulation of presynaptic DA receptors, or alternatively 
by stimulation of a2-adrenergic receptors, or both. It is known that various 2- 
aminotetralins are able to stimulate also a2-adrenergic receptors in the CNS 1331. Both 
the nonhydroqlated compound N-0425 and deprenyl failed to induce any form of 
stereotyped behaviour. N-0425 caused a state of hypomotility that lasted for about 20 
min, whereas deprenyl produced locomotor stimulation. 
In addition to the stereotypy model, reversal of reserpine induced hypomotility in 
mice was used as a measure of postsynaptic DA receptor stimulation. It was found that 
(Table 3.6) that the dihydroxylated compounds were able to reverse reserpine induced 
hypomotility, as did the DA agonist apomorphine. The fact that the dihydroxylated 
compounds were found to be active, in contrast to the monohydroxylated ones, suggests 
that this effect was mainly due to postsynaptic receptor stimulation rather than to MA0 
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inhibition. This idea is supported by the finding that the in vivo MA0 inhibitory effects 
of the monohydroxy derivatives, especially with the 7-OH substituent, were more 
pronounced than the effects of the dihydroxylated compounds. Pargyline, a MAO-B 
inhibitor, did not reverse the reserpine effect either, whereas deprenyl, another MAO-B 
inhibitor, had a stimulant effect. 
Table 3.6. Effects of various compounds indicated on the reserpine-induced immobility of mice. Mice (n 
= 3 per dose) were pretreated with reserpine (5 mg/kg i.p.) about 17 h prior to injection of the test 
compound. Motility counts were made during a 2 h period starting 5 min after test compound injection. 
Data were expressed as the mean score, with the range in parentheses, as determined in 3-6 independent 
experiments. The significance of the increase in motility compared to vehicle treated controls is indicated. 
NS = not significant increase (P < 0.05; Man Whitney U-test, one tailed). 
Compound Dose Motilty Level of signifi- 
(pmoVkg ip) X counts/2h (range) cance (P) 
controls 
13a (N-0425) 42.5 
14b (5-OH) 40 
1 4 ~  (7-OH) 40 
14d (5,6-OH) 3 7 
14e (6,7-OH) 3 7 
Deprenyl 45 




We have demonstrated that both the monohydroxylated and dihydroxylated N- 
methyl-N-propargyl-2-aminotetralins possess a combination of MAO-inhibiting and 
dopamine receptor stimulating properties. The DA agonistic effect dominates in the 
catechols, whereas MA0 inhibitory effects are stronger in the monohydroxylated and 
especially the non-substituted analogues. None of the compounds was very selective for 
either of the MAO-subtypes. Thus it would appear difficult to obtain a high order of 
both activities in one molecule, at least for the 2-aminotetralin structures. 
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The rediscovery of apomorphine in Parkinson's disease is one of the best 
examples of the value of 'old drugs' in modern therapy. Apomorphine is one of the 
most potent dopamine agonists now available and, used together with domperidone, 
peripheral side effects are prevented. Subcutaneous or sublingual administration also 
lead to a potent and rapid antiparkinsonian effect. 
There are two reasons indicating that 5,6-dihydroxy-2-(N-methyl-N-propar- 
gylamino)-tetralin deserves further evaluation. Firstly, it has about the same potency as 
apomorphine and the availability to the brain is further improved through the 
development of new routes of administration. Secondly, several significant changes in 
non-dopaminergic systems have also been described in Parkinson's disease. Reduced 
concentrations in the striaturn, substantia nigra, globus pallidus, nucleus accumbens, 
limbic and cortical regions, hippocampus, cerebellar cortex and spinal cord have been 
described for norepinephrine, serotonin, substance P, neurotensin, etc. [34]. The 
compound has a moderate, but 5-fold selectivity for the MAO-A enzyme, leaving in the 
periphery enough MAO-B intact to metabolize indigested indigested tyramine. The 
levels of norepinephrine and serotonin and to a certain amount dopamine, can be 
increased by the MAO-A inhibiting properties of this compound. However, in spite of 
the novelty of such a concept, these compounds may become new and valuable 
therapeutics in Parkinsonism. 
3.8 Experimental Section 
Melting points were determined with an Electrothermal digital melting apparatus and 
are uncorrected. IR, NMR, and MS data were determined for all compounds and were 
evaluated as consistent with the indicated structures. These data are presented only 
where required for structural assignment. Infrared Spectra were recorded on a Jasco A- 
100 spectrofotometer. The 60 MHz 1~ NMR spectra were recorded on a Hitachi 
Perkin-Elmer R-24 B specmeter. The chemical ionization (CI) mass spectra were 
obtained on a Finnegan 3300 system. For purity tests, TLC was performed on 
fluorescent silicagel plates developed in at least two different systems. For all the 
compounds, only one spot (visualized by UV light and I2 vapor) was obtained. 
Elemental analysis were performed in the Department of Chemistry, University of 
Groningen. Where elemental analysis are indicated results obtained were within 0.4% 
of theoretical values. 
2-(N-Methyl-N-propargylamino)-1,2,3,4-tetrahydronaphthalene (13a) 
A solution of 2-tetralone (1, 2.8 g, 19 mmol), N-methylpropargylamine (1.6 g, 24 
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mmol) and and a catalytic amount of p-toluenesulfonic acid (1 mmol) in 60 mL of dry 
benzene was refluxed under nitrogen in a Dean-Stark apparatus. After 2 h the volatiles 
were evaporated in vacuo to give the enamine 12a. The enamine was quickly dissolved 
in 75 mL of dry THF and 5 mL of methanol, acidified (pH 5) with ether saturated with 
gaseous HC1 and rapidly reduced by sodium cyanoborohydride (1,3 g, 21 mmol). The 
resulting mixture was stirred 2 h at room temperature, then freed of solvent in vacuo 
and taken up in a sodium carbonate solution. The aqueous solution was extracted four 
times with 40 mL portions of ether. The combined extracts were washed with brine (20 
mL) and dried over magnesium sulfate and evaporated in vacuo. The resulting oil was 
dissolved in dry ether, and ether saturated with gaseous HC1 was added slowly to 
produce the amine hydrochloride as a white solid. Recrystallization from ethanol-ether 
yielded 2.6 g (57%) of white crystals: mp 180-182 "C. 
5-Methoxy-2-(N-methyI-N-propargylamino)-l,2,3,4-tetrahydronaphthalene (l3b) 
By use of the procedure used for 13a, the 5-methoxy derivative gave the methyl ether 
hydrochloride 13b in a 69% yield after recrystallization from ethanol-ether: mp 199-201 
"C; IR (KBr) 3230 cm-1 (propargyl-H), 2460 (NH+); NMR (CDC13) free base, 6 3.7 
(OCH3); MS (CI + NH3), m/e 230 (M + 1). Anal (C15H2oNOCl) C, H, N, C1. 
7-methoxy-2-~-methyI-N-propargylamino)-1,2,3,4-tetrahydronaphthalene (13c) 
The reaction was carried out as described above for 13a. Conversion to the HC1 salt and 
recrystallization from ethanol ether gave pure 13c (60%): mp 206-208 OC; IR (KBr) 
3200 cm-1 and 2120 (propargyl-H), 2500 (NH+); NMR (CDC13) free base, 6 2.4 (s, 
3H, N-CH3), 3.7 (s, 3H, OCH3); MS (CI + NH3), m/e 230 (M + 1). Anal. 
(C15H20NOCl) C, H, N, C1. 
5,6-dimethoxy-2-(N-methyl-N-propargylamino)-l,2,3,4-tetrahydronaphthalene 
(13d). 
The reaction was carried out as described above for 13a. Conversion to the HCL salt 
and recrystallization fiom ethanol yielded 53% of pure product: mp 198-199 "C; IR 
(KBr) 3190 and 2100 cm-1 (propargyl-H), 2500 (NH+), 1600 ArH; NMR (CDC13) 6 
2.4 (s, 3H, NCH3), 3.7 (s, 6H, OCH3); MS (CI + NH3), m/e 260 (M + 1). Anal. 
(C16H22N02Cl) C, H, N, C1. 
6,7-dimethoxy-2-(N-methyl-N-propargylamino1,2,3,4-tetrahydronaphthalene 
(13d). 
The reaction was carried out as described above for 13a. Conversion to the HC1 salt and 
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recrystallization from ethanol yielded 59% of product: mp 2 16-2 19 ' C; IR (KBr) 3 190 
(propargyl-H), 2120 cm-l (propargyl), 2520 (NH+), 1610 (ArH); NMR 6 2.3 (s, 3H, 
NCH3), 3.8 (2 x s, 6H, OCH3), 6.7 (s, 2H, ArH); MS (CI + NH3), m/e 260 (M + 1). 
Anal. (C16H22N02Cl) C, H, N, C1. 
Demethylation of Methoxy Compounds. 
The appropriate methoxy compound (2 mmol) was dissolved in 30 mL of 
dichloromethane, and the temperature of the solution was lowered to -60 ' C .  An excess 
(6 rnrnol) of a 1 M solution of boron tribromide in dichloromethane was then added. 
The reaction mixture was initially stirred for 2 h at a temperature between -30 and -40 
'C and was then allowed to rise to room temperature and the reaction was stirred for 
another 20 h. The reaction mixture was then poured into water (100 mL) and made 
alkaline by the addition of ammonia. The separated aqueous layer was extracted with 
ether (4 x 30 mL). The combined organic extracts were washed with brine (3 x 10 mL) 
and dried over magnesium sulfate. Removal of the solvents under reduced pressure 
yielded an oil followed by conversion to the HCI salt. 
5-Hydroxy-2-(N-methyl-N-propargylamino)l,2,3,4-teahydronaphthaIene (14b) 
The crude 14b.HCI resulting from demethylation of 13b.HCI was recrystallized from 
ethanol-ether: yleld 68%; mp 195-198 'C; IR (KBr) 3220 cm-1 (OH), 2120 (propargyl- 
H); NMR (CDC1-j) free base, 6 2.4 (s, 3H, NCH3), 6,2 (br s, lH, ArOH); MS (CI + 
NH3), d e  216 (M + I). Anal. (C14H18NOC1) C, H, N, C1. 
7-Hydroxy-2-(N-methyI-N-propargylamin0)1,2,3,4-tetrahydronaphtha1ene (14c) 
The crude 14c.HCI resulting from demethylation of 13c.HCI was recrystallized from 
ethanol-ether: yield 79%; mp 198-202 'C (dec); IR (KBr) 3200 cm-1 (ArOH), 2620 
(NH+), 31 10 @ropargyl-H); NMR (CDC13) free base, 6 2.4 (s, 3H, NCH3), 6.5-6.9 (m, 
3H, ArH), 8.3 (s, 1 H, ArOH); MS (CI + NH3), mle 216 (M + 1). Anal. (C14Hl gNOC1) 
C, H, N, C1. 
5,6Dihydroxy-2-(N-methyl-N-propargylamino)-1,2,3,4-tetrahydronaph#alene 
(14d) 
The demethylation was carried out with 8 mmol boron tribromide. The crude 14d.HCI 
resulting from demethylation of 13d.HCI was recrystallized from ethanol: yield 77%; 
mp 107-110 'C; IR (KI3r) 3200 cm-I (OH), 2600 (NH+), 3120 (propargyl-H); NMR 
(CDC13) free base, 6 2.5 (s, 3H, NCH-j), 3.4 (d, 2H, N-CH2), 4.5 (br s, 4H, ArOH + 
H20), 6.3 (m, 2H, ArH); MS (CI + NH3), m/e 268. Anal. (Cl4HlgN02Cl.H20) C, H, 
N, C1. 
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6,7-Dihydroxy-2-(N-methyl-N-propargylamino)-1,2,3,4-tetrahydronaphthalene 
(14e) 
The demethylation was carried out with 8 mmol boron tribrornide. The crude 14e.HCI 
resulting from demethylation of 13e.HCI was recrystallized from ethanol: yield 84%; 
mp 176-179 'C; IR (KBr) 3200 cm-1 (ArOH), 2650 (NH+), 21 10 (propargyl); NMR 
(CDC13) free base, 6 2.4 (s, 3H, NCHs), 3.5 (d, 2H, NCH2), 6.5 (s, 2H, ArH), 7.5 (s, 
2H, ArOH); MS (CI + NH3), m/e 268. Anal. (C14H18N02Cl) C, H, N, C1. 
Pharmacology. Assay of Monoamine Oxidase Activity I n  Vitro and En Vivo. MA0 
activity was assayed by the radiometric technique of Buckhotz and Boggan [35]. In 
short, female Wistar rats were decapitated, and the brain was removed and 
homogenized in cold 0.25 M sucrose. Homogenates were centrifuged for 15 rnin at 350 
x g and 4 'C. The supernatant was saved and used as the enzyme preparation. Part of 
the supernatnat was boiled for 10 min to give the enzyme blank. 5-[2- 
1 4 ~ ] h ~ d r o x ~ t r ~ ~ t a m i n e  with a specific activity of 50.7 mCi/mmol and B-[ethyl-1- 
14~]~hen~le th~ lamine  w th a specific activity of 50.0 mCi/mmol were used as 
radiolabelled substrates. Reaction mixtures were preincubated at 37 " C for 30 min with 
drug solution or water, then 50 pl of unlabelled and 50 pl of radioactivily labelled 
substrate were added and the incubation was continued for another 20 min. Blanks were 
carried out during the intire procedure. For the ex vivo experiments drugs were adminis- 
tered i.p. to female Wistar rats (180-200 g) and the animals were killed 4 h later by 
decapitation. Striatal and cerebellar tissues were dissected, 10% homogenates in 0.25 M 
sucrose were prepared and MAO-A and MAO-B inhibition were determined as 
previously described. 
Displacement of the Specific Binding of [ ~ ~ ] - ~ - n - ~ r o ~ ~ l a ~ o m o r ~ h i n e  in Rat 
Striatum. This assay was performed with homogenized and washed membrane 
preparations from rat striatum tissue was carried out as described previously [36]. In 
each experiment the amount of [~HINPA bound was determined in the absence (total) 
and presence of (nonspecific) of 10-6 M (+)-butaclamol, the difference yielding the 
specific  HI-NPA binding. The ability to compete with  HI-NPA was tested over an 
concentration range of 10-1 1-1 0-5 M. 
Inhibition of Gamma-butyrolactone-induced Increase in DOPA Concentrations in 
Rat Striatum. In vivo autoreceptor activation was assessed by measuring the inhibition 
of DOPA accumulation following the administration of gamma-butyrolactone, and 
NSD 101 5 as a decarboxylase inhibitor according to the method of Walters and Roth 
[37]. Striatal DOPA levels were determined according to the method of Westerink and 
- - -  - - - - - - -  - - 
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Mulder [38]. 
I n  Vivo Neurochemical Evaluation of MA0 Inhibition and of Dopamine Receptor 
Stimulation. Drugs were administered i.p. to rats and the animals were killed by 
focussed microwave irradiation at various times after drug administration. Groups of 
drug-treated rats were matched with 5 animals injected with saline which served as 
controls for each experiment. The brain structures dissected included striaturn, frontal 
cortex and cerebellum. The determination of 3-MT levels required combination of the 
striata from each rat. The isolation procedure on Sephadex G-10 columns and assay of 
the dopamine metabolites by HPLC and electrochemical detection were carried out 
according the procedure of Westerink [39]. 
Stereotyped Behaviour in Rats. Sterotyped behaviours were scored according to 
Costall at al. [32]. 
Reversal of Reserpine Induced Hypomotility in Mice. Reserpine (5 mg/kg) was 
administered i.p. to mice between 1700 and 1730 h followed by the test compound (or 
saline) 16-20 h later. Immediately after the latter injections the animals were placed 
inrectangular perspex cages (3 mice per cage). The cages were placed on ~utomex@ 
activity meters (Columbus Instruments, Ohio) set at maximum sensitivity. Recordings 
were started at 5 min after the injections and the accumulated activity counts over a 2 h 
period were recorded. The data were analysed statistically using the Mann-Witney U- 
test (one tailed). 
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CHAPTER 4 
8-HYDROXY-2-(N-METHYEN-PROPARGYLAMIN0)- 
TETRALIN: A ~ - H T ~ A  AGONIST WITH MA0 INHIBITING 
ACTIVITY 
Summary. The N-methyl-N-propxgylamino derivatives (3,4) of the potent ~ H T ~ A  agonist 8- 
OH-DPAT (2) have been prepared and tested for their potential effects as competitive inhibitors of 
MAO-A and MAO-B. The in vitro aflhity for 5-I-lTl~ receptor was determined with radioligand 
binding studies and the in vivo activity was evaluated by determination of the effects on the extracellular 
levels of DA and 5-HT and their metabolites by means of brain microdialysis in freely moving rats. A 
comparison was made with clorgyline (5) and Ldeprenyl (6), respectively, which are known to be 
selective MAO-A and MAOB inhibitors. 
4.1 Introduction 
Clinical observations of the mood elevating effects of the anti-tubercular agent 
iproniazid (1) [l] in 1952 were followed by Zeller's observation that this compound has 
an inhibitory effect on MA0 [2]. This heralded the development of numerous inhibitors 
that were enthusiastically proclaimed as agents for the treatment of depression. 
Figure 4.1. Structures of iproniazid (I), 8-OH-DPAT (2), 2-(N-methyl-N-pr0gargyko)-tetralins 3 
and 4 OD9 104), and clorgyline (5) and L-deprenyl(6). 
However, from 1963, enthusiasm for MA0 inhibitors waned as reports of life- 
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treatening hypertensive crises associated with the ingestion of tyramine containing 
foods (the cheese effect) appeared [3]. 
Research in the basic biology of MA0 over the past few years has been 
extensive, and has afforded new insight into the two main enzyme subtypes (MAO-A 
and MAO-B), substrate selectivity, and tissue distribution. The two forms have recently 
been shown to be similar, and it has been suggested that they may derive fiom a 
common progenitor gene [4]. The distribution of the two types of MA0 varies markedly 
between different organs and different species. The highest activity of MA0 can be 
found in liver: in the human liver both MAO-types are present in about equal amounts. 
In human intestine, 75% of the total MA0 is of type A. The role of intestinal MA0 is to 
metabolize the biologically active amines in food. Both forms of MA0 are present in 
the human brain, but the relative concentration of MAO-B is higher than that of MAO- 
A, which is the reverse in comparison with rat brain. In human brain about 70% of the 
total MA0 activity is of type B, whereas in rat only 5% is of MAO-B [5,6]. 
Serotonin, adrenalin and noradrenalin are preferably metabolized by MAO-A, 
whereas benzylamine and 8-phenylethylamine are predominantly metabolized by MAO- 
B. Tyramine and dopamine are common substrates for both forms of the enzyme. 
Recent reviews have appeared, which cover the current biological understanding 
of MA0 and the role of MA0 inhibition in the treatment of depression [7,8]. It is 
believed that the beneficial effect in depression results fiom the inhibition of MAO-A in 
the brain, whereas the 'cheese effect' is a consequence of the inhibition of MAO-A in 
the periphery [9]. Thus a MAO-A inhibitor selective in the brain can be expected to be 
a safe drug for use in depression. MAO-A-inhibition in the brain is believed to lead to 
an increase in the leveIs of noradrenaline and/or serotonin [lo] which, in turn, leads to 
down-regulation of adrenergic and/or serotonergic function. Numerous well-controlled 
trials now support the efficacy of the non-selective MAO-inhibitors as well the specific 
MAO-A inhibitor, clorgyline (S), in the treatment of more typical as well as the severe 
forms of major depression. The efficacy of MAO-inhibitors is at least equivalent to that 
of the tricyclic antidepressants [12]. MAO-inhibitors possess additional therapeutic 
properties. They appear to have anxiolytic activity. This might account for the apparent 
unique benefits of MAO-inhibitors in managing anxiety disorders, as well as treating 
depression. 
The primary mechanism of action of all types of antidepressant drugs, not only 
the MAO-inhibitors, remains an enigma despite intensive biological investigations 
devoted to this question. The advent of selective serotonin uptake inhibitors and 
~ - H T ~ A  receptor agonists, both classes of drugs showing antidepressant activity, has 
recently focussed increased attention on serotonergic mechanisms as being central to 
the pathophysiology of mood disorders. Serotonin neuonal systems have become a 
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primary target for new drug research in mood disorders. 
4.2 Site Selective Inhibitors of M A 0  
It can be safely assumed that MAO-inhibitors exert their therapeutic effect 
through a central mechanism [12], and that the majority of side effects arise fiom 
inhibition of the peripheral enzyme. The ideal inhibitor would be one that acts 
exclusively in the brain. 
Our first research effort directed towards this site-selectivity has been the 
synthesis of 8-methoxy- and 8-hydroxy-2-(N-rnethyl-N-propargy~o>tetralin (3,4). 
Because 8-hydroxy-N-methyl-N-propargylaminotetra (DD9104) is an analogue of the 
~ - H T ~ A  agonist 8-OH-DPAT, it may also be a substrate for the ~ - H T ~ A  binding sites. 
Because oxidation by MAO-A constitutes the major route of elimination of 5-HT, the 
combination MAO-inhibiting properties and ~ - H T ~ A  selectivity can enhance the 
specificity as MAO-A inhibitor. 
4.3 Chemistry 
The synthesis of the target compound is outlined in Scheme 4.1. Condensation of 
8-methoxy-2-tetralone (7) with N-methyl-N-propargylarnine yielded the intermediate 
enamine 8. This enamine was reduced with sodium cyanoborohydride to the 8- 
methoxy-2-aminotetralin 3, and the latter was demethylated with BBr3 to yield the 
phenol 4. 
Scheme 4.1. Synthesis of 8-hydroxy-2-(N-rnethy1-N-propargylamino)t (DD9104,4). Reagents: (a) 
N-methyl-N-proparsylamine, TsOH; @) NaBH3CN, H+; (c) BBr3. 
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4.4 Results and Discussion 
Brain dialysis. In the present study, we have examined the role of the test 
compounds on the regulation of striatal DA and 5-HT release and metabolism using in 
vivo brain microdialysis [13,14]. In a previous brain microdialysis study on selective 
MAO-inhibitors, only the in vivo effects on DA efflux md its DA metabolism were 
studied [15]. The effects of MA0 idubitors on the 5-HT release are of particular 
interest, because the therapeutic effects of these compounds may be mediated in part by 
their ability to enhance serotonergic transmission. To obtain measurable signals of 5- 
HT, 0.5 mmol/L of a serotonin reuptake inhibitor (imipramine) was added to the Ringer 
solution. 
With a dose of 45 pmoVkg of the selective MAO-B inhibitor L-deprenyl, the 
concentration of one of the major metabolites of DA, DOPAC (3,4-dihydroxypheny- 
lacetic acid) was decreased to 30% of the control values (Fig 4.2). This reduction was 
maintained for at least 24 h after administration of the drug. This result is in agreement 
with the results found by others [ 1 5,16,17]. 
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Figure 4.2. Effect of L-deprenyl(45 pmoVkg, i.p.) on the release of DA, DOPAC and 5-HIAA from 
the striatum of rats. Data represent percent of control values f SEM (n = 3) 
It has been suggested that deprenyl possesses: (a) some uptake inhibiting proper- 
ties [18] and (b) the ability to increase the dopamine turnover and (c) inhibition of 
metabolism. Therefore an increase in DA levels was expected [19]. However, the 
relevance of MAO-B for the metabolism of striatal DA remains unclear. As the 
extracellular concentrations of DOPAC were decreased the DA levels were uneffected 
by the doses used in this experiment. That deprenyl acts as an uptake inhibitor is 
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unlikely, since Butcher et al. [15] have shown that it does not inhibit amphetamine 
induced DA-efflux. 
The 5-HT (results not shown) and the 5-hydroxyindole acetic acid (5-HIAA) 
concentrations are not significantly changed by deprenyl. This is in accordance with the 
well-known MAO-B inhibitor activity of this compound and the fact that 5-HT is not a 
substrate for MAO-B. 
The results were more dramatic with the selective MAO-A inhibitor clorgyline 
(Fig 4.3). Clorgyline administration leads to a decrease of 5-HIAA and even to an 
almost complete disappearance of DOPAC. The latter results were expected as DA is a 
substrate both for MAO-A and MAO-B. However, in the shiatum Clement et a1 [17] did 
not find a decrease in levels of 5-HIAA in their in vivo voltametric studies 
In contrast to deprenyl, clorgyline was able to increase the DA and 5-HT 
concentration in the dialysate to 280% of controls. As stated earlier, DA is a substrate 
for both MAO-A and MAO-B and the relative concentration of MAO-A in the rat brain 
is higher than that of MAO-B. 
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Figure 4.3. Effect of  clorgyline (32 pmoVkg) on the release of DA, DOPAC, 5-HT and 5-HIAA from the 
striaturn of rats. Data represent percent of control values f SEM (n = 2-3). 
The effects of DD9104 (40 pmoVkg) in the same brain microdialysis test model are 
shown in Fig. 4.4. DA and 5-HT efflux was elevated maximally to 120% and 170% of 
controls, respectively. The extracellular concentrations of DOPAC and 5-HIAA were 
reduced to 40% and 63% of controls, respectively. Thus, the results observed for 
DD9104 are comparable to clorgyline but are less dramatic. However, compared to 
clorgyline, there is a shift in the ratio for the increase in 5-HT over DA extracellular 
concentrations. 
~ - H T ~ A  Agonist with MA0 Inhibiting Properties 63 
~ - H T ~ A  receptor agonists produce the "serotonin syndrome" consisting of a flat 
body posture, abduction of the hind legs, wet dog shakes, forepaw treading, and Straub 
tail. After i.p. injection (40pmolflng) of DD9104 (4) this 5-HT syndrome was observed. 
This ~ - H T ~ A  agonistic effects should give a decrease in 5-HT levels. Therefore, these 
results suggest that, possibly through the similarity with the ~ - H T ~ A  agonist 8-OH- 
DPAT, site-selectivity is introduced resulting in a relative stronger inhibition of MAO- 
A. 
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Figure 4.4. Effect of DD9104 (40 pmolkg i.p.) on the release of DA, DOPAC, 5-HT and 5-HIAA from 
the striaturn of the rats. Data represents percent of control values k SEM (n = 3). 
Binding experiments. The &ty for the ~ - H T ~ A  receptor was assessed by 
detennining each compounds Ki (nM) for the displacement of  HI-8-OH-DPAT from 
cortical ~ - H T ~ A  binding sites in vitro. The dopaminergic afflmiity was determined in 
vitro by determining the Ki (nM) for displacing [ 3 ~ ] - s ~ i ~ e r o n e  from membrane 
homogenates of calf striatum, which is a measure of D2 binding activity. 
Table 4.1 The ability of DD9103 and DD9104 to displace [ 3 H l - 8 - ~ ~ - ~ ~ ~ ~  and [3H'J-~ i~erone from 
~ - H T ~ A  [20,21] and D2 receptor sites [22], respectively. 
Compound Ki (nM) 
 HI-8-OH-DPAT [ 3 ~ ] - ~ ~ i ~ e r o n e  
DD9 103 19 NT 
DD9 104 10 1500 
8-OH-DPAT 3 
64 Chapter 4 
The results are shown in Table 4.1. As can be seen from the table, both 
compounds display a high af i ty  for the ~ - H T ~ A  receptor, however, with less potency 
than than 8-OH-DPAT. Furthermore, as expected, the phenol was slightly more potent 
than the methoxy analogue. Analogous to 8-OH-DPAT, DD9104 displayed a low 
affinity (KI 1500 nM) for the dopamine D2 receptor. 
DD9104 has the interesting combined activity of predominantly MAO-A over 
MAO-B inhibition and ~ - H T ~ A  agonistic activity. The compounds may be useful for 
the treatment of disorders in the central nervous system, especially those related to the 
dopaminergic and serotonergic systems. 
In conclusion, DD9104, discussed in this chapter, illustrates the advantage of 
designing enzyme inhibitors based on close structural analogues of substrates of the 
enzyme andlor receptor. Not only can these compounds function as irreversible 
inhibitors but, in the most favourable cases, they may be able to take advantage of other 
biological processes to achieve site-selectivity. Moreover, they have the potential to 
mimic the physiological effect of the (natural) substrate on which they are based. For 
example 4 is an ~ H T ~ A  agonist, as well as an inhibitor of predominantly MAO-A. 
DD9104 can become a useful tool for studying the full therapeutic potential of MA0 
inhibitors in depression. 
4.5 Experimental Section 
Melting points were determined with an Electrothermal digital melting point apparatus 
and are uncorrected. IR, NMR, and MS data were determined for all compounds and 
were evaluated as consistent with the indicated structures. These data are presented only 
where required for structural assignment. Infrared spectra were recorded on a Philips 
spectrophotometer, and only the important absorptions are given. The 300 MHz NMR 
spectra were recorded on a Varian XL-300 instrument. The chemical ionization (CI) 
mass spectra were obtained on a Finnegan 3300 system. For purity tests, TLC was 
performed on fluorescent silicagel plates developed in at least two different systems. 
For all the compounds, only one spot (visualized by UV light and I2 vapor) was 
obtained. Elemental analysis were performed in the Department of Chemistry, 
University of Groningen. Where elemental analysis are indicated results obtained were 
within 0.4% of theoretical values. 
&Methoxy-2-(N-methyl-N-propargylamino)-lnaphthalene (3). A 
solution of 8-methoxy-2-tetralone 7 (3 g, 17 mmol) and a catalytic amount of p-toluene 
sulfonic acid (1 mmol) in 60 mL of dry toluene was refluxed under nitrogen in a Dean- 
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Stark apparatus. After 5 h the volatiles were evaporated under reduced pressure to gave 
the enamine 8 (IR: C=C-N 1630 cm-1). The enamine was quickly dissolved in 75 mL of 
dry THF and 5 mL of methanol, acidified to pH 5 with ether saturated with gaseous 
HCl and rapidly reduced by sodium cyanoborohydride (1.6 g, 25 mmol). The resulting 
mixture was stirred at room temperature for 2 h, then freed from solvent in vacuo and 
taken up in a sodium carbonate solution. The aqueous solution was extracted four times 
with 40 mL portions of ether. The combined extracts were washed with brine, dried 
over MgS04 and evaporated in vacuo. The resulting oil was dissolved in dry ether, and 
ether saturated with gaseous HCl was added slowly to produce amine hydrochloride as 
a white solid. Recrystallization fiom ethanol-ether yield 2.3 g (86.6%): mp 193-195 "C; 
IR (KBr) 3210 cm-l (propargyl-H), 2500 (NH+), 1600 (Ar); NMR (CDCL3), base, 6 
2.2 (t, J=2Hz, lH, propargyl-H), 2.4 (s, 3H, N-CH3), 3.5 (d, J=2Hz, 2H, N-CH2), 3.8 
(s, 3H, OCH3); MS (CI + NH3) 230 (M+l). Anal. (C15H19NO.HCl) C, H, N 
8-Hydroxy-2-(N-methyl-N-propargylamino)-l,2,3,tetrahydronaphthalene 4. 
The methoxy compound 3 (0.56 g, 2.1 mmol) was dissolved in 30 mL dichloromethane, 
and the temperature was lowered to -60°C. An excess of a 1 M solution of boron 
tribromide (6 mmol) in dichloromethane was added. The reaction mixture was initially 
stirred for 1 h at a temperature between -30 and -40°C and was then allowed to rise to 
room temperature and the mixture was stirred for another 5 h. The reaction mixture was 
poured into water made alkaline by the addition of ammonia and extracted with ether ( 
4 x 30 mL). The organic layer was washed with brine (3 x 10 mL) and dried over 
magnesium sulfate. Removing of the solvent under reduced pressure yielded an oil with 
was converted to the HCl salt. mp 212-214 OC; IR (KBr) 3280 cm-1 (OH), 3230 
(propargyl-H), 2600 (NH+), 2125 (propargyl); NMR (CDC13), free base, 6 2.1 (t, 
J=2Hz, lH, propargyl-H), 2.4 (s, 3H, NCH3), 2.5 (d, J=2Hz, NCH2), 6.0 @r. s, lH, 
OH); MS (CI + NH3) 2 16 (M+ 1); Anal (C 14H 17NO.HCl) C, H, N. 
Brain dialysis and Surgery. On-line brain microdialysis in freely moving animals has 
been described previously [13,14]. In brief: rats were anaesthetized with chloral hydrate 
and placed in a stereotaxic frame. Holes were made in the temporal bones to allow the 
I-shaped canula to be inserted. The Qalysis device was fured on the head and the rat 
was given one day to recover. The experiments were done 24-48 h after implantation of 
the cannula. The inlet of the dialysis tube was connected to a Braun perfusor VI and the 
outlet to the injection valve of the HPLC apparatus by means of polyethylene tubing 
(inner diameter 0.28 mm). The sample valve was held in the load position for 20 min 
and was switched automatically to the inject position for 15 s. The sttiata were perfused 
with a Ringer solution (mM: 147 NaCl, 4 KCl, 1.2 CaC12 and 0.02 ascorbic acid) at 6-7 
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pVmin. The in vitro recovery of the probes for DA was approximately 12-15%. DA was 
assayed by HPLC with electrochemical detection. 
Displacement of the Specific Binding of  HI-8-OH-DPAT (S-HTl*) in Rat Brain 
Membranes [20,21]. 
The affinity of the test compounds for serotonergic receptors can be found from binding 
studies using  HI-DPAT as ligand. This assay which was performed with homogenized 
and washed membrane preparations from rat frontal cortex was carried out as described 
previously [20,21]. 
Displacement of the Specific Binding of [ 3 ~ ] - ~ ~ i ~ e r o n e  (D2) in Calf Striatal 
Membranes [22]. 
This assay which was performed with homogenized and washed membrane preparations 
from calf striatal tissue, was carried out as described previously [22]. In each 
experiment the amount of B HI-spiperone bound was determined in the abscence (total) 
and presence (nonspecific) of 10-6 M (+)-butaclamol, the difference yielding specific 
 HI-spiperone binding. The ability to compete with [ 3 ~ ] - s ~ i ~ e r o n e  was tested over a 
concentration range of 10-11-104 M. 
Acknowledgement. The authors wish to thank Dr. I. van Wijngaarden and Dr. M.T.M. 
Tulp (Solvay-Duphar, Weesp) for performing the ~ - H T ~ A  radioligand-binding assays. 
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CHAPTER 5 
SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF THE 
HEXAHYDRO-4H-NAPHTH[1,2b][1,4]-OXAZINES: A NEW SERIES OF 
POTENT DOPAMINE RECEPTOR AGONISTS. 
Summary. The synthesis in 8 steps of a new series of potent dopamine @A) agonists, 
the trm-hexahydro-4H-naphth[l,2b][l,4]oxazines (3), is described. The yields of all steps are 
good to excellent. The dopaminergic activity of these new compounds was evaluated in rats in 
three test systems, i.e. for the ability to displace the specific in vitro binding of [~H]-DP-s,~- 
ADTN to rat brain homogenates, for the effects on DA metabolism in the corpus striaturn and 
for their ability to induce stereotypy. The activity of trans-N-n-propyl-9-hydroxy- 
2,3,4a,5,6,lOb-hexahydro-4H-naphth[l,2b][l,4]oxe (N-0500) was found to be comparable 
to that of the known potent DA agonists RU 29717. 
5.1 Introduction 
Certain trans octahydrobenzo[flquinolines (1) (Fig 5.1) have been shown to be 
potent dopamine receptor agonists [I-51. However, the main problem in working with 
these compounds is that the synthetic procedures involve time consuming separations of 
cis and trans isomers resulting fiom reductions of intermediate enamides. Anderson et 
al. [6] and Nedelec et al. [7] have shown that certain trans oxaergolines (2) also behave 
as potent dopaminergic agonists in the CNS. Because no difficulty had been encounte- 
red in the preparation of the trans isomers of the latter compounds and due to our 
interest in oxygen isosteres [8] we decided to synthesize and investigate the 
dopaminergic activities of various Zoxa analogues of trans octahydrobenzo[fJquinoline 
i.e. the trans-hexahydro-4H-naphth-[1,2b][l,4]oxazines (3). 
Figure 5.1. Structures of the octahydrobenzo[flquinolines (I), oxaergolines (2), and the naphthoxazines 
(3). 
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In a preliminary communication we have described some of the pharmacological 
properties of these new compounds [9]. During the course of this work a patent by 
Jones [lo] appeared which described a somewhat similar approach to the synthesis of 
the above compounds. However, full experimental details of the methods of synthesis 
and the physical and chemical properties of the three compounds described in this 
paper have not been reported by Jones. In addition our yields (above 70%) of final 
products in the last step are very much better than those reported in the patent of Jones. 
5.2 Chemistry 
The trans amino tetralols 7 have been prepared by the use of known methods 
[11,12], using the corresponding a-tetralones 4 as starting material. The a-tetralones 
were allowed to react with n-butyhtrite and potassium ethoxide to yield the 2- 
hydroxymino-1-tetralones 5 (Scheme 5.1). 
a. R' = R' = H 
b. R' = OCH,, R2 = H 
c. R' = H, R2 =OCH, 
Scheme 5.1. Synthetic route to the trans-aminoalcohols 7. Reagents: a BuONO, KOEt; H2, Pd- 
BaS04; NaBH4. 
The latter compounds were reduced over a palladium-barium sulfate catalyst to 
yield the Zamino-1-tetralones 6. Reduction with sodium borohydride led exclusively to 
the trans 2-amino-1-tetralols 7, as established by the presence of a doublet in the NMR 
spectrum at 6 4.2 ppm (J = 8.5 Hz; diaxial protons). These values are in full agreement 
with those reported for similar structures [13,14]. 
Treatment of 7 with chloroacetyl chloride yielded the chloroacetamides 8 
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(Scheme 5.2). Reaction of 8 with sodium hydroxide resulted in a ring closure leading to 
the lactams 9. Reduction of these lactams with LiAlH4 yielded the amines 10. 
Allcylation of the latter amines with n-propyl iodide gave the tertiary amines 11. 
R hH 6,) R i b 3 - c c 3 * 7  LJ a. R' = R' = H b. R' = OCH,, R2 = H 
c. R1 = H, R* =OCH, 
I Oa-c l la -c  
Scheme 5.2. Synthetic route to the N-propylnaphthoxazines 11. Reagents: a ClCH2COC1, NaOH; b 
NaOH; LiAlH4; n-C3H71. 
Selective cleavage of the methoxy group without significantly affecting the 
morpholine ring system was achieved by the use of boron tribromide at low 





Scheme 5.3. Dernethylation with BBr3 to rnonohydroxynaphthoxazines 3a and 3b. 
5.3 Results and Discussion 
The primary advantage of this new series of dopamine agonists from a synthetic 
point of view is that no difficulties were encountered in preparing the trans isomers. 
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This was our initial objective as it has been shown that the isomeric trans octahydro- 
benzo[flquinolines (1) are potent dopamine agonists whilst the cis isomers are virtually 
inactive [2]. As previously mentioned [2,3,4] the main chemical problem with the latter 
compounds is the need for a laborious chromatographic separation of the cisltrans 
mixture. Most of the yields in the present series are good to excellent, and although we 
had envisaged possible problems with the selective demethylation of the methoxy 
group in the last step, due to the presence of a second ether function in the molecule, 
this step was also achieved in a yield of 73%. 
In addition to the octahydrobenzo[flquinolines (I), comparisons may also be made with 
the oxaergolines (2). In this case the hexahydro-4H-naphth[1,2b][l,4]oxazines (3) 
possess the advantage that one can readily prepare various phenolic and catecholic 
analogues of the basic system, i.e. they have a dimension of isomeric variability that is 
probably harder to achieve with the indolic analogues. 
Table 5.1. Dopaminergic activity of N-propyl-hexahydronaphthoxazine analogues in comparison with 
the indolic structural analogue RU 29717 (2). a IC50 (nM) in rat striatal membrane homogenates; 
values are the mean of 3 independent experiments, each analyzed in triplicate over a concentration 
range of 10-I - M [15]. Percentage decrease of striatal HVA concentrations vs controls (1.01 * 
0.05 pg/g tissue, wet weight) following 0.4 pmoykg i.p. of test compounds after 1 h; expressed as 
mean s.e.m., n = 8 [16]. Dose (pmoVkg, s.c.) inducing a state of continuous sniffing behaviour in 
rats, corresponding to a score of 2 according to Costal1 et a1 [17]. d Lowest active dose (i.p.) inducing 
stereotyped behaviour; data calculated fkom results of Boissier [IS]. e ED50 values represent the dose 
in pmoYkg i.p., producing 50% reversal of DOPA accumulation and were determined graphically from 
the log dose-effect curves, in which each point represented the mean DOPA content of 8 striata. 
Test procedure N-0500 N-0499 N-0498 RU 29717 
(9-OH) (7-OH) (non-OH) 
[~HIDP-5,6-ADTN bindinga 2.8 80. 110 3.0 
HVA decreaseb 56 k 2 14*7 1 5 k 3  5 6 k 2  
stereotyp yc 0.50 7.5 ND 0.50d 
GBL-DOPA' 0.090 0.86 ND 0.030 
Four tests of dopaminergic activity were used, i.e. rat brain striatal homovanillic 
acid (HVA) decrease and the antagonism of GBL-induced rise in dopa levels, both of 
which reflect presynaptic dopaminergic activity [26], induction of stereotypy in rats, 
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which is an indication of post-synaptic dopaminergic actions [27] and finally inhibition 
of the in vitro binding to rat striatal homogenates of [~HIDP-5,6-ADTN, which is a 
measure of D2 DA affinity [15]. 
In all four test models N-0500 was found to be equipotent to RU 29717, whilst N- 
0498 and N-0499 were much less active (Table 5.1). It is of interest that, with regard to 
the first two tests, N-0498 and N-0499 do not differ in potency. Thus, the 7-OH group 
does not appear to increase the dopaminergic activity of the basic ring system. RU 
29717 has been shown to be the most potent compound within a series of oxaergolines 
prepared by Anderson et al. [6] and by Nedelec et al. [7], who reported that it had a 
potency comparable to that of pergolide. 
In addition, a l l a2  adrenergic and 5-HT115-HT2 affinities were investigated in 
vitro by studying the ability of the compounds to displace [3Hlprazosin, [3~]clonidine, 
[3~]5-HT and [3~]mianserin binding to rat membranes, respectively [24]. 
Table 5.2. IC50 values of selected dopamine agonists and reference dopamine agonists in 
various receptor binding models. aDisplacement of [3~]~razozin binding to rat brain membranes. 
Values are the mean of 3 independent experiments in triplicate. b~isplacement of [3~]~ lonid ine  to rat 
brain membranes. Number of experiments as in a. I C ~ O  clonidine = 2.9 nM. CDisplacement of [3~] -5-  
HT binding to rat frontal cortex membranes. Number of experiments as in a. ICSO 5-HT = 2.5 nM. 
d~is~lacement of [3~]~ ianser in  binding to rat frontal cortex membranes. Number of experiments as 
in eBoissier et al. [18]. f~nderson et al. [6]. 
Compound Ic50 
[3H]~razosina  HI ~lonidineb 
  HI serotonin [3H]~ianserind 
N-0498 (non-OH) 7000 700 71 17000 
N-0499 (7-OH) 9000 1050 2100 15000 
N-0500 (9-OH) 34000 1500 480 12500 
RU 297 1 7 5100 72 25e 470 
Apomorphine 5900 500 > l0000f 7300 
The abilities of the various drugs to Inhibit the specific binding towards 5-HT1, 5- 
HT2, a 1  and a 2  sites are summarized in Table 5.2. The non-hydroxylated structure 
was the most potent compound of the naphthoxazines in the displacement of  HI-~HT, 
however, three times less effective as RU 29717. All the members of the 
naphthoxazines displayed a very weak affhity to the 5-HT2 binding site. From the data 
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it can be concluded that the naphthoxazines and in particular N-0500 showed a weaker 
a f f i  for a 1  and a2 binding sites than RU-29717. It can therefore be concluded from 
these binding experiments that especially the 9-OH isomer possesses not only very high 
a f i t y  for D2 receptors but it is more selective than the oxaergoline RU 29717 and 
much more selective than bromocriptine [25]. 
The f~nding that N-0500 was more potent than N-0499 agrees with the reported 
work on the octahydrobenzo[fJquinolines (OHB[flQ), where it has been shown that the 
9-OH isomer is a more potent DA receptor agonist than the 7-OH compound [1,2]. The 
absolute configuration of the active trans-7-OH-OHB[qQ is (4aS, 10bS) and Wikstriim 
et al. [19,20] have suggested that the active enantiomer of trans-9-OH-OHB[flQ has the 
(4aR, 1ObR) configuration, thus 9-OH-OHB[flQ must be turned around 180' in order 
to have the 9-OH group and the N-atom in the same relative position as that occuning 
in the 7-OH isomer when the latter binds to the DA receptor (Fig. 5.2.c7d). It is very 
likely that the active configurations of N-0499 and N-0500 correspond to those of the 
7-OH and 9-OH-OHB[flQ's respectively, and it therefore seems logical to suggest that 
N-0500 must also be turned around to fit the pharmacophore of N-0499 (Fig. 5.2.a7b). 
Similar differences in configurational geometry have been found for the 5-and 7- 
monohydroxy-2-aminotetralins [21]. Although Bach et al. [22] have stated that the 
pyrrole-ethylamine moiety is responsible for the dopaminergic properties of the ergots, 
it is interesting to note that the ergot analogue lergotrile is metabolically activated to 
13-OH lergotrile, thus the 13-OH group may correspond to the 9-OH position in the 
hexahydronaphthoxazines (Fig. 5.2.e) [19]. 
CI 
a. X = 0 (N-0499) b. X = 0 (N-0500) e. 13-OH IegotrOle 
c X = CH, (7-OH OHBNQ) d. X = CH2 (9-OH OHBmQ) 
Figure 5.2. Possible modes of receptor interaction of various classes of DA agonists. 
The present series of compounds is synthetically readily accessible and we 
conclude that N-0500 is a very interesting candidate for further preclinical research. 
Martin et al. [23] have independently reached the same conclusions, and they have 
stated that the (+)-enantiomer of N-0500 is the most potent dopamine agonist yet 
discovered. 
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5.4 Experimental section 
Melting points were determined with a Reichert melting point microscope and are 
uncorrected. Elemental analyses were performed in the Department of Chemistry, 
University of Groningen. Where elemental analyses are indicated, results obtained were 
within 5 0.4% of the theoretical values. Proton NMR spectra were recorded fiom a 
Perkin-Elmer R 24 60 MHz instrument. The chemical shifl values are with reference to 
tetramethylsilane which was used as internal standard. Infrared spectra were run on a 
Beckman Acculab 2. Mass spectra were obtained using a Finnigan 3300 system. All 
reactions were run under an atmosphere of nitrogen. 
Trans-2-chloroacetamido-7-methoxy-1,2,3,4-tetrahydronaphthalen-l-ol(8c) 
To 8.2 g (35.7 mmol) of the HC1 salt of the amino-alcohol 7c, dissolved in 400 mL 
dichloromethane, a solution of 10 g sodium hydroxide in 85 mL water was added. 8.2 g 
(72.6 rnmol) of chloroacetylchloride was then added dropwise and the mixture was 
stirred for 2 h at room temperature. The mixture was then poured into 200 mL water. 
The separate aqueous layer was extracted with dichloromethane (3 x 25 mL). The 
combined organic extracts were washed with water (3 x 50 mL) and thereafter dried 
over anhydrous magnesium sulfate. The solvents were removed under reduced pressure 
to yield a solid. The resulting solid was recrystallized from ethyl acetate and a yield of 
7.7 g (80%) of white crystals was obtained: mp 166-167" C; IR (KBr) 3250 cm-1 (NH, 
OH), 1650 cm-1 (CONH); NMR (CDC13) 6 4.6 (d, J = 8 Hz, lH), 4.1 (s, 2H, CH2C1), 
3.8 (s, 3H, OCH3); MS, m/e 2691271 (M+); Anal. C13H16N03Cl (C, H, N, Cl). 
Trans-2-chloroacetamido-1,2J,4tetrahydronaphthalen-l-ol(8a) [14] 
The chloroacetamide 8a was prepared from 7a as described above for the preparation of 
8c. Recrystalhation from ethyl acetate resulted in pure 8a (yield 78%): mp 138-140°C; 
IR (KBr) 3260 cm-l (NH, OH), 1655 cm-1 (CONH); NMR (CDCL3), 6 4.5 (d, J = 8 
Hz, lH), 4.0 (s, 2H, CH2Cl). 
Trans-2-chloroacetamido-5-methoxy-l,2,3,4-tetrahydronaphthalen-l-ol(8b) 
The chloroacetamide 8b was prepared fiom 7b according to the method used for the 
preparation of 8c. Recrystallization fiom ethyl acetate gave pure 8b (yield 77%): mp 
158-159°C; IR (KBr) 3280 cm-l (NH, OH), 1660 cm-1 CONH); NMR (CDC13) 6 4.6 
(d, J = 8 Hz, lH), 4.1 (s, 2H, CH2C1), 3.8 (s, 3H, OCH3); MS, m/e 2691271 (M+); 
Anal. C13H16N03Cl (C, H, N, Cl). 
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Trans-9-methoxy-2,3,4a,5,6,10b-hexahydro-4H-naphth[1,2b][1,4]oxazin-3-one (9c) 
To a solution of 6.4 g (23.7 mmol) of the chloroacetamide 8c in 300 mL of propanol-2 
a solution of 1.6 g sodiumhydroxide in 3.2 mL of water was added dropwise at room 
temperature. After stirring for 2 h at room temperature, the mixture was neutralized 
with 1 N HCl. The solvents were evaporated as much as possible and the resulting 
residue was slurried in 200 mL of water and extracted with 4 x 50 mL of 
dichloromethane. The organic layer was washed with water (3 x 50 mL), dried over 
magnesium sulfate and then reduced to dryness. Recrystallization from acetone-hexane 
gave the lactam 9c as white crystals. Yield 5.5 g (78.5%); mp 230-232 OC; IR (KBr) 
3 180 cm-1 (NH), 1670 (CONH); NMR (CDC13) 6 7.5 (br. s, lH, NH), 4.5 (s, 2H, 
COCH2N), 3.8 (s, 3H, OCH3); MS, mle 233 (M+); Anal. C13H15N03 (C, H, N). 
Trans-2,3,4a,5,6,10b-hexahydro-4H-naphth[l,2b] [1,4]oxazin-3-one (9a) 
The chloroacetamide 8a, was converted to the lactam 9a as described above for 9c. 
Recrystallization from acetone-hexane gave pure 9s (yield 81%): mp 217-219 OC (lit. 
213-215 "C) [14]. 
Trans-7-methoxy-2,3,4a,5,6,1Ob-hexahydro-4H-naphth[1,2b] [1,4]oxazin-3-one (9b) 
By using the procedure described for the lactam 9c, the chloroacetamide 8b gave the 
lactam 9b in a 75% yield after recrystallization from acetone-hexane: mp 275 OC (dec); 
IR (KBr) 2160 cm-l (CONH); NMR (CDC13) 6 4.5 (s, 2H, COCHzN), 3.8 (s, 3H, 
OCH3); MS, mle 233 (M+); Anal. C13H15N03 (C, H, N). 
Trans-9-methoxy-2,3,4a,5,6,10b-hexahydro4H-naphth[1,2b][1,4]oxazine (10c) 
To a stirred suspension of of LiAlH4 (2 g) in 50 mL of THF was added a solution of 
the lactam 9c ( 3.2 g, 13.7 mmol) in THF (50 mL). The reaction was heated at reflux 
for 3 h and then cooled to 10 "C. Excess LiAlH4 was destroyed by careful addition of 
2mL of water, followed by 2 mC of 4 N sodium hydroxide and a further 6 mL of water. 
The mixture was filtered and the solid washed with ether. The organic solvents were 
dried over magnesium sulfate and evaporated under reduced pressure. The resulting oil 
was dissolved in dry ether and HC1-ether was added slowly to produce the amine 
hydrochloride as a white solid. Recrystallization fiom ethanol-ether yielded 3.16 g (90 
%) of white crystals: mp 235-237 OC; NMR (CDC13), fiee base, 6 4.0 (d, J = 9 Hz, 
IH), 3.7 (s, 3H, OCH3), 2.5 (s, lH, NH); MS m/e 2 19 (hi+); Anal. C 13HlgN02Cl (C, 
H, N, Cl). 
Trans-2,3,4a,5,6,1Ob-hexahydro-4H-naphth[1,2b] [1,4]oxazine (10a) 
Reduction of the lactam 9a with LiAlH4 as described above for 10c gave the desired 
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amine. Conversion to the HC1 salt and recrystallization fiom ethanol-ether gave a yield 
of 82 % : mp 254-256 "C [14]. 
Trans-7-methoxy-2,3,4a,5,6,1Ob-hexahydro-4H-naphth[1,2b][1,4]oxazine (lob) 
Reduction of the lactam 9b with LiAlH4 as described above for 10c gave the desired 
amine. Conversion to the HC1 salt and recrystallization from ethanol-ether gave a 94 % 
yield of lob: mp > 275 "C (dec); NMR (CDC13), fiee base, 6 4.2 (d, J = 9 Hz, lH), 3.8 
(s, 3H, OCH3), 2.7 (s, lH, NH); MS, m/e 219 (M+); Anal. C13H18N02Cl (C, H, N, 
Cl). 
Trans-N-n-propyl-9-methoxy-2,3,4a,5,6,10hexahydr4H-naphth[l,2b][1,4]- 
oxazine (1 lc) 
Anhydrous potassium carbonate 4 g (34 mmol) and 8.5 g (50 mmol) of propyl iodide 
were added to a solution of 2.27 g (8.9 mmol) of the above mentioned amine 10c in 200 
mL of DMF. The mixture was stirred for 2 h at 55 "C and then poured into 300 mL of 
water and extracted with ether (5 x 50 mL). The combined organic layer was washed 
with saturated saline (4 x 20 mL) and once with a 10 % ammonium chloride solution 
(20 mL). The ether layer was then dried over magnesium sulfate and evaporated to 
dryness. The resulting oil was converted to the HCl salt of the amine. The yield after 
recrystallization fiom ethanol-ether was 2.2 g (83 %): mp 224-227 "C; NMR (CDC13), 
free base, 6 4.2 (d, J = 8 Hz, lH), 3.7 (s, 3H, OCH3), 0.9 (t, 3H, CHg-propyl); MS, m/e 
261 (M+); Anal. C16H24N@Cl (C, H, N, Cl). 
Trans-N-n-propyl-2,3,4a,5,6,10b-hexahydr4H-naphth[l,2b] [1,4]oxazine (1 la)  
The reaction was carried out as described above for 1 lc. Conversion to the HCl salt and 
recrystallization from ethanol-ether gave pure l l a  (yield 91 %): mp 228-230 OC; NMR 
(CDC13), fiee base, 6 4.3 (d, J = 8 Hz, lH), 6 1.0 (t, 3H, CH3-propyl); MS, d e  231 
(M+); Anal. C 15H22NOCl (C, H, N, Cl). 
Trans-N-n-propyl-7-methoxy-2,3,4a,5,6,1Ob-hexahydro-4H-naphth[1,2b][l,4]- 
oxazine (1 1 b) 
The reaction was performed as described above for 1 lc. Conversion to the HC1 salt and 
recrystallization fiom etheanol-ether gave pure l l b  (yield 87 %): mp 217-220 OC; NMR 
(CDC13), free base, 6 4.2 (d, J = 8 Hz, lH), 3.7 (s, 3H, OCH3), 1.0 (t, 3H, CH3- 




One g of the above amine salt l l c  was dissolved in 70 mL of dichloromethane and the 
temperature of the solution was lowered to -60 "C. 4.5 rnL of 1 molar solution of boron 
tribromide in dichloromethane was then added. The reaction was initially stirred for 2 h 
at a temperature between -30 and -60 "C, which was then allowed to rise to room 
temperature after which the reaction was stirred for a further 20 h. The reaction mixture 
was then poured into water (200 mL) and then made alkaline by the addition of a dilute 
solution of sodium bicarbonate. The separated layer was extracted with ether (4 x 50 
mL). The organic extracts were washed with saturated saline (3 x10 mL) and dried over 
magnesium sulfate. Removal of the solvents under reduced pressure yielded a semi- 
solid product. Conversion to the HC1 salt and recrystallization from ethanol-ether 
yielded 0.7 g (73 %) of pure product: mp >260 "C (dec); IR (KBr) 3200 cm-1 (OH); 
NMR (CDC13), fiee base, 6 6.2 (s, lH, OH), 4.3 (d, J = 8 Hz, lH), 0.9 (t, 3H, CH3); 
MS, d e  247 (M+); Anal. C15H22N02Cl (C, H, N, Cl). 
Trans-N-n-propyl-7-hydroxy-2,3,4a,5,6,1Ob-hexahydro-4H-naphth[1,2b] [1,4]- 
oxazine (l2a) 
The 7-methoxy derivative l l b  was 0-demethylated by use of boron tribromide in 
dichloromethane as described for 12b. Conversion to the HC1 salt and recrystallization 
fiom ethanol gave 12a. This compound was found to be pure by TLC analysis, and the 
NMR spectra were compatible with the assigned structure: yield 75 %; mp >275 "C 
(dec); IR (KBr) 3200 cm-l (OH); NMR (CDC13), free base, 6 4.3 (d, J = 8.5 Hz, lH), 
1.0 (t, 3H, CH3); MS (CI with NH3), m/e 248 (M + 1); Anal. ~ ~ ~ ~ ~ ~ ~ 0 ~ ~ 1 . 0 . 1 ~ ~ 6  
(C, H, N, CI). 
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CHAPTER 6 
SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF 
THE ENANTIOMERS OF trans-9-HYDROXY-4-N-n-PROPYL- 
2,3,4a,5,6,10 b-HEXAHYDRO-2H-NAPHTH [1,2b] [I ,4] -0XAZINE 
6.1 Introduction 
Racernic $-substituted hexahydronaphthoxazines have been shown to be very 
potent and selective dopamine (DA) D2 receptor agonists [l-41. Because of the 
strikingly different pharmacological actions of the enantiomers of some drugs, e.g. N- 
0437 and 3-PPP [5,6], we have synthesized the enantiomers of trans-9-hydroxy-4-N-n- 
propy1-2,3,4~5,6,10b-hexahydro-2H-naphth[1,2b][1,4]-oxazine (1) (PHNO, N-0500) 
the most potent derivative of this series. The effects of local infusion of the two 
enantiomers of PHNO on the release of DA by means of brain microdialysis are studied 
[9,101. 
6.2 Chemistry 
The synthetic strategy used for the construction of the oxazine ring has been 
described in chapter 5. The racemic amine 1 was resolved by fractional crystallization 
of the diastereomeric salts obtained with the enantiomers of the two 4-phenyl-5,5-dime- 
thyl-2-hydroxy-1,3,2-dioxaphosphorane-2-odes (2a, phencyphos; 2b, 2-chlocyphos) 
[71. 
One crystallization yielded optically pure products. The enantiomeric excess of 
the amines could be determined through [31~]-NMR and  HI-NMR spectroscopy 
(integration of the signals of the benzylic proton of the phosphoric acid) using the 
adduct of the acid chloride of 2a (Scheme 6.1). This acid chloride was readily prepared 
by reaction of phosphorus pentachloride with the corresponding phosphoric acid. 
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Scheme 6.1. Formation of diastereomeric amides 4. Reagent (a) is acid chloride of the phosphoric acid 
2a. 
The steps of the reactions with the enantiomers were carried out exactly as 
described in Chapter 5 (Scheme 6.2). The enantiomeric purities of (+)-PHNO ((+)-1) 
and (-)-PHNO ((-)-I) were determined by the Analytical Pharmaceutical Department of 
the University of Uppsala using the method described by Karlsson et al. [8] and were 
found to be >99.2 and >99.6%, respectively. 
Scheme 6.2 
After performing the resolution by fractional crystallization, Melillo et al. [13] 
have published a simple enantioselective route to the (R,R)-4-propyl-9- 
hydroxynaphthoxazine (Scheme 6.3). The key step in their synthetic route was the 
acylation of 2-chloroanisole with (R)-aspartic anhydride, wherein chlorine acts as a 
removable, directing group. Cyclization of the (R)-homotyrosine derivative to the 
tetralone and reduction to the tetralol occured with preservation of the configuration. 
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However, the method we used is more efficient for research purposes, because 
fiequently also the other enantiomer has interesting properties, e.g 3-PPP [I 31 
NHC0,Y. 
a 0 NHC0,Mo 
C 
"aC woo> "aC HC0,Me 
AICI, - CI 4 steps 6~ 
7 stops I 
(4aR,lObR)-1 
Scheme 6.3. Enantioselective synthesis of (+)-PHNO according to Melillo et el. [ll] 
6.3 Results and Discussion 
, . , . , . , . , . (  infusion 
-30 0 90 m m 120 
T i e  (min) 
Figure 6.1. Effect of 10-7 M infusion of the enantiomem of PHNO (1) on DA release from the 
striatum. The results are means +- SEM of data obtained from 3-4 rats. 
Infusion of 10-6 M solution (+)-PHNO (Fig 6.1) induced a 60% decrease in the 
release of DA. Doparnine levels returned to control values within 1 h after cessation of 
infusion. (-)-PHNO displayed at this concentration no effect on the DA release. These 
results are in agreement with the findings of Timmerman et al. [12]. However, they also 
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tested (+)-PHNO at lower concentrations, and found the same decrease with a 10-7 M 
infusion. Infusion at 10-8 M (+)-PHNO still induced a decrease of 25%. A higher 
concentration of (-)-PHNO (10-5 M) displayed a weak DA agonistic activity, as 
manifested by a small decrease (25%) in DA release. 
The displacement of  HI-N-0437 [14] from calf striatal membranes supported 
the biochemically established stereoselectivity of the enantiomers of PHNO. The IC50's 
for (+)-PHNO and (-)-PHNO were respectively, 23 and 3200 nM, 
6.4 Experimental Section 
Melting points were determined with an Electrothennal digital melting point 
apparatus and are uncorrected. Specific rotations were determined at 20°C on a Perkin 
Elmer 241 polarirneter. Concentrations (c) for specific rotations are reported in units of 
g/100 mL. IR, NMR, and MS data were determined for all compounds and were 
evaluated as consistent with the indicated structures. These data are presented only 
where required for structural assignment. Infrared spectra were recorded on a Philips 
spectrophotometer, and only the Important absorptions are given. The 300 MHz NMR 
spectra were recorded on a Varian XL-300 instrument. The chemical ionization (CI) 
mass spectra were obtained on a Finnegan 3300 system.  HI-NMR spectra were 
recorded on a Perkin-Elmer R-24B spectrophotometer. [31~]-NMR spectra were 
recorded on a Nicolet NT-200 spectrophotometer. 
(4aR,lObS)- and (4aS,lbS)-(+)- Trans-9-methoxy-2,3,4a,5,6,1Ob-hexahydro-4H- 
naphth[l,2b][1,4]oxazine (+)- and (-)-3 
A mixture of 1.65 g (7.53 mmol) amine 1,2.1 g (-)-phosphoric acid (2b, 2-chloro, 7.59 
mmol), and 175 rnL of 2-propanol was heated until solution take place. The heating 
mantle was removed, and the solution was allowed to cool to room tempertature with 
stirring. After 5 h, the product was sucked off and washed with a litle cold 2-propanol 
to gave 0.7 g (1.41 mmol, 19%) of the salt with [a1578 +65.7'. This salt was stirred for 
0.5 h with 1 g NaOH dissolved in 25 mL of water, then chlorofonn was added, and the 
mixture stirred for additinal 30 min. The layers were separated, and the aqueous layer 
extracted with chloroform. The combined chloroform layers were washed with water, 
dried over MgS04, and evaporated to gave an oil. Yield 320 mg amine (+)-3 (1.46 
mmol, 19%) with [a1578 +120e. The filtrate after evaporation under vacuo and 
treatment of the residue with NaOH solution and chloroform gave impure amine. This 
amine, 1.49 g (+)-phosphoric acid (2a, phenyl, 6.16 mmol), and 37 mL of 2-propanol 
was heated to solution. According to the procedure as described above, 1.28 g salt was 
obtained with [a1578 -21.3" (2.78 mmol, 37%). Treatment with alkaline gave 650 mg 
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the amine (-)-3 with [a1578 -121.3O. From the filtrate, there was obtained another 530 
mg amine (+)-3 (2.42 mmol, 32%) with [a1578 +73.3 (optical purity = 60%). 
Determination of the optical purity. 
The amine (+)-3 200 mg (0.9 mmol) was dissolved in 7 mL of THF and cooled to -35 
OC, and 0.65 mL (1 mmol) n-butyllithium was added. The mixture was stirred for 25 
min while the temperature raised to -10 "C (yellow-orange solution), then 260 mg (-)- 
acid chloride was added. The solution was stirred for 5 min by -10 OC and for 16 h by 
room temperature. The colourless solution was then poured into 25 mL of water and 
extracted with chloroform (3x10 mL). The combined layer was washed with water, 
dried over Na2S04 and concentrated (yield 360 mg, >95%). Afterwards the 
enantiomeric excess was determined fiom the NMR spectra of the diastereomeric 
amides. The decoupled [ 3 1 ~ ]  NMR spectrum showed a 0.18 ppm difference between 
the amides (1.425 and 1.248 ppm), and the benzylic proton of the phosphoric acid 
showed in the IH NMR spectrum showed a 0.09 ppm difference (6 5.15 and 5.05 ppm). 
The enantiomeric purity determined was according this method was > 98%. 
(4a~lObS)-(+)-Trans-9-methoxy-N-n-propyl-2,3,4a,5,6,1Ob-hexahydro-4H- 
naphth[l,2b]l,4]oxazine (+)-5 
Anhydrous potassium carbonate (0.8 g, 5.7 mmol) and 1.7 g (10 mmol) propyl iudide 
were added to a solution of (+)-3 (0.38 g, 1.73 rnmol) in 40 mL DMF. The mixture was 
stirred for 2 h at 55 OC and then poured into 100 mL of water and extracted with ether 
(5 x 25 mL). The combined layers were washed with brine, dried over magnesium 
sulfate and evaporated to dryness. The resulting oil was converted to the HCl salt. The 
product was dried in vacuo to afford 460 mg (89%) of (+)-5.HC1 as a white solid, 
having the same characteristics as racemic 5. An analytical sample was recrystallized 
fiom ethanol-ether: mp 2 19-22 1 "C; [a]589+ 47.g0(c 0. I, EtOH), lit 47.2" [13]. 
(4aS,1ObS)-(->Trans-9-methoxy-N-n-propyl-2,3,4a,5,6,1Ob-hexahydro-4H- 
naphth[l,26] 1,4]oxazine (-)-5 
The reaction was carried out described above for (+)-5. Recrystallization fiom ethano- 
ether gave pure (-)-5.HCL (yield 73.6%); mp 222-224 "C [a1589 -48.4" (c 0.5, EtOH). 
(4aR,1ObR)-(+)-Trans-9-hydroxy-N-n-propyl-2,3,4a,5,6,1Ob-hexahydro-4H- 
naphth[l,2b]1,4]oxazine (+)-I 
The methoxy compound (+)-5 (100 mg, 0.34 mmol) was dissolved in 20 rnL of 
dichloromethane and the temperature was lowered to -60 OC. 0.4 mL of an 1 M boron 
tribromide solution in CH2C12 was added and the reaction was initially stirred for 2 h at 
a temperature between -30 and -60 OC, which was then allowed to rise to room 
temperature after which the reaction was stirred for a further 20 h. The reaction mixture 
was then poured into 30 mL of water and made alkaline by the addition of a solution of 
sodium bicarbonate. The separated layer was extracted with ether (4 x 15 mL). The 
organic layer washed with brine, dried over magnesium sulfate and concentrated in 
vacuo. Conversion to the HC1 salt and recrystallization from ethanol yielded 65 mg 
(65.1%): mp > 250 OC, mp (base) 157-159 "C; [a1589 +59.0° (c 0.1, MeOH), lit. [ a  
1589 +55.9' [4]. Enantiomeric purity > 99.2% [8]. 
(4aS,1ObS)-(-)-Trans-9-hydroxy-N-n-propyl-2,3,4a,5,6,1Ob-hexahydro-4H- 
naphth[1,26]1,4]oxazine (-)-I 
Demethylation of the methoxy compound (-)-5 as described above for (+)-5 gave the 
desired phenol. Conversion to the HCl salt and recrystallization from ethanol gave a 
yield of 70%: mp (base) 156-158 OC; HCl salt > 250 OC [a1589 -58.8' (c 0.1, MeOH). 
Enantiomeric purity > 99.6% [8]. 
Micro Brain Dialysis and Surgery. 
On-line brain microdialysis in fkely moving animals has been described previously [9, 
101. In brief: rats were anaesthetized with chloral hydrate and placed in a stereotaxic 
frame. Holes were made in the temporal bones to allow the transstriatal dialysis probe 
to be inserted. The dialysis device was fixed on the head and the rat was given one day 
to recover. The experiments were done 24-48 h after implantation of the cannula. The 
inlet of the dialysis tube was connected to a Braun pe&sor VI and the outlet to the 
injection valve of the HPLC apparatus by means of polyethylene tubing (inner diameter 
0.28 mm). The sample valve was held in the load position for 20 min and was switched 
automatically to the inject position for 15 s. The striata were perfused with a Ringer 
solution (mM: 147 NaCl, 4 KCl, 3.4 CaC12 and 0.02 ascorbic acid) at 6-7 pYmin. The 
in vitro recovery of the probes for DA was approximately 12-15%. DA was assyed by 
HPLC with electrochemical detection. 
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CHAPTER 7 
SYNTHESIS AND PHARMACOLOGY OF trans-4-n-PROPYL 
-3,4,4a,lOb-TETRAHYDR0-2H,5H-l-BENZOPYRANO- 
[4,3b] [1,4]-OXAZINE-7- AND 9-OLS: THE SIGNIFICANCE OF 
NITROGEN pKa VALUES FOR CENTRAL DOPAMINE 
RECEPTOR ACTIVATION. 
Summary. The 6-0xa analogues of potent dopamine agonists, hexahydronaphthoxazines (44 
4b), have been tested for dopamine receptor binding and stimulating activity, and were found to be 
almost inactive. pKa value detenninatim indicated that these compounds are protonated to -2%, 
whereas potent compounds are protonated to a much greater extent. To obtain further evidence, the 
(under physiological conditions nonprotonated) $-naphthylamines (6) were also prepared and biologically 
tested. They were found to be inactive. The results of this study strongly support the assumption that the 
protmated fom of DA agonists is the active species at the receptor. 
7.1 Introduction 
Several reviews outlining the structural requirements for agonist activity at 
dopamine receptors have been published [1,2,3]. Current models of both the Dl and D2 
receptor are based on a model proposed by McDermed et al. [4] and Tedesco et al. [ 5 ] ,  
who studied the dopaminergic activity of some Zaminotetralins. The main features of 
this model include binding sites for the basic nitrogen and the meta-hydroxyl group of 
the 2-aminotetralins. It also contains a zone of steric intolerance. In the literature there 
is a controversy about the role of the nitrogen atom at the receptor. It has been proposed 
that the basicity of the amine is a critical factor in activating the receptor [6]. Some 
studies indicate that an uncharged nitrogen atom is required for binding [7,8], whereas 
others have reported that a charged form of the nitrogen atom is a prerequisite for 
activity [1,9]. Nichols [lo] has suggested that the real importance of this atom lies in 
the orientation of its unshared electron pair, whether fiee or protonated. An optimal 
receptor interaction might be dependent on the orientation of the unshared pair. Despite 
all these suggestions, the nitrogen atom will exist mainly in the protonated form at 
physiological pH. The most direct evidence for the suggestion that the charged form of 
the nitrogen atom is of importance comes from the work of Miller et al. [11,12], who 
have prepared the dimethylsulfoniurn analogues of dopamine and ADTN, and have 
shown that these compounds possess D2 receptor agonistic activities, whereas their 
non-charged counterparts display no such activities. Cannon [l] has defined the a- and 
D-conformers of dopamine (la,b), in which the catechol ring is coplanar with the plane 
of the ethylatnine side chain, and he proposed that these conformations represent two 
different DA agonist receptor interactions. 
a-conformers pconformers 
kc,H7 6a. R = n-C3H7 
I b. R 5 phenylethyl 
6a-b R 
Figure 7.1 Structures of various dopaminergic compounds. Dopamine (I), aminotetralins (2), 
chro-s (3, naphthoxazines (4), W p y r a n o W e s  (5), and naphthylamines (6). 
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Results fiom various groups [I, 13,141 working with semi-rigid analogues of DA, 
such as the 2-aminotetralins, have shown that phenolic groups at the 5 and 7 positions 
yield analogues with high dopaminergic activity. In addition, a N,N-dipropyl substituent 
pattern has also been found to provide maximum potency (2a,b). It has been shown that 
the isosteric replacement of the methylene group at C4 in the 2-aminotetralins by an 
oxygen atom yields a potent DA agonist, the 3-chromanamine (3a) [16]. 
Encouraged by the interesting pharmacological profile of the trans-hexahydro- 
naphthoxazines (4a,b) [17,18] and 3-(dipropy1amino)-3,4-dihydro-2H-1-benzo- 
pyran-&ol(3a) [16] we have combined elements of the structures of 3 and 4 and have 
prepared the 6-oxa analogues of 4, i.e. the tram-4-n-propyl-3,4,4a,lOb-tetrahy- 
dro-W,5H-1-benzopyrano[4,3b][l,4]-oxazin7- and 9-01s (PTBO, 5a,b). These 
particular compounds were chosen because an inspection of molecular models of the 
trans-octahydrobenzo[f]quinolines and the tram-hexahydronaphthoxazines and the title 
compounds reveal a close similarity in shape and size, as well as a locational 
correspondence between the hydroxyl and amine functions. To complete the series, the 
D-conformer 3-(dipropylamin0)-3,4-dihydro-2H-l-be~-6-01 (3b) was also 
prepared. For the same reason, the two P-naphthylamine derivatives 6 were also 
synthesized. Because it is fully aromatic, with a planar ring system, the amino group 
can adopt a position in reasonable agreement with the equatorial position in the most 
stable conformations of the semi rigid compounds 1-5. In 6,7-di-OH-ATN for example 
N lies in the plane of the aromatic ring [27]. 
Because lipophilicity has an important impact on dopaminergic potency, log P 
values for these compounds were determined. In addition, due to the possible influence 
of the isosteric change on the basicity of the nitrogen atom, pKa values were also deter- 
mined. The in vivo dopaminergic activity of the compounds was evaluated by studying 
their effects on the stereotypy in rats and also for their effects on DA turnover. 
Compound 4b was also tested for its pharmacological action on DA D2 autoreceptors in 
vivo, by measuring DA release by on-line brain microdialysis in fieely moving rats with 
local administration. Their in vitro affinities were evaluated by examining their ability 
to displace [ 3 ~ ] - ~ ~ - 5 , 6 - ~ ~ ~ ~  and [ 3 ~ ] - - 0 4 3 7  from striatal (rat, calf) membranes. 
7.2 Chemistry. 
The synthesis of the 1-benzopyrano-1,4-oxazines 5 is outlined in Scheme 7.1. 
We started with the known 4-chromanones 7, which were readily converted into the 
tosyl oximes 9. Neber rearrangment of 9 with sodium ethoxide afforded the desired 
amino ketone 10, which was isolated as the hydrochloride in good yields. The fiee base, 
however, decomposed immediately upon liberation from its salt. Without purification, 
the amino-ketones were acylated with chloroacetyl chloride. When 11 was reduced with 
sodium borohydride a two-component mixture 12 was obtained. The mixture was read- 
ily separated by medium-pressure flash chromatography using hexane-ethyl acetate 
(1:l) as eluent. The compound with the lower Rf value, obtained in 75% yield was the 
trans component (J=8Hz, diaxial protons). The faster moving component (25%) was the 
cis-chloroacetamide (J=3Hz). 
l l a -b  12a-b 13a-b 
a. RI = H, R' = OCH, 
b. R' = OCH,, R2 = H 
Scheme 7.1. Synthetic route to the monohydroxy-benzopyranoxazines 5.Reagents: a NH2OH ; TsCI; 
c NaOEt, HCl, H20; d ClCH2COCl; e NaBH4; N~OH;  g LiAlHq; C3H7I; BBq. 
The cyclization of the chloroacetamide 12 by means of 50% NaOH in iso-propanol at 
room temperature gave satisfactory yields of the cyclized derivative 13, which in turn 
was reduced with LiAlH4 to the oxazine 14. Alkylation of the amine with propyl iodide 
in DMF afforded the tertiary amine 15. Cleavage of the rnethoxyl group in 15 was 
achieved without significantly affecting the two other ether functions in the molecule 
by using BBr3 at a low temperature. 
The 3-dipropylamino-3,4-dihydro-2H-l-benzop~ (3b) was readily prepared 
from one of the intermediates in the synthesis of 5 (Scheme 7.2) according to a 
modification of the method described by Horn et al. [16]. 
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Scheme 7.2. Synthetic route to 6-hydroxy-3-(N,N-dipropy1amino)benzopyra 3b. Reagents: a Ac20; 
H2, Pd-C; c HCI; C2H5COOH, NaBH4; BBr3. 
The most staightforward synthetic route to 6a and 6b is the Bucherer reaction 
(Scheme 7.3). 
Scheme 7.3. The Bucherer reaction. 
5-Methoxy-2-naphthol is converted to the amine 18, followed by alkylation of the 
amino group. However, this reaction needs rigorous reaction conditions and the starting 
material is not commercially available. 
Therefore we have chosen the route outlined in Scheme 7.4. The starting material, 5- 
methoxy-B-tetralone 19, was converted to the enatnines 20. These enamines were 
oxidized with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to the correponding 
naphthylamines 21. The aromatization of 20 with DDQ was a reaction free from side 
products. Demethylation was performed at low tempeature with boron tribrornide. 
?-C,H7 ?4,H7 qyO& \ q y " - R L 4 V  \ \ / 
OCH, OCH, OCH, 
19 20a-b Zla-b 
Scheme 7.4. Synthetic route to the P-naphthylamines 6. Reagents a dialkylamine, p-TsOH; DDQ; 
BBr3. 
7.3 Results and Discussion 
Dopamine D2 receptor binding affinity was determined in vitro as the ability of 
the test componds to displace [ 3 ~ ] - ~ ~ - 5 , 6 - ~ ~ ~ ~  [19], CO HI-N-0437 [20] and  HI- 
spiperone [2 1) from calf striatal membranes. The results are summarized in Table 7.1 
Table 7.1. Affinties of various structural classes of dopamine receptor agonists as measured by their 
ability to displace [%I-DP-5,6-ADTN from rat striatal membranes [19], [ 3 ~ - ~ - 0 4 3 7  [20] and [3m- 
spiperone [21] from calf striatal membranes. The values are the mean of 3 determinations in triplicate 
over the concentration range of 10-1 1~ - 1 0 4 ~ .  
compound IC50 (nM) 
 HI-DP-5,6-ADTN  HI-N-0437 [3~]-spiperone 
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As can be seen from Table 7.1, the 1-benzopyrano-oxazines exhibited a very 
weak D2 binding &ty. The naphthylamines did not display any D2 receptor affi iy.  
Determination of brain striatal HVA and DOPAC decreases, both of which 
reflect presynaptic dopaminergic activity [15], and the induction of stereotypy, which is 
an indication of postsynaptic dopaminergic actions [22], were used as in vivo models. 
For compounds 5a, Sb, 6a and 6b there was no decrease in striatal HVA and DOPAC 
levels, and these compounds were also incapable of inducing stereotypy, even at doses 
up to 40 pmoVkg (6a, 6b) (Table 7.2). 
Table 7.2 In vivo effects of various dopamine receptor agonists on the concentration of the dopamine 
metabolites DOPAC and HVA in rat striaturn and on the induction of stereotypy. aCompounds were 
administered i.p. 1 h before termination, h h e  EDjo value for stereotypy is the dose (pol lkg)  needed to 
induce a continuous sniffing behaviour in rats, corresponding to a score of 2 according Costall et al. [22]. 
CValues taken from ref [25]. d~alues  taken from ref [18]. eI = Inactive. NT = not tested. 
compound dose (pmolkg) rat brain concentrations f SEM stereotypyb 
(YO of controls) ED50 
DOPAC HVA 
The very weak activity of 5a-b compared with the aminotetralins 2, 
chromanamines 3 and the naphthoxazines 4 cannot readily be explained simply on the 
basis of molecular conformations. An inspection of the molecular models of the 
chromanamines 3, the trans-naphthoxazines 4 and the trans-1-benzopyranoxazines 5 
reveal a close similarity in size and shape as well as in location of the hydroxyl and 
amino functions. In these in vivo experiments, 40 pmol/kg (i.p.) of the naphthylamines 
6a and 6b did not induce any stereotypy or any changes in the concentration of DA or 
its metabolites. 
In order to investigate the effect of the introduction of one or two oxygen atoms 
on the physicochemicd properties of these compounds, we have determined their 
partition coefficients (log P values) and ionization constants @Kd (Table 7.3). 
Table 7.3. Partition coefficients (log P) and ionization coostants ( p Q  for various dopamine agonists 
The pK, values were determined according to the method of Albert and Serjeant [23]. The values are the 
mean of 3-4 determinations.   he pK, of 21a was determined. ND = not detected. 
compound log P octanol- Pkal (N) %N pKa2 (OH) 
buffer pH 7.4 protonated 
2a 1.53 9.4 99% 10.9 
2b 1.45 9.4 99% 10.7 
3a 2.44 8.2 97% 9.9 
3b 2.39 8.1 97% 9,6 
4a 2.22 7.4 50% 10.5 
4b 2.09 7.5 50% 10.9 
5a 1.93 5.8 2% 10.2 
5b 1.97 6.1 2% 10.3 
6 ND 4.5 a 0.1% ND 
From the data of Table 7.3, all compounds appear to be sufficiently lipophilic to 
pass the blood-brain barrier. However, introduction of one or two oxygen atoms has a 
profound effect on the ionization constants of these compounds. In comparison to the 
2-aminotetralins, the pKa values decrease by 1.2 units for the chromanamines 3, 2.0 
units for the naphthoxazines 4 and as much as 3.4 units for the 1-benzopyranoxazines 5. 
The p K d  values in this series remain constant. On comparison with simpler molecules, 
such as the methoxy derivatives of 4 and 5, it seems reasonable to conclude that the 
lower pKa values can be attributed to the NH+ group and the higher pKa to the 
phenolic OH. One can also infer from these results that the aminotetralins, 
chromanamines and naphthoxazines exist to an extent of 99%, 97% and 50% 
respectively, in the protonated form at physiological pH. In contrast, the 
1-benzopyrano-oxazines are only protonated ,to an extent of 2-4% at this pH, whereas 
the naphthylamines are present, exclusively in the uncharged form. As shown in the 
Tables 7.1, 7.2 and 7.3 in the series of compounds 1-6 there is a good correlation 
between the ionization constants (&I) and their biological activities. 
Since the 1-benzopyranoxazines described in this paper contain a fully extended 
phenylethylamine moiety, analogous to that found in the aminotetralins, 
trans-octahydrobenzo[flquinolines and naphthoxazines, it seemed appropriate to expect 
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similar structure-activity relationships. It is also likely they will fit the DA receptor 
models of McDermed et al. [4,5] and Wikstrbm et al. [24]. We therefore conclude that 
the unexpectedly low activity of 5a-b is a consequence of their low pKa values. 
This work supports the conclusions reported by Miller, Uretsky and coworkers [11,12], 
who have shown that the nitrogen atom in dopamine agonists can be replaced by a 
charged sulfur atom, indicating that it is the charged species that interacts with the 
active site of the receptor. This general conclusion is also in agreement with suggestions 
made by Seeman and Guan [9] based on MI HI-~~~23390/a~omorphine and  HI- 
spiperonelapomorphine competition experiments at different pH. Their results suggest 
that the charged fonn of apomorphine is the more active species at Dl and D2 recep- 
tors. 
DeWald et al. [28] later published a paper, in which they reported that the 
compounds possess moderate in vivo and in vitro activity. These results are somewhat 
in contrast with our findings. Our lack of in vivo effects on DA turnover may be due to 
a combination of the low dose of 5b used (2.5 v.s. 30 mglkg) and changes in 
dopaminergic levels, which reflect both pre- and postsynaptic effects, may not be as 
sensitive a measure of DA agonist activity as are the effects on DA synthesis and 
neuronal h g  activity. These two latter tests reflect effects on presynaptic DA 
receptors, which are inherently more sensitive than postsynaptic DA receptors. 
I infusion I 
, . , . , . ( . , . , .  
JO 0 90 m 90 1m 
Figure 7.2 Effect of infusion of (+)-PHNO and 5b on the DA reIease from the striatum. The compounds 
were dissolved in Ringer solution and applied at the concentdon indicated The results are the mean f 
SEM of data obtained fnnn 4-5 rats. 
In order to test this, compound 5b and (+)-PHNO were assayed in the 
presynaptic brain microdialysis model. As can be seen (Fig 7.2), infusion of 10-5 M 
solution of 5b induced a decrease (40%) in the release of DA. The compound has 
indeed presynaptic activity, although much less potent than (+)-PHNO. Timmerman et 
al. [30] have found that the same decrease in DA release can be obtained with a 10-8 M 
infusion of (R)-(+)-PHNO. Although the tetrahydrobenzopyranoxazinol5b is less active 
than the hexahydronaphthoxazine (4b), the compound showed selectivity for the 
autoreceptor sites. Introducing some steric hindrance is a well known method to 
increase seleclvity for the DA autoreceptor. Our results indicate, that a second way to 
increase the selectivity for DA autoreceptors, is manipulating (lowering) the pKa value 
of the nitrogen atom in these molecules. 
The data of this study suggest that the activity of dopaminergic agonists may 
depend on the ability of the doparnine ligand to interact in the protonated form with a 
carboxylate group, may be that of an aspartate residue. This can be one of the aspartate 
residues (ASP30 and ASP-308) strictly conserved in a number of neurotransmitter 
receptors and which apparently play pivotal roles in drug binding and in the regulation 
of receptor coupling to signalling pathways [29]. 
7.4 Experimental Section 
Melting points were determined with an Electrothennal digital melting apparatus and 
are uncorrected. Infrared spectra were recorded on a Jasco A-100 spectrophotometer, 
and only the important absorptions are given. The 60 MHz 1~ NMR spectra were 
recorded on a Hitachi-Perkin Elmer R-24 B spectrometer. Chemical shifts are denoted 
in ppm relative to tetramethylsilane as internal standard. Splitting patterns are 
designated s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. Mass 
spectra were obtained with a Finnegan 3300 system. Elemental analysis were performed 
in the Department of Chemisq, University of Groningen. Where elemental analysis are 
indicated, results obtained were within 0.4% of theoretical values. 
3-Chloroacetamido-8-methoxy-3,4-dihydro-2H-l-benzopyran-4-one (lla). 
To a stirred solution of sodium bicarbonate (4 g) in water (50 mL) layered with ethyl 
acetate (200 mL) was added 3-amino-8-methoxy-3,4-dihydro-2H-l-be~-one 
hydrochloride (4.0, 17.4 mmol) [16]. After the solid had dissolved, chloroacetylchloride 
(1.6 mL, 17.4 mmol) was added dropwise over a period of 10 minutes. Afler stining at 
ambient temperature for 1 h the ethyl acetate layer was separated. The aqueous layer 
was extracted once with ethyl acetate (50 mL). The combined organic phase was 
washed with brine, dried over magnesium sulfate and concentrated to a small volume 
whereupon colorless crystals formed. Recrystallization fiom ethyl acetate gave (2.8 g, 
59.6%) of 3-chloroacetamido-8-methoxy-3,4-dihydro-2H-l-bepyran-4-one; mp 
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1 7 5 ~  - 1 7 6 ~  'C; IR (KBr) 3225 cm-l (N-H), 1690 (C=O), 1655 (CONH); NMR 
(CDC13) 6 3.8 (s, 3H, OCH3), 4.1 (s, 2H, CH2-Cl); MS (CI with NH3) m/e 270 (M+l), 
287 (Mt-18). Anal. (C12H12N04Cl) C, H, N, C1. 
3 - C h l o r o a c e t a m i d o - 6 - m e t h o x y - 3 , 4 - d i h y d r ~ - o n e  (1 1 b). 
The 6-methoxy-chloroacetamide l l b  was prepared by exactly the same procedure as 
described for the preparation of the 8-methoxy analogue. The yield of l l b  was 68%, 
and the pure material had the following properties: mp 154-155 'C; IR(KBr) 3275 cm-1 
0 , 1 6 9 0  cm-l (C=O), 1655 cm-l (CONH); NMR (CDC13) 6 3.7 (s, 3H, OCH3), 4.1 
(s, 2H, -CH2Cl), 4.8 (m, 2H, 2-CH2), 6.9 - 7.4 (m, 4H, Ar-H, NH); M.S. (CI with 
NH3) m/e 270 (M+l). Anal. (C12H12N04C1) C, H, N, C1. 
T r a n s - 3 - c h l o r o a c e t a m i d o - 8 - m e t h o x y - 3 , 4 - d ~ - 0 1 ( 1 2 a ) .  
To a solution of lg  (3.7 mrnol) of l l a  in ethanol (25 mL) and dichloromethane (10 mL) 
sodium borohydride (200 mg) was added in portions. After 1 h several drops of acetic 
acid were added to destroy excess sodium borohydride. The mixture was poured into 
water (100 mL) and the product was extracted with dichloromethane (3 x 30 mL). The 
organic layer was washed with water and dried (MgS04). The resulting mixture (800 
mg) after solvent removal was shown to contain two components (TLC). The major 
one, constituting 74% of the mixture by GLC examination, was the desired compound, 
the other component being the cis isomer. These isomers were separated cleanly by me- 
dium-pressure chromatography (ethyl acetate-hexane 1 : 1). Fractions were collected and 
concentrated in vacuo to give 225 mg (22.3%) of the cis compound and 700 mg 
(69.4%) of the trans compound of 12a: mp 128-129 'C; IR (KBr) 3300 cm-1 (OH), 
1665 (C=O), 1040 (C=O); NMR (CDC13) 6 3.7 (s, 3H, OCH3), 3.9 (s, 2H, CH2Cl), 3.9 
-4.6 (m, 5H, 2-CH2, OH, 3-CH, and 4-CHax), 6.6-7.2 (m, 4H, ArH, NH); MS (NICI 
with OH- ), mle 270 (M-1). Anal. (C12H14N04) C, H, N. 
Tran~3-chloroacetamido-6-methoxy-3,4-dihydr2H-l-benzopyran-4-ol(12b). 
The chloroacetamide 12b was prepared from l l b  according to the method used for the 
preparation of 12a. Medium pressure chromatographic separation with ethyl ace- 
tate-hexane (1:l) as eluent yielded pure trans-l2b (72.4%) and cis-12b (15%). Trans- 
l l b ;  mp 129-1 30 'C: IR (KBr) 3225 cm-1 (OH), 1670 (C=O); NMR (CDC13) 6 3.7 (s, 
3H, OCH3), 4.0 (s, 2H, CH2C1), 3.9 - 4.7 (m, 5H, OH, 2-CH2, 3-CH, 4-CH), 6.8 (m, 
3H, ArH), 7.2 (br, 1 H, NH); MS (CI + NH3) rnle 272 (M+l). Anal. (C12H14N04C1) 
C, H, N. 
Trans-7-methoxy-3,4,4a,l0b-tetrahydro-2H,5H-l-beazopyrano[4,3b] [1,4]-oxazin- 
3-one (13a). 
To a solution of 3.2 g (1 1.8 mmol) of the m-chloroacetamide 12a in 150 mL of iso- 
propanol a solution of 1.0 g NaOH in 2.0 mL of water was added dropwise at room 
temperature. The mixture was stirred 3 h before being neutralized with 10% HC1. The 
solvents were evaporated as much as possible and the resulting residue was slurried in 
100 mL of water and extracted with dichloromethane (4 x 25 mL). The organic layer 
was washed with brine (25 mL), dried over magnesium sulfate and then concentrated to 
dryness. Recrystallization from acetone-hexane gave 13a as white crystals, 2.9 g 
(72.2%); mp 232-234 'C; IR (KBr) 3 175 cm-1 (NH), 1670 (C=O); NMR (DMSO-d6) 6 
3.8 (s, 3H, OCH3), 3.9 - 4.5 (m, 3H, 4a- CH, 5-CH2), 4.2 (s 2H, 2-CH2), 4.7 (d, J=8.5 
Hz, lH, lob-CH), 6.8 (m, 3H, ArH), 8.3 (s, lH, NH); MS (CI with NH3) m/e 236 
(M+l). Anal. (C12H13N04) C, H, N. 
Trans-9-methoxy-3,4,4a,l0b-tetrahydro-2H,5H-l-beazopyrano-[4,3b] [1,4]- 
oxazin-%one (13b). 
The chloroacetamide 12b, was converted to the lactam 13b as described above for 13a. 
Recrystallization from acetone-hexane gave pure 13b (66.0%): m.p. 249-251 'C;  IR 
(KBr) 3160 cm-l (NH), 1675 (C=O); NMR (DMSO-d6), S 3.8 (s, 3H,OCH3), 3.9 - 4.4 
(m, 3H, 4a-CH, 5-CH2), 4.2 (s, 2H, 2-CH2), 4.6 (d, lH, 1 0b-CHA, 6.8 (m, 3H, ArH), 
8.3 (br, lH, NH); MS (CI with NH3) mle 236. Anal. (C12H13N04) C, H, N. 
Trans-7-methoxy-3,4,4a,l0b-tetrahydr0-2H,5H-l-opan[4,3b] [l,4]-oxazine 
Hydrochloride (14a). 
A solution of 0.5 g (2.1 mmol) of the trans-lactam 13a in THF (60 mL) was added to a 
stirred solution of 0.2 g (5.3 mmol) of L i  in 10 mL THF cooled at 50C. The 
reaction mixture was allowed to warm to room temperature and then heated at reflux 
for 1 h. After cooling, excess hydride was destroyed by the careful addition of 0.2 mL 
of water followed by 0.2 mL of 4N sodium hydroxide and a further 0.6 mL of water. 
The mixture was filtered and the solid washed with ether. The organic solvents were 
dried over magnesium sulfate and then evaporated under reduced pressure. The 
resulting oil was dissolved in dry ether and ether saturated with gaseous HC1 was added 
slowly to produce the oxazine hydrochloride 14a as a white solid. Recrystallization 
from ethanol yielded 0.42 g (76.6%) of white crystals: mp 225 - 227 'C; IR (free base) 
3300 cm-1 0; NMR (CDC13) free base, 6 2.1 (br, lH, NH), 3.7 (s, 3H, OCH3), 4.3 
(d, J=8Hz, lH, lob-CH& 6.9 (m, 3H, ArH); MS (CI with NH3) m/e 222. Anal. 
(C12H16N03Cl) C, H, N, Cl. 
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Trans-Pmethoxy-3,4,4a,l0b-tetrahydro-2H,5H-l-benzopyrano-[4Jb] [1,4]-oxazine 
Hydrochloride (14b). 
Reduction of the lactam 13b with L m  as described above for 14a gave the desired 
amine. Conversion to the HCl salt and recrystallization from ethanol gave 79.9 % yield 
of 14b. Mp >260 'C (dec); IR, free base, 3250 cm-1 (NH); NMR (CDC13), free base, 6 
1.8 (br, lH, NH), 2.7 - 3.3 (m, 4H, 2-CH2), 3.7 (s, 3H, OCH3), 3.7 - 4.2 (m, 3H, 
4a-CH, 5-CH2), 4.3 (d, J=8Hz, lH, lob- CH), 6.8 (m, 3H, ArH); MS ( CI with NH3) 
mte 222 (M+l). Anal ( C12H16N03C1) C, H, N, C1. 
T r a n s - 7 - m e t h o x y - 4 - n - p r o p y l - 3 , 4 , 4 a , l O ~  
[4,3b][l,4]-oxazine (15a). 
Anhydrous potassium carbonate (0.45 g, 3.3 mmol) and 1 mL (1.74 g, 10.2 mmol) 
propyl iodide were added to a solution of 0.26 g (1.0 rnmol) of the amine HCI 14a in 30 
mL of DMF. The mixture was stirred for 5 h at 55 OC and then poured into 100 mL of 
water and extracted with ether (5 x 35 mL). The combined organic layer was washed 
with brine (5 x 10 mL) and once with a 10% ammonium chloride solution (10 mL). The 
ether layer was then dried over magnesium sulfate and evaporated to dryness. The 
resulting oil was converted to the HCl salt of the amine. The yield after crystallization 
from ethanol was 0.28 g (92.6%): tnp 199 - 200 'C; IR (KE3r) 2450 cm-1 (NH+), 1590 
(Ar); NMR (CDC13), free base 6 0.9 (t, 3H, 3'-CHz), 2.1 - 3.0 (m, 6H, 2-CH2, 3-CH2, 
1'-CH2), 3.8 (s, 3H, OCH3), 3.7 - 4.2 (my 3H, 4a-CH, 5-CH2), 4.5 (d, J=9H, lH, 
lob-CH), 6.6 - 7.1 (m, 3H, ArH); MS (CI with NH3) 264 (M+l). Anal. 
(ClgH21ClN02.0.2H20) C, H, N, Cl. 
Tran~9-methoxy-4-n-propyl-3,4,4a,lOb-tetrahydro-2H~H-l-benzopyrano- 
[4,3b][l,4]-oxazine (15b). 
The reaction was carried out as described above for 15a. Conversion to the HC1 salt and 
recrystallization from ethanol gave pure 14b (83.6%): mp 217 'C (dec); IR (KE3r) 2470 
cm-l (NH+), 1610 (Ar); NMR (CDC13), fiee base, 6 0.8 (t, 3H, ~ ' - cH~) ,  1.5 (m, 2H, 
2'-CH2), 2.0 - 3.0 (m, 6H, 2-CH2, 1'-CH2), 3.7 (s, 3H, OCH3), 3.7 - 4.7 (m, 4 ~ ,  
4a-CH, 5-CH2, lob-CH), 6.8 (m, 3H, Ar.H); MS (CI with NH3) 264 (M+l). 
Anal.(Cl~H21ClN02) C, H, N, C1. 
Trans-4-n-propyl-3,4,4a,lObtetrahydr~l-benzopyrano- 
[4,3b] [1,4]-oxazine-9-01(5b). 
Axnine HCl 15b (0.20 g, 0.70 mmol) was dissolved in 25 rnL of dichloromethane and 
the temperature of the solution was lowered to -60 OC. A 0.25 molar solution (5 mL) of 
trans- Tetrahydrobenzopyrano[4,3b]oxazinols 10 1 
boron tribrornide in dichloromethane was then added. The reaction was initially stirred 
for 2 h at a temperature between -30 and -40 OC and was then allowed to rise to room 
temperature and for which the reaction was stirred for a further 20 h. The reaction 
mixture was poured into water (100 mL) and made alkaline by the addition of ammonia. 
The separated aqueous layer was extracted with ether (4 x 30 mL). The combined 
organic extracts were washed with saturated saline (3 x 10 mL) and dried over 
magnesium sulfate. Removal of the solvents under reduced pressure yielded an oil. 
Conversion to the HC1 salt and recrystallization fiom ethanol-ether yielded 0.14 g 
(73%) of pure product: mp > 220 OC (dec); IR (KBr) 3250 cm-1 (OH), 2500 (N&); 
NMR (CDC13), fiee base, 6 0.9 (t, 3H, 3'-CH3), 1.5 (m, 4H), 2.6 (m, 4H), 3.9-4.6 (m, 
4H, 4a-CH, 5-CH2, lob-CH), 6.2 (s, lH, OH), 6.7 (s, 3H, ArH); MS (CI + NH3) mle 
250 (M+l). Anal. (C 14H20N03C1.0.2H20) C,H,N,Cl. 
Trans-4-n-propyl-3,4,4a,1Ob-tetrahydro-2~5H-l-benzopyrano-[4,3b] [l,4]-oxazine- 
7-01 (5a). 
By using the procedure used for the phenol 5b, the 7-methoxy derivative gave the 
phenol 5a in a 67% yield after recrystallization fiom ethanol-ether: mp 144- 145 OC; IR 
(KBr) 3200 cm-1 (OH), 2525 (NH'); NMR (CDC13), fiee base, 6 0.9 (t, 3H, 3'-CH3), 
1.5 (m, 4H), 2.5 (M, 4H); MS (CI + NH3) m/e 250 (M+l). Anal. (C14H20N03Cl) 
C,H,N,Cl. 
6-Methoxy-3-(dipropylamino)-3,4-dihydr-n (16b). 
Propionic acid ( 15.0 g, 203 -01) was dissolved in 250 mL of dry toluene under an 
atmosphere of nitrogen. Sodium borohydride (2.4 g, 63 mmol) was then added and the 
mixture was stirred until the evolution of hydrogen had ceased. 
6-Methoxy-3-chromanamine.HC1 6b [25] (1.15 g, 5.3 mmol) was added and the 
solution was kept at 80 O C  for 15 h. After cooling, the reaction mixture was poured into 
200 mL of water. The separated organic layer was washed with 2N NaOH (4 x 50 mL) 
and with a saturated solution of NaCl. After drying over magnesium sulfate and removal 
of the solvent, the resulting oil was submitted to column chromatography with ethyl 
acetate-petroleum ether ( 40-60 OC) (1:2) as the eluent. Conversion of the resulting 
colorless oil into the HC1-salt yielded 1.24 g (77.6%) of 15 as a white solid: mp 
122-124 "C; IR (KBr) 2250 cm-l (NH+); NMR (CDC13), fiee base, 6 0.9 (t, 6H, 
3'-CH3), 1.5 (m, 4H, 2'- CH2), 2.5 (t, 4H, 1'-CH2), 2.8-3.5 (m, 3H), 3.8 (s, 3H, OCH3), 
3.8-4.4 (m, 3H), 6.6-6.9 (m, 3H, ArH); MS (CI + NH3) m/e 264 (M+l). Anal. 
(C 16H26N02Cl) C,H,N,Cl. 
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2600 (NH+); NMR 6 (CDC13), base, 6 0.9 (t, 3H, CH3), 5.4 (br s, lH, OH), 6.5-8.2 (m, 
6H, ArH); Anal ( C16H2lNO.HBr) C, H, N, Br. 
2-(N-n-propyl-N-phenylethylamin0)-naphtol(6b). 
Demethylation of the methoxy compound 21b as described above for 6a gave the 
desired phenol. Conversion to the HCl salt and recrystallization from propanol-ether 
gave a yield of 85.9%: mp 190-193 'C; IR(KBr) 3200 cm-1 (OH), 2600 (NH+); 
NMR(CDC13) 6 0.9 (t, 3H, CH3), 5.5 (s, br, lH, OH) 6.5-8.2 (m, 1 lH, ArH) Anal 
(C21H23NO.HCl) C, H, N, C1. 
Estimation of pKa Values. The negative logarithms of the compounds were 
determined by potentiometric titration as described by Albert and Serjeant [23]. For 
each compound 3-4 apparent pKa values were determined. 
Determination of n-OctanoWater Partition Coefficients. To obtain a measure of 
lipophilicity at physiological pH the n-octanol-water distribution coefficients were 
determined at pH 7.4. The substances were dissolved in N~+/K+-phosphate buffer satu- 
rated with n-octanol. After shaking in a closed tube with n-octanol saturated with phos- 
phate buffer the two phases were separated by centrifugation. The concentrations were 
determined by HPLC with electrochemical detection [15]. A 15 cm Nucleosil 5-C18 
column was used for the separation. 
Pharmacology. 
Determination of Metabolites of Dopamine. Female albino rats of a Wistar-derived 
strain (C.D.L., Groningen, The Netherlands) were used. The body weights of the rats 
varied from 180 to 220 g. The compounds were administered by intraperitoneal (ip) in- 
jection in a volume of 2.0 mL,kg-l of saline. After 1 h, during which time the 
behavioral effects were scored according the method of Costal1 et al. [22], the rats were 
killed by cervical dislocation. The corpora striata were rapidly dissected, frozen on dry 
ice, and stored at -80 'C. Following weighting of the frozen samples, homogenization 
in 0.1 M perchloric acid, and centrifugation (3000 g, 7 'C, 15 min), the amounts of the 
metabolites HVA and DOPAC in the supernatants were determined according the 
method of Westerink and Mulder [15] by use of purification on Sephadex G 10, 
separation on a reversed phase (RP 18) HPLC column, and electrochemical detection. 
Brain dialysis and Surgery. On-line brain microdialysis in freely moving animals has 
been described previously [3 1,321. In brief rats were anaesthetized with chloral hydrate 
- 
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and placed in a stereotaxic frame. Holes were made in the temporal bones to allow the 
transstriatal canula to be inserted. The dialysis device was fixed on the head and the rat 
was given one day to recover. The experiments were done 24-48 h after implantation of 
the cannula. The inlet of the dialysis tube was connected to a Braun perfusor VI and the 
outlet to the injection valve of the HPLC apparatus by means of polyethylene tubing 
(inner diameter 0.28 mm). The sample valve was held in the load position for 20 min 
and was switched automatically to the inject position for 15 s. The striata were perfused 
with a Ringer solution (mM: 147 NaCl, 4 KCl, 3.4 CaC12 and 0.02 ascorbic acid) at 6-7 
pVmin. The in vitro recovery of the probes for DA was approximately 12-1 5%. DA was 
assyed by HPLC with electrochemical detection. 
Displacement of the Specific Binding of  HI-DP-5,6-ADTN in Rat Striatum. This 
assay which was performed with homogenized and washed membrane preparations 
from rat striaturn tissue was carried out as described previously [19]. In each 
experiment the amount of  HI-DP-5,6-ADTN bound was determined in the absence 
(total) and presence (nonspecific) of 10-6 M (+)-butaclamol, the difference yielding 
specific [3~]-DP-5,6-ADTN binding. The ability to compete with  HI-DP-5,6-ADTN 
was tested over a concentration range of 10- 11 M to 10-4 M. 
Displacement of the Specific Binding of [ 3 ~ ] - ~ - 0 4 3 7  in Calf Striatal Membranes. 
The binding experiments were carried out according the procedure of Van der Weide et 
al. [20] Specific binding was defined as the difference in the amount of radioactivity in 
the absence or presence of 10-6 M unlabelled N-0437. The ability to compete with 
 HI-N-0437 was tested over a concentration range of 10-1 1 M to 1 0 4  M. 
Displacement of the specific binding of [ 3 ~ ] - s ~ i ~ e r o n e  binding in calf striatal 
membranes. The D2 receptor binding was performed essentially as described 
previously [21]. In each experiment the amount of [ 3 ~ ] - s ~ i ~ e r o n e  bound was 
determined in the absence (total) and presence (nonspecific) 10-6 M (+)-butaclamol, the 
difference yielding the specific [3~] - s~ i~erone  binding. The ability to compete was 
tested over a concentration range of 10-1 1 to 10-4 M. 
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CHAPTER 8 
A SIMPLE, UNEXPECTED REGIOSELECTIVE CHLORINATION 
OF A SERIES OF 5-OH-2-(ALKYLAMIN0)TETRALINS: 
POTENTIAL DOPAMINERGIC AGENTS 
Abstract. A series of 8chloro-5-hydroxy-2~alkylamino~ were prepared in a one-step 
reaction using a hexachlorocyclohexadienone as regioselective chlorinating agent. The reaction proceeds 
in a highly selective but un- manner. 
8.1 Introduction 
A number of monophenolic Zaminotetralins (1) are potent and selective dopami- 
ne receptor agonists with potential therapeutic utility in a number of diseases, such as 
e.g. Parkinson's disease [I]. As part of our current efforts to elucidate the structure 
activity relationship of dopaminergic agents, we have synthesized the 8-chloro deri- 
vatives 2 (Scheme 8.1). 
Scheme 8.1 
Compared to the hydroxylated Zaminotetralins 1, chlorination will cause a 
change in the electronic density of the aromatic ring. One of the consequences of this is 
an altered pKa of the phenol. This change may contribute to the pharmacological 
profile of these compounds, when tested in vivo and in vitro for their affmity at 
different receptors [2]. 
8.2 Chemistry 
In reported syntheses of chlorinated aminotetralin derivatives, the compounds 
are usually constructed starting with a commercially available polysubstituted benzene 
derivative [3]. The presence of the corresponding non-chlorinated aminotetralins on the 
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shelf made such a lengthy synthesis unattractive and prompted us to investigate the 
feasibility of a single step reaction for the regioselective production of the desired 
compounds. Guy et al. [4] have shown that a remarkable regioselectivity can be 
obtained by using specific chlorinating agents such as hexachloro-2,4-cyclohexadieno- 
nes (3a,3b). The regioselectivity is attained by using a reagent tailored in such a way 
that it is capable of participating in donor-acceptor and H-bonding interactions. Since 
the aromatization energy of the cyclohexadienones acts as the driving force, reactions 
can be performed under extremely mild conditions. We have therefore applied this 
approach to the synthesis of chloro-aminotetralins. It seemed reasonable to expect that 
by use of the two tailor-made hexachlorocyclohexadienones, 3a and 3b, the 
aminotetralins would be chlorinated at the 6- and 8-positions, respectively (Scheme 
8.2). We did indeed find that the combination of 1.2 equivalents of 2,3,4,5,6,6- 
hexachloro-2,4-cyclohexadiene- I -one 3a (the ortho chlorinating agent) and the sparing- 
ly soluble hydrochloride salts of the aminotetralins 1 
Scheme 8.2. Proposed reaction mechanism according to Guy et a1 [4qb]. 
in DME at room temperature monochlorinate the substrates within 3 h in good yield. 
However, under the reaction conditions used, the 8-chloro isomers, and not the 
expected 6-chloro-5-hydroxy-2-(dialkylamino)tetral hydrochlorides precipitated com- 
pletely from solution upon addition of diethyl ether. The regioselectivity was esta- 
blished by comparing the 1~ and 1 3 ~  NMR spectra of the chlorinated products with 
those of products obtained via an unambiguous route. Using 6- or 7-hydroxy isomers as 
substrates, in which only ortho positions are available, the reaction leads to poor yields, 
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even after 24 h. These findings indicate that the reactions, in this case, do not proceed 
according to the proposed mechanism [3a,3b]. A possible explanation may be that the 
hexachlorocyclohexadiene slowly reacts with the hydrochloric acid to give a very low 
concentration of chlorine (Scheme 8.3). The main evidence in support of this 
mechanism is as follows: (a) Pentachlorophenol was formed in a dry HC1-DME soluti- 
on of 3a. (b) A 12 : 1 mixture of mono brominated and monochlorinated products was 
obtained when the hydrobromide salt was used in stead of the hydrochloride salt. In that 
case, the halogenating species is probably the interhalogen compound (Br-Cl). (c) Very 
poor yields were obtained when the free amines were halogenated under the same 
conditions, when chlorine is less easily formed. (d) The reaction of a mixture of 50% of 
the free amine and 50% of the hydrochloride salt gave a yield of about 50%. 
DME 
I 
ArH + I - ArCl + HCI 
Scheme 8.3. Proposed reaction mechanism. 
With the less activated 5-methoxy derivatives only a 50% yield is obtained after 
24 h. This reaction is strongly catalyzed by the Lewis acid AlCl3, probably by polari- 
zing the chlorine. 
Since chlorine is a very reactive and small chlorinating agent, it would be ex- 
pected to give the lowest paralortho ratio and considerable dichlorination even when 
less than 1 equivalent of chlorine is formed; however, only para-chlorinated products 
were obtained. GC/MS analysis have indicated that the total yield of other isomers 
(ortho chloro- and dichloro-compounds) did not exceed 1.1 %. Apparently, the very low 
concentration of the chlorine formed is, as in reactions of NBS and NCS, a reason for 
the observed selectivity. In addition, hydrogen bonding could play a major role in 
determining the observed high regio selectivity. Formation of hydrogen bonds between 
the phenolic proton and the solvent DME sterically hinders the ortho approach of the 
electrophile [ 5 ] .  Another mechanism for the chlorination of the phenol is feasible 
according to the same scheme as proposed by Lindsay Smith and coworkers [6]. In the 
first step of the reaction, 1 and 3a undergo halogen exchange to produce the N-chlori- 
nated aminotetralins. These authors have shown that a remarkable para selectivity can 
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be obtained by using N-chloroamines. However, in this mechanism the route to the 
brorninated products would become very complicated. 
In summary, the observed regioselectivity may be rationalized by a very low 
steady-state concentration of chlorine, formed from the reaction of hexachloro-2,4- 
cyclohexadienone with the hydrochloride salts of the aminotetralins, and steric effects 
due to the formation of hydrogen bonds between the solvent and the phenolic proton. 
These preliminary results show that the method is very suitable for the para- 
chlorination of hydroxylated aminotetralins and related compounds, because of the ease 
of handling, acceptable reaction rate, and nondestructivity towards the phenol and 
atnine functions and should be a valuable reaction in the repertoire of the synthetic 
medicinal chemist. For the less reactive methoxy derivatives, Lewis acid catalysis may, 
however, be necessary. We are currently investigating the scope and limitations of this 
reaction. 
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7. Typical Procedure: Under a nitrogen atmosphere, in a three-neck round-bottom 
flask were placed 5 mmol of 5-hydroxy-2-(dipropylamino)tetralin.HCI (I.HC1, 
R%-P~) and 300 mL of dry DME. To this stirred suspension was added 7 
mmol of 2,3,4,5,6,6-hexachloro-2,4-cyclohexadien-1 (h). The progress of 
the reaction was monitored by tlc and was complete in 2 to 3 h. The mixture was 
diluted with 200 mL ether and the solid was collected by filtration. The resulting 
hydrochloride salt was recrystallized from MeCN-Et20 to give 86% of &Chloro- 
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5-hydroxy-2-(dipropy1amino)tetralin: mp 204-205 OC; MS (CI with NH3) m/e 
282 (M+l), 284 (M+3); 13c-NMR (300 MHz, D20) 153.80, 131.83, 126.70, 
124.62, 122.49, 113.48, 58.91, 51.80, 51.46, 27.57, 22.99, 21.78, 17.89, 11.15; 
IH-NMR (300 MHz) 7.19 (d, lH, J = 1.92 Hz), 6.83 (d, IH, J = 1.92 Hz); Anal. 
(C 16H24NClO.HCl), C, H, N, C1. 
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CHAPTER 9 
SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF 
A SERIES OF DOPAMINERGIC AND SEROTONERGIC 
8-CHLORO-5-HYDROXY-2-(DIALKYLAMIN0)-TETRAS 
Summary: A series of 8 - c h l o r o - 5 - h y d r o x y - 2 ~ d i ~ h o ) ~ i n s  (5b, 6b, 7b) were prepared in a one 
step reaction using a hexachlorocyclohexadienone as a regioselective chlorinating agent. The reaction 
proceeds in a highly selective but unexpected manner. In in vitro and in vivo tests of dopaminergic 
activity, chlorination was found to diminish the DA agonist activity. The effect of chlorination was most 
remarkable in the brain microdialysis of 5b, where the activity is changed from DA receptor agonist to an 
antagonist. In addition, we have evaluated the ability of these compounds to displace [ 3 ~ - 8 - ~ ~ ~ ~ ~ ~  
from 5-I- lTll~ binding sites. All of the chlorinated compounds display Wty for this receptor. 
9.1 Introduction 
Until recently, the classification of dopamine (DA) receptors was based on their 
association with the enzyme adenylyl cyclase [I]. DA receptors positively linked to this 
enzyme were termed Dl, whereas those either negatively coupled or not associated to 
CAMP generation were designated D2. Sokoloff et al. [2] have recently identified a 
novel dopamine receptor, which they called the D3 receptor. Although this finding is 
exciting, the functional significance of the D3 receptor is as yet unknown. This study 
will focus only on Dl  and D2 DA receptors. 
From our research on CNS active compounds, particularly on DA and ~ - H T ~ A ,  
we have several times encountered a close relationship between the structure activity 
(SAR) of these agents. This article will be focussed on the structural class of the 2- 
aminotetralins. 
Figure 9.1. Chemical structures of various classes of Z-aminotetralins 
The aminotetralins are semi-rigid structures that lock the phenylethylamine side 
chain in the extended, presumed bioactive, conformation. The tetralin template could be 
modified to give selective ligands to other monoamino receptors as well as being 
effective probes to explore the relative similarities and differences in the topology of 
central neurotransmitter receptors. In practice, the modification of the tetralin structure 
has led to the discovery of selective dopamine @A) D2 receptor agonists (I), e.g. 5- 
hydroxy-2-(di-n-propy1amino)tetralin (5-OH-DPAT) [3]; putative DA autoreceptor 
antagonists (2) e.g cis-(lS,2R)-5-methoxy-l-methyl-2-(di-n-propyl~ ((+)- 
UH 232) which has a 3-4 times higher affinity for D3 than for D2 DA receptors [2,4]; 
and ~ - H T ~ A  agonists (3), e.g. 8-hydroxy-2-(di-n-propy1amino)tetralin (8-OH-DPAT) 
[5]. The recent finding that 7-OH-DPAT has a 70 times preference for the D3 over the 
D2 DA receptor is intriguing and will lead to even more interest in these 2- 
aminotetralins. Weinstock et al. [6] have found that, in contrast to benzazepines, 
replacement of either the 6- or 7-hydroxyl group of ADTN with a halogen did not 
change the activity from a dopamine receptor agonist to an antagonist. However, their 
data suggest that &chloro- (4), but not 5-chloro substitution of ADTN results in a 
relatively selective agonist for the Dl subpopulation of dopamine receptors. The 5- 
chloro substitution produced a relatively high degree of D2 receptor potency. In order 
to explore the influence of &chloro substitution on the structure activity relationship of 
a series of potent D-2 agonists, the &chloro analogues Sb, 6b and 7b of the 5-hydroxy- 
2-aminotetralins 5a (5-OH-DPAT), 6a (N-0434) and 7a (N-0437) [7] have been synthe- 
sized. The regioselective synthesis and pharmacological evaluation of these monohy- 
droxylated Zaminotetralins are the subject of this paper. 
5a. X = H, R = n-propyl; 5b. X = CI, R = n-propyl 
6a. X = H, R = phenylethyl; 6b. X = CI, R = phenylethyl 
7a. X = H, R = thlenylethyl; 7b. X = CI, R = thlenylethyl 
9.2 Chemistry. 
The presence of the non-chlorinated aminotetralins in our lab prompted us to 
look for a single step reaction for the regioselective production of the desired 
compounds. Most attempts to achieve site-selectivity in aromatic chlorination have 
been directed towards controlling the approach of the chlorinating agent to the 
substrate. These attempts have been made with bulky [8] or micellar chlorinating agents 
[9], complexes between substrate and chlorinating agent etc. [lo]. Recently, Lindsay 
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Smith et al. [ l  11 have shown that remarkable selectivity can be obtained by using N- 
chloroamines. A certain number of reagents for selectivity control have a cyclo- 
hexadienic structure [lo]. As the aromatization energy of cyclohexadienes acts as the 
driving force, reactions can be performed under extremely mild and selective 
conditions. The regioselectivity of the aromatic substitution can also be controlled by 
use of an appropriate solvent and of cyclohexadienone in particular. Guy et al. [lo] 
believe that the selectivity and their dramatic response to experimental conditions can 
only be explained by the formation of an intermediate complex formed as a result of 
non-covalent, donor-acceptor and hydrogen-bonding interactions between reagents and 
substrate. Surprisingly, it was possible to obtain the para-chlorinated products 5b, 6b 
and 7b with the ortho-chlorinating agent i.e. 2,3,4,5,6,6-hexachloro-2,4- 
cyclohexadiene- 1 -one 8 (Scheme 9.1) 
Scheme 9.1. Synthesis of the p-chlorinated aminot&ahs 
The mechanism suggested by Guy et al. [lo] is not valid for the reaction circum- 
stances that we have used. We suggest that the hexachlorocyclohexadienone slowly 
reacts with the hydrochloric acid to give a low concentration of chlorine. The function 
of the hexachlorohexadienone is therefore to provide a source of C12 in a low steady- 
state concentration. The HCl will be liberated again in step 2. Evidence for this reaction 
mechanism is shown in chapter 8 [24]. The chlorinations with the enantiomers of 5a, 6a 
and 7a were carried out as described for the racemic compounds. 
9.3 Results and Discussion 
The dopaminergic affinity of the racemic compounds was measured in vitro by 
determining the ability of the test compounds to displace  HI-SCH 23390 and [ 3 ~ ] -  
spiperone from calf striatum membrane homogenates as a measure of the afhity for 
Dl and D2 binding activity, respectively. The results are shown in Table 9.1. As can be 
seen from the table, all compounds display affinty for both the Dl and the D2 receptor. 
However, the chlorinated compounds have lower affinity than their non-chlorinated 
counterparts. Moreover, introduction of a chloro atom in the 8-position did not result in 
compounds with a higher selectivity for either of these receptor subtypes. This is in 
contrast with results found for the 8-chlorinated ADTN derivatives, which resulted in 
compounds with a higher selectivity for the Dl receptor [6]. However, the selective Dl 
affinity in this study was based on comparison of Ki values for the displacement of a 
Dl agonist  HI-fenoldoparn) with those for the displacement of a D2 antagonist 
( [ 3 ~ ] - ~ ~ i ~ e r o n e ) .  Murray and Waddington [18] concluded that l h s  method might lead 
to an inappropriate conclusion of selectivity for Dl receptors. 
Table 9.1. Affinity of various aminotetdins as measured by their ability to displace in vitro [ 3 ~ ] -  
SCH 23390, [ 3 ~ ] - ~ ~ i ~ e r o n e  fr m striatal membranes and [ 3 ~ ] ~ - ~ ~ - ~ ~ ~ ~  from cortical and 
hippocampal membranes The values are expressed in nM f SEM for 3 4  separate determinations 
performed in triplicate. Each displacing compound was used at concentrations ranging from 10-1 1 to 
M. a I is Inactive [S]. NT is not tested. 
Compound Ki 
 HI-spiperone [ 3 ~ ] - ~ ~ ~ 2 3 3 9 0   HI-8-OH-DPAT 
The affinities of 5b, 6b, and 7b and their enantiomers for ~ H T ~ A  receptors were 
also evaluated. All the compounds showed a pronounced affrnity for this receptor. 
Consequently, 8-chlorination gave a dramatic shift from no affinity for the ~ - H T ~ A  
receptor to compounds with a considerable affinity for this receptor, whereas the 
binding affinty for the Dl and D2 receptor decreased. The binding studies further 
demonstrated no significant affinity differences between the enantiomers of the 
chlorinated compounds. With the concentrations applied in the 6-hydroxydopamine 
model (5-10 pmollkg), no 5-HT syndrome was observed. Of particular interest is, that 
the affinity for the (R)-enantiomer is a little higher than that for the (S)-enantiomer. 
In an attempt to find an explanation for this pharmacological shift, we performed 
semi-empirical calculations with the MOPAC-package program PM3, accessible 
through the the SYBYL program from Tripos. The results of the computational model 
are not as dramatic as the pharmacological results, but it emphasizes, that in the highest 
occupied molelcular-orbital (HOMO) state, the charge on the chlorine atom differs 
from the charge on the hydrogen atom. In addition, it is polarizable and can participate 
in a H bond from e.g. serine in the receptor. 
Figure 9.2 MOPAC charges of 5-OH-DPAT and 8-C13-OH-DPAT. In the aromatic ring the total 
charge of the xelectron system is given. 
There seems to be a delicate balance between the ~ - H T ~ A  and DA receptor. In 
this case H-bond acceptance by the chlorine atom is probably sufficient for inducing 5- 
H T ~ A  receptor interaction. 
The compounds were also tested for their pharmacological action on DA D2 
autoreceptors in vivo, by measuring DA release by on-line brain microdialysis in freely 
moving rats during administration [12-141. An advantage with brain microdialysis is 
that the drug studied can be applied locally in the area from which the release is being 
measured, thus providing useful information clarify~ng its intracerebral site of action 
The compounds (1 0-6 M) were infused via the dialysis membrane in the striaturn during 
60 min. 
Agonists of dopamine receptors, with activation at the D2 receptor subtype 
reduce the in vivo release, as well as its turnover rate. On the other hand Dl and D2 
specific antagonists of DA receptors increase the in vivo release of DA. Local 
application of racemic 5a and 5b induced a 50% and 30% decrease in DA release, 
respectively (Fig. 9.3). The onset of the decrease was immediate after the start of the 
infusion. 
o . , . , . , . l . l . , . l . , .  [ infusion 1 
-30 0  30 60 90 120 150 180 
Time (rnin) 
Figure 9.3 Effect of a M infusion of 5-OH-DPAT (5a) and (*)-8-CI-5-OH-DPAT (5b) on DA 
release from the striatum. The compounds were dissolved in Ringer solution. The results are the mean + 
SEM of data obtained from 3-4 rats. 
-=- 1 8  M 7a 
-IJ- l# M 7b 
infusion 
JO 0 30 80 90 120 150 180 
Time (min) 
Figure 9.4. Effect of a 10-6 M infusion of N-0437 ( 7 4  and (f)-8-C1-N-0437 (7b) on DA release !?om 
the striatum. The compounds were dissolved in Ringer solution. The results are the mean f SEM of data 
obtained from 3 -4 rats. 
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N-0437 (7a) and racemic 8-C1-N-0437 (7b) infusion induced a decrease in DA 
release of 50% and 25%, respectively (Fig 9.4). The decreases induced by the 
chlorinated analogues 5b and 7b was less pronounced than those of the non-chlorinated 
compounds 7a and 7a.. 
A 10-6 M infusion of N-0434 (6a) also gave, as expected, a 45% decrease of the 
DA release (Fig 9.5). However, a striking effect was obtained with the chlorinated 
analogue ((*I-8-Cl-N-0434,6b). This compound induced, immediately after infusion an 
increase of 50% in DA release. Thus, infusion of racemic 6b resulted in antagonistic 
effects on receptors mediating DA release. Timmerrnan et al. [13,14] have 
demonstrated that the (+)-enantiomer of 7a displayed a weak antagonistic action in this 
model. However, in contrast to racemic 8-C1-N-0434 (6b) in the racemic mixture of N- 
0437 (7a) the agonistic effect predorninatates over the antagonistic effect. Because of 
the resemblance with N-0437, we have also prepared the enantiomers of 8-C1-N-0434. 
+-I@ M 6 a  
4 - 1 f f  M6b :! , . ! . , . . , . , . , . , , 
infusion 
0 
-3a 0 24 a W 120 150 180 
Time (min) 
Figure 9.5. Effect of M infusion of N-0434 (6a) and (k)-8-C1-N-0434 (6b) on DA release from the 
striaturn. The compounds were dissolved in Rmger solution. The results are the mean 2 SEM of data 
obtained from 3-4 rats. 
The testing of enantiomers of 6b (Fig 9.6) showed that the antagonistic activity 
resided in the (R)-(+)-enantiomer. Infusion of 10-6 M S-(-)-6b did not influence DA 
and DOPAC levels (results not shown). This is surprising because S-(-)-6b has a Ki of 
65 nM at the D2 receptor and this must result in a biochemical effect. 
I infusion I 
O . , . , . , , , . , . , . , . , <  
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time (min) 
Figure 9.6. Effect of a lo4 M infusion of the enantiomers of 6b on DA release from the striatum. The 
compounds were dissolved in Ringer solution. The results are the mean + SEM of data obtained from 3-4 
rats. 
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Figure 9.7. Contralateral turning behaviour of unilateral 6-OHDA-lesioned rats as a result of i.p. 
administration (on t = 0) of 5 polkg of the test compounds. Each value (mean; n = 6) are the sum of all 
contralateral turns during a time interval of 1 h. For clanty the SEM have been left out of this graph (see 
also figure 9.7). 
The animal model most commonly used to investigate the central effects of DA 
agonists on motor function is turning behaviour in rats with unilateral 6- 
hydroxydopamine (6-OHDA) induced lesions of the nigrostriatal pathway. In this 
- -  
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model, both Dl- and D~agonists produce contralateral rotational .behaviour, 
presumably by acting on striatal receptors rendered supersensitive by the lesion [15]. 
The resulting contralateral turning was used to measure the post-synaptic activity of the 
test compounds (Fig 9.7). 
compounds 
Figure 9.8. The area under the curve (AUC) from the time interval 1-15 h. of vehicle and the 
aminotetralins after i.p. administration. Error bars are * SEM (n = 6). 
By calculating the area under the curve (AUC) of the time-effect curves, a 
sigmficantly lower total activity was found for the halogenated compounds during the 
measured time interval 1-15 h (Fig.9.8). A surprising result was the complete inability 
of 8-chloro-N-0437 (7b) to induce contralateral turning, since this compound 
possessed, although lower than N-0437, a high affmity for the D2 receptor and was 
active in the brain microdialysis model. 
Although on a low level, racemic 6b still induced contralateral turning. Separate 
administration of both enantiomers (Fig 9.9) revealed that only the (S)-(-)-enantiomer 
demonstrated some post-synaptic stimulation 
An explanation of this decreased in vivo activity could be the metabolism. 
Introduction of a chlorine atom in the 8-position dramatically increases the 
glucuronidation speed in human and rat liver microsomes [16]. Through this first-pass 
effect, the concentration of the drug in the striatum will be presumably very low after 
i.p. administriation. It is known that especially the thiophene derivatives are very 
sensitive to glucuronidation [17]. 
Time (h) 
Figure 9.9. Contralateral turning behaviour of unilateral 6-OHDA-lesioned rats as a result of i.p. 
administration (on t = 0) of 5 and 15 pmoVkg of the enantimers of 3b. Each value (mean SEM; n = 6) 
is the summation of all wntralateral turns during a time interval of 1 h. 
In summary, the regioselective para chlorination of the hydroxylated aminote- 
tralins is mild, fast and non-destructive towards the phenol and mine functions, and it 
is facile to perform, as compared to other routes described in the literature. The non- 
chlorinated compounds are DA agonists with selectivity for the D2 receptor. 
Substitution of chlorine in the 8-position resulted in compounds with a decreased 
affinity for the Dl  and D2 receptor. The results of our study of the 8-chlorinated 5- 
hydroxyaminotetralins, in contrast to the &chlorinated ADTN derivatives, have not 
resulted in compounds with a higher affinity for the Dl receptor. Chlorination resulted 
in compounds with a greatly decreased agonistic activity in the test involving post- 
synaptic receptors. The effect of chlorination was most remarkable in the brain dialysis 
of racemic 6b. In this model the activity of the compound is changed from a dopamine 
receptor agonist to an antagonist. Thus in contrast to most other 5-OH-aminotetralins, 
the effects of the (+)-enantiomer predominate over those of the (-)-enantiomer in this 
racemate. Most surprising was the dramtical shift from amnity for the DA receptor 
into affinity for the ~ - H T ~ A  receptor, indicating that small modifications within these 
molecules yield compounds which show affities for another G-protein coupled 
receptor. The potential biochemical and physiolological profile of some of these 5- 
H T ~ A  receptor agents described should be further elucidated. 
9.4 Experimental section 
Melting points were determined with an Electrothermal digital melting point apparatus 
and are uncorrected. IR, NMR, and MS data were determined for all compounds and 
were evaluated as consistent with the indicated structures. These data are presented only 
where required for structural assignment. l&ared spectra were recorded on a Philips 
spectrophotometer, and only the important absorptions are given. The 300 MHz NMR 
spectra were recorded on a Varian XL-300 instrument. The chemical ionization (CI) 
mass spectra were obtained on a Finnegan 3300 system. For purity tests, TLC was 
performed on fluorescent silicagel plates developed in at least two different systems. 
For all the compounds, only one spot (visualized by UV light and I2 vapor) was 
obtained. Specific rotations were determined at 20 'C on a Perkin Elmer 241 
polarimeter. Concentrations (c) for specific rotations are reported in g1100 mL. 
Elemental analysis were performed in the Department of Chemistry, University of Gro- 
ningen. Where elemental analysis are indicated results obtained were within 0.4% of 
theoretical values. 
8-Chloro-5-hydroxy-2-(di-n-propylamino)tetrain (5b). 
2.15 g (7.1 mmol) 2,3,4,5,6,6-hexachloro-2,4-cyclohexadien-10 was added to a 
stirred suspension of 1.55 g (5.5 mmol) of 5a.HCI in 300 mL dry DME. Stirring was 
continued at room temperature for 2 h under nitrogen. The mixture was diluted with 200 
mL ether and the solid was collected by filtration. The resulting hydrochloride was 
recrystallized from MeCN-Et20 to give 1.5 g (86.3%) of crystals, mp 204-205 OC. MS 
(CI with NH3) m/e 282 (M+l), 284 (M+3); NMR (DMSO-Q) 13~-NMR (300 MHz, 
D2O) 153.80, 131.83, 126.70, 124.62, 122.49, 113.48, 58.91, 51.80, 51.46, 27.57, 
22.99, 21.78, 17.89, 11.15; IH-NMR (300 MHz) 6 7.19 (d, lH, J = 1.92 Hz), 6.83 (d, 
lH, J = 1.92 Hz); Anal. (C16H24NClO.HCl), C, H, N, C1. 
(R)-(+)-8-Chloro-5-hydroxy-2-(di-n-propylamino)tetralin (R)-(+)-(5b). 
The procedure described above for the synthesis of (+)-5b was followed for the 
enantiomers. All spectral data for (R)-(+)-5b were identical with those described above 
for (*)-5b. The resulting HC1 salt was recrystallized from MeCN-Et2O to give in 83.1 
% yield (R)-(+)-5b: mp 216-2 19 'C; [a] = + 75.9' (c = 0.1, MeOH). 
(S)-(-)-8-Chloro-5-hydroxy-2-(di-n-propylamino)tetralin (Sb). 
The procedure described above for the synthesis of (f)-5b was followed for the 
enantiomers. All spectral data were for (S)-(-)-5b were identical with those described 
above for (9-5b. The resulting HCl salt was recrystallized fiom MeCN-Et20 to give in 
75 %yield (S)-(-)-5b: mp 218-220 "C; [a] = -74.8" (c = 0.1, MeOH). 
8-Chloro-S-hydroxy-2-(N-n-propyl-N-phenylethylamino)tetralin (6b). 
By using of the procedure described for Sb, the phenol 6a gave the chlorinated 
compound Sb.HC1 in a 86.3% yield after crystallization from ethanol-ether: mp 180-182 
OC; IR (KI3r) 3200 cm-1 (OH), 2500 (NH'); MS (CI with NH3) mle 344 (M+l), 346 
(M+3); NMR (DMSO-dg) 6 9.08 (s, lH, OH), 6.6-7.4 (m, 7H, ArH), 0.9 (t, 3H, CH3). 
Anal. (Cl7H26NClO.HCl) C, H, N. 
(R)-(+)-8-Chloro-5-hydroxy-2-~-n-propyl-N-phenethamino)tetralin (+)-6b 
These enantiomer was obtained fiom (+)-Sa according to the procedure described above 
for the preparation of the racemic 5b. The resulting HCl salt was recrystallized fiom 
MeCN-Et20 to give in 75.1 % yield a compound having the same characteristics of 
racemic 6b in TLC, IR, MS and NMR; mp 152-153 'C; [a1589 =+57.9" (c = 0.1, 
MeOH). 
(S)-(-)-8-chloro-5-hydroxy-2-(N-n-propyl-N-phenylethylamino)tetralin (-)-6b 
These enantiomer was obtained fiom (-)-Sa according to the procedure described above 
for the preparation of the racemic 6b. The resulting HC1 salt was recrystallized fiom 
MeCN-Et20 to give in 72.8 % yield a compound having the same characteristics as (+)- 
6b and the racemic 6b in TLC, IR, MS and NMR; mp 153-155 OC; [a1589 = -57. lo (c = 
0.1, MeOH) 
&Chloro-5-hydroxy-2-~-n-propyl-N-2-thienylethylamino)tetra1in (7b). The 
chlorinated compound 7b was prepared from 7a according to the method used for the 
preparation of 5b. Recrystallization from 2-propanol gave pure 7b.HCI (yield 82.9%): 
mp 185-186 OC; NMR (D20) 6 6.69 (d, J = 2.25 Hz, lH, Ph-H), 7.12 (d, J = 2.25 Hz, 
lH, Ph-H); MS (CI with NH3), m/e 350 (M+l), 352 (M+3). Anal. (ClgH24NCl- 
OS.HC1) C, H, N, Cl, S. 
(R)-(+)-8-Chloro-5-hydroxy-2-(N-n-propyl-N-2-thienylethylamino)tetralin (R)-(+)- 
(7b); These enantiomer was obtained from (-)-7a according to the procedure use descri- 
bed above for the preparation of the racemic 5b. The resulting HC1 salt was recrystal- 
lized from MeCN-Et20 to give in 68.4 % yield a compound having the same 
characteristics as (+)-7b and the racemic 7b in TLC, IR, MS and NMR; mp 145-147 "C; 
[a1589 = + 54.3O (c = 0.1, MeOH). 
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(S)-(-)-&Chloro-5-hydroxy-2-(N-n-propyl-N-2-thienylethylamino)tetralin . (S)-(-)- 
(7b). These enantiomer was obtained fiom (-)-7a according to the procedure use descri- 
bed above for the preparation of the racemic 5a. The resulting HC1 salt was recrystal- 
lized from MeCN-Et20 to give in 65.2 % yield a compound having the same 
characteristics as (+)-7b and the racemic 7b in TLC, IR, MS and NMR; mp 148-150 OC; 
[a1589 = -54.7' (c = 0.1, MeOH). 
Pharmacology 
Displacement of the Specific Binding of [ 3 ~ ] - ~ ~ i ~ e r o n e  (Dz) in Calf Striatal 
Membranes. 
This assay which was performed with homogenized and washed membrane preparations 
from calf striatal tissue, was carried out as described previously [19]. In each 
experiment the amount of [3~]-spiperone bound was determined in the abscence (total) 
and presence (nonspecific) of M (+)-butaclamol, the difference yielding specific 
[3~]-spiperone binding. The ability to compete with  HI-spiperone was tested over a 
concentration range of 10-1 1- 10-4 M. 
Displacement of the Specific Binding of  HI-SCH 23390 (Dl) in Calf Striatal 
Membranes. 
The binding of  HI-SCH 23390 was determined using membranes as prepared above 
[19]. In each experiment the amount [ [ 3 ~ ] - ~ ~ ~  23390 bound was determined in the 
absence (nonspecific) and presence (nonspecific) 10-6 M cis-(Z)-flupentixol, the 
difference yielding the specific  HI-SCH 23390 binding. The ability to compete with 
 HI-SCH 23390 was tested over a concentration range of 1 0 - ~ ~ - 1 0 - ~  M. 
Displacement of the Specific Binding of  HI-&OH-DPAT (5-HT~A) in Rat 
Cortical and Hippocampal Membranes. 
The binding of H HI-&OH-DPAT was determined using membranes as prepared 
according [24]. In each experiment the amount  HI-8-OH-DPAT bound was 
determined in the absence (nonspecific) and presence (nonspecific) 10-6 M 5-HT.HC1, 
the difference yielding the specific [ 3 ~ ] - 8 - ~ ~ - ~ ~ ~ ~  binding. 
Brain dialysis and Surgery. 
On-line brain microdialysis in freely moving animals has been described previously [20, 
211. In brief: rats were anaesthetized with chloral hydrate and placed in a stereotaxic 
fiame. Holes were made in the temporal bones to allow the transstriatal canula to be 
inserted [17]. The dialysis device was fixed on the head and the rat was given one day 
to recover. The experiments were done 24-48 h after implantation of the cannula. The 
inlet of the dialysis tube was connected to a Braun perfusor M and the outlet to the 
injection valve of the HPLC apparatus by means of polyethylene tubing (inner diameter 
0.28 mm). The sample valve was held in the load position for 20 min and was switched 
automatically to the inject position for 15 s. The striata were perfused with a Ringer 
solution (mM: 147 NaCl, 4 KCl, 3.4 CaC12 and 0.02 ascorbic acid) at 6-7 pVmin. The 
in vitro recovery of the probes for DA was approximately 12-15%. DA was assayed by 
HPLC with electrochemical detection. 
Turning behaviour and surgery. 
Rats were anaesthesized with chloral hydrate (400 mgkg) and placed in a sterotaxic 
instrument (Kopf). After removing skin and tissue a small hole was drilled into the s M  
and 6-OHDA (8 pg dissolved in 1 p1 0.9% NaCl containing 3 mg/ml of ascorbic acid) 
was injected in the left medial forebrain bundle at coordinates A 4.8, L2.2 and V2.4 
[22] to destroy the dopaminergic input to the striaturn. Succesfully denervated animals 
were selected by testing one week after surgery the response to 2 pmoYkg apomorphine 
for their fkequency of turning. Rotational behaviour was automatically recorded in 
rotameters according to the method of Ungerstedt and Arbuthnott [15]. Only animals 
showing more than 100 contralateral turnings per half hour were selected for the expe- 
riments. Registration of the turning behaviour started 10 min after injection. The time of 
every contralateral and ipsilateral turn of a maximum of 5 rats was registered and 
counted on a microcomputor. For comparison all doses were equimolar i.e. pmoVkg. 
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CHAPTER 10 
DISCUSSION 
Potential therapeutic DA agents 
The aim of the research described in this thesis is to gain more insight into 
factors that determine the activity at dopaminergic and serotoninergic receptors and to 
use this knowledge for the development of new more selective dopaminergic and 
serotonergic agents. 
10.1 DA Agonists 
Until recently, the main interest in developing new and efficient DA agonists 
was for the treatment of Parkinson's disease. This development is still important, 
because at this moment there are only a few centrally active compounds on the market. 
However, with these drugs (L-DOPA, bromocryptine, lisuride), psychotropic side 
effects are observed. 
The 2-aminotetralins, being one of the most important group of compounds, have 
increased our understanding of the neurobiology of the dopaminergic systems. The two 
most studied and potent DA receptor agonists 5-OH-DPAT and 7-OH-DPAT were 
resolved, and it was shown that the active enantiomers have the (S) and (R) configurati- 
on, respectively. This has led to the McDermed receptor concept [I] which is the basis 
for the development of almost all the compounds synthesized in this thesis. 
The most potent DA agonist we have prepared is the 4-propyl-9-hydroxy- 
hexahydronaphthoxazine (PHNOIN-0500). This compound has been shown by 
ourselves and others [2] to be a very potent D2 agonist 
in various in vitro and in vivo test systems. In addition, 
its activity at various other recepto;s (a, 5-HT, NE) is 
low. The activity resided, as expected, in the (R)-(+)- 
H enantiomer. Martin et al. [3] have stated that the (R)- 
(+)-enantiomer is "the most active DA agonist yet 
discovered". The compound has reached the clinic 
and, unlike the phenolic aminotetralins (e.g. N-0437), 
it is readily absorbed in primates when given either transdermally or subcutaneously, as 
well as orally. 
The discovery that the selective MAO-B inhibitor ~elegiline@ is free of the 
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tyramine effect and is able to prevent the toxicity of MPTP, has led to the reassessment 
of se1egiline@ and it is now widely used in the early management of Parkinson's 
disease. Therefore we have introduced some MA0 inhibiting properties within the 
dopaminergic 2-aminotelralins to try to combine the benefits of both properties. The 
results we have indicate that, at least for the Zaminotetralins, it is very difficult to 
obtain a high degree of both properties in one and the same molecule. The 
dopaminergic effect dominates in the catechols, whereas the MAO-inhibitory effects are 
stronger in the non- and monohydroxylated compounds. The catechols have in some 
models potencies, comparable with those of apomorphine. New delivery systems have 
lead to the rediscovery of apomorphine in the treatment of Parkinson's disease [4]. In 
combination with domperidone, a peripheral DA antagonist that blocks peripheral side 
effects, the compound significantly reduces daily "off' periods in Parkinsonian patients. 
This make these dopaminergic catecholamines 
with MAO-inhibiting properties interesting for 
further research in relation to Parkinson's disease. 
- Reduced neurotransmitter concentrations have 
.  
I 
CH, also been described for non-dopaminergic sys- 
5,6-(OH),-N~pmpargyi-ATN tems, e.g. 5-HT and NE, in several parts of the 
CNS [5 ] .  It is noteworthy that no practical 
consequences have yet resulted from these observations. 5,6-Dihydroxy-2m-methyl-N- 
propargy1amino)tetralin has a moderate but 4-5 fold selectivity for MAO-A, leaving in 
the periphery enough MAO-A/B intact to metabolize ingested tyramine. The levels of 
NE, 5-HT and to a certain degree DA, can be increased by these MA0 inhibiting 
properties. 
10.2 DA autoreceptor agonists 
Many DA receptor antagonists have become efficient medicines for treating 
psychoses. However, most of them induce severe extrapyrimidal side effects akin to 
Parkisonian symptoms and tardive dyskinesias. The main interest in developing 
selective autoreceptor agonists is based on the idea that they may be useful in treating 
schizophrenia [6]. Thus if the latter diseased state is due to an overactivity in one or 
several of the DA systems in the CNS, then selective stimulation of the autoreceptor 
should reduce DA synthesis andlor release and lead to improvement of the 
symptomatology of the disease. 
On the basis of data indicating that the trans-hexahydronaphthoxazines and 8- 
hydroxy-chromanamines possess good biological activity, we have synthesized, as a 
structural extension of these compounds, the tram-tetrahydrobenzopyranoxazines. 
132 Chapter 10 
Surprisingly these compounds have weak 'to modest 
activity for D2 receptors. This weak activity cannot 
readily be explained on the basis of molecular 
conformations. The inspection of the molecular models of 
the 2-aminotetralins, naphthoxazines, chromanamines and 
Benzopyranoxazine benzopyranoxazines reveals a close similarity in size and 
shape, as well as in location of the hydroxyl and amino functions. We have found that 
all compounds are lipophilic enough to pass the blood brain barrier. The only 
demonstrable difference was the degree of protonation of the nitrogen atom under 
physiological conditions. The benzopyranoxazines were only protonated to an extent of 
2-4%. We therefore conclude that the unexpectedly low activity is a consequence of the 
low pKa values. This suggestion is supported by studies of Miller et al. [7] and Seeman 
and Guan [8] who showed that permanently charged residues have affinity for, and can 
activate D2 receptors. However, the 9-hydroxy derivative has demonstrated DA 
autoreceptor activity [9]. Because some partial DA agonists can produce antipsychotic- 
like effects, Arndt and Hyttel [lo] have stated, that the apparent autoreceptor selectivity 
of many DA agonists stems from low intrinsic activity at D2 receptors rather than 
absolute &ties for presynaptic versus postsynaptic DA receptors. Hitherto, the most 
used methods to produce an autoreceptor selective profile were i) introduction of steric 
bulk, which is likely to bring about some degree of steric hindrance at the drug receptor 
interaction; ii) variation of the position of the aromatic hydroxyl groups; iii) variation of 
the N-substituents [ l l ]  . From the results presented in Chapter 7 it seems a sound 
strategy to diminish the intrinsic efficacy of full agonists by manipulation of the pK, 
value of the nitrogen atom making them only active at the more sensitive presynaptic 
receptors. However, several other possible strategies might work as well. 
10.3 DA / ~ - H T ~ A  Balance 
The ~ - H T ~ A  receptor has greater homology with dopaminergic receptors than 
with the other serotonergic subtypes. The pharmacological results of the 8-chlorinated 
5-hydroxy-2-aminotetralins indicate 
OH that a small modification within 
dopaminergic molecules can give @ % compounds which have affinity also CI for the ~ - H T ~ A  receptor. So, it is R OH likely that there is a delicate balance 
8-OH-DPAT between the SAR of dopaminergic 
and serotonergic (5-HT 1 ~ )  
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compounds. In 8-OH-DPAT the hydroxyl function can act as hydrogen bond donor. 
Obviously, H-bond acceptance by the chlorine atom is sufficient for inducing ~ - H T ~ A  
interaction. The stereoselectivity is low, the R-enantiomers have a slightly higher 
mty for the ~ - H T ~ A  receptor than the S-enantiomers. The (R)- and (S)-enantiomers 
of 8-C1-5-OH-DPAT are equipotent. However, there seems to be a trend to higher 
enantiomeric differences when one n-propyl group is replaced by a larger substituent 
like phenylethyl. 
A11 the chlorinated compounds display affmity for the Dl and D2 DA receptor 
sites. However, the chlorinated compounds have lower affinities than their non- 
chlorinated analogues. Surprisingly, for the enantiomers of 8-chloro-N-0434 (R = 
phenylethyl), the Ki values for [ 3 ~ ] - s ~ i ~ e r o n e  displacement were not significantly 
different. This is in agreement with results found in competition experiments with the 
enatiomers of the non-chlorinated compound and with the DA agonist  HI-N-0437 as 
the radioligand [12]. In these experiments, the (S)-(-)- and (R)-(+)-enatiomers both 
display a high affinity for the D2 receptor, IC50 values of 0.5 and 5.5 nM, respectively. 
The effect of chlorination was also remarkable in the presynaptic brain 
microdialysis model. While (&)-N-0434 shows a decrease in DA release, racemic 8- 
chloro-N-0434 and its (R)-(+)-enantiomer showed a increase, indicating that these 
compounds have DA antagonitic effects. (R)-(+)-8-chloro-N-0434 exhibited in the 
postsynaptic 6-OHDA model no contralateral turning, so the compound behaves as an 
real antagonist. 
8-C1-N-0437 gave, after infusion, a decrease in DA release in the brain 
microdialysis model, whereas no activity was displayed in the 6-OHDA model. An 
explanation for this discrepancy between the two models could be the higher speed of 
glucuronidation [21]. 
A New &OH-DPAT Analogue with Combined MAO-inhibiting and ~ - H T ~ A  
Agonistic Activities 
The advent of selective ~ - H T ~ A  receptor agonists, showing antidepressant 
activity, has focussed increased attention on PY serotonergic mechanisms as being central to the pathophysiology of mood disorders. Further it is 
OH CH3 believed that there is a beneficial effect of MAO-A 
inhibition in depression. It is assumed that MAO- 
8-oH-N-methyl-N-pmpa~-ATN inhibitors exert their therapeutic effect through a 
central mechanism [14]. To acquire site selectivity two 
structural analogues of the ~ - H T ~ A  receptor agonist 8-OH-DPAT were synthesized. 
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The first studies in the brain microdialysis model indicate that, compared with the 
selective MAO-A inhibitor clorgyline, there is a shift in the ratio for the increase in 
5-HT over DA extracellular concentrations. However, further research is needed to 
elucidate this selectivity. The compounds also induced the 5-HT syndrome. Therefore, 
these results suggest that, possibly through the similarity with the ~ - H T ~ A  receptor 
agonist 8-OH-DPAT, site-selectivity is introduced which resulted in a relative stronger 
inhibition of MAO-A. 
General Remarks 
The results of several years of chemical and pharmacological studies of 
dopaminergic agonists permit some general conclusions to be drawn. 
i) Many of the structure-activity relationships that have been made in the past by us, as 
well by others, do not necessarily reflect the true nature of the agonist receptor 
interactions. However, these correlations can be used to stimulate the creativity in 
design of new biologically active compounds. 
ii) The results obtained with the enantiomers of 8-C1-N-0434 and with the enantiomers 
of several other aminotetralins [13], emphasize the importance of testing enantiomers 
instead of racemic mixtures. 
iii) Differences in metabolic fate of isomeric aminotetralins emphasize the need for a 
greater consideration of metabolic factors in design of new candidate molecules for 
DA/~-HT~A activity. In the 2-aminotetralins, differences in metabolic pathways seem 
to be an important factor in determining spectrum and sites of dopaminergic effects. 
It is recommendable therefore, that bioavailability studies should be carried out 
as early as possible since lack of the desired response may be attributable to an agent's 
ability to reach therapeutic concentration in the circulation. Such finding could warrant 
the synthesis of suitably modified derivatives or the development of alternative dosage 
formulations to maximize bioavailability. 
iv) Because the receptors coupled with G-proteins share a variety of structural and 
functional similarities, it is therefore not surprising that also ligands possess structural 
similarities. In this respect the aminotetralins are many-faced compounds, showing 
activities on various receptors or receptor subtypes. In Figure 10.1 a collection of 
different aminotetralins is taken from literature [ 1,15-201. 
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D,-agonist [1] D,-agoni.1 [20] 
Figure 10.1. Various aminotetralins interacting with different G-protein coupled receptors 
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Summary 
The main interest of our research group is the medicinal chemisq of agonists 
and antagonists of the neurotransmitters dopamine (DA) and serotonine (5-HT) and 
their modes of pharmacological interaction with dopaminergic and serotonergic 
neurotransmitter systems in the brain. The group is currently interested in the rational 
design, synthesis and pharmacological evaluation of new dopaminergic and serotonergic 
agents with clinical potential. 
Dopamine is an important neurotransmitter in the brain and is known to play an 
important role in Parkinson's disease, schizophrenia, and possibly depression. 
Serotonine is thought to be involved in various functions such as anxiety, aggression, 
depression, stress, sexual behaviour, and body temperature. 
Chapters 1 and 2 give the background information for chapters 3-9. Chapter 1 
is divided into three parts. The first part gives an introduction about G-protein coupled 
receptors. It illustrates that those receptors that interact with G-proteins share a variety 
of structural and functional similarities. The second part deals with dopamine, the 
dopaminergic system, related pathology and the classification of the dopamine 
receptors. Part three deals with the serotonergic system in the same way. 
Chapter 2 contains a review of the structure-activity relationships (SAR) of 
dopaminergic and serotonergic agonists and antagonists, with the emphasis on 2- 
aminotetralins and related tricyclic compounds. The receptor concept of McDermed, the 
basis for the development of almost all the compounds synthesized is this thesis, is 
briefly described and compared with some other models reported in the literature. 
In chapter 3 the synthesis of a series of 2-(N-methyl-N-propargy1amino)tetralins 
is described, which are studied with respect to their dopamine agonist and monoamine 
oxidase inhibitory activities. It was concluded that the mono and dihydroxylated 
compounds have MA0 inhibiting and dopamine receptor stimulating activities. The 
MA0 inhibitory activity predominates in the monohydroxy structures, whereas the 
dopamine agonistic effect is predominant in the catecholic compounds. 
Chapter 4 describes the synthesis and pharmacological activity of the N-methyl- 
N-propargyl analogue of the potent ~ - H T ~ A  agonist &OH-DPAT. The results 
demonstrate that the compound has a high affimity for the ~ - H T ~ A  receptor. The 
compound is a ~ - H T ~ A  agonist, as well as an irreversible inhibitor of MAO-A, and may 
be useful for the treatment of disorders of the central nervous system, especially those 
related to the serotonergic system. 
The synthesis of the 4-propylhexahydronaphthoxazines is described in 
chapter 5. From the pharmacological data in this study it can be concluded that the 
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naphthoxazines, and in particular the 9-hydroxy isomer, possess not only a very high 
affinity for the DA D2 receptor but are also very selective for this receptor subtype. 
In chapter 6 the resolution of 4-propyl-9-hydroxynaphthoxazine (PHNO) is 
described. A single crystallization of the diastereomeric salts, obtained with the 
enantiomers of phencyphos and chlocyphos, yielded optically pure products. The 
effects of the enantiomers on the dopaminergic striatal system, studied by means of in 
vivo microdialysis in freely moving rats, proved that the activity mainly resided in the 
(+)-enantiomer. (-)-PHNO displayed only a weak DA agonistic activity at higher doses. 
Chapter 7 describes the 9-steps synthesis of some tetrahydrobenzopyranoxazi- 
nes. The activities of these compounds were evaluated in vivo and in vitro. In all the test 
models, the compounds give a low response. However, the 9-hydroxy isomer was found 
to display presynaptic activity in the brain microdialysis model. This chapter also 
focuses on the importance of pKa values for central dopamine receptor activation. It 
was shown that a correlation exists between the pKa value of the nitrogen atom and the 
biological activity at the dopamine receptor. The conclusion is that the protonated form 
of the dopamine agonists is the active species at the dopamine receptor. Our results 
indicate that diminishing the intrinsic activity by lowering the pKa value of the nitrogen 
atom might be a method to increase the selectivity for DA autoreceptors. 
Chapter 8 describes a very useful reaction for the para chlorination of some 5-  
hydroxy-2-(dia1lrylamino)tetralins. The regioselectivity in these chlorination reactions 
was excellent but unexpected. Scope and limitations of this reaction are discussed and a 
plausible reaction mechanism is given. 
The results of the study in Chapter 9 show that substitution of chlorine in the 
phenyl ring of the 2-aminotetralins has much influence on the activity and selectivity of 
the test compounds. Substitution of chlorine in the 8-position resulted in compounds 
with a decreased a££inity for Dl and D2 receptors. The non-chlorinated and chlorinated 
2-aminotetralins, were also studied in the brain microdialysis and in the 6- 
hydroxydopamine (6-OHDA) models. Chlorination resulted in compounds with a 
greatly decreased agonistic activity for pre- and postsynaptic dopamine receptors. The 
effect is most dramatic in N-0434, in which chlorination gives a compound with DA 
antagonistic properties. Surprising is also the high affinity of the chlorinated compounds 
for the ~ - H T ~ A  receptor, indicating that a small modification within these molecules 
gives compounds with affinities for another G-protein coupled receptor. 
It can be concluded from these investigations that subtle changes in the structures 
of the compounds tested in this thesis have a large effect on the activity and selectivity 
for different receptorslreceptor subtypes. 
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Samenvatting 
Een belangrijke onderzoekslijn binnen de werkgroep Fannacochemie is de 
bestudering van de relatie tussen de struktuur en de aktiviteit (SAR) van verbindingen 
die werkzaam zijn op het centrale zenuwstelsel. Het onderzoek beschreven in dit 
proefschrift spitst zich vooral toe op de synthese en fannacologische evaluatie van 
verbindingen werkzaam op het dopaminerge en serotonerge systeem. Dopamine is een 
belangrijke neurotransmitter in de hersenen. De pathofysiologie van een aantal 
ziektebeelden wordt in verband gebracht met afwijkingen in het functioneren van het 
dopaminerge systeem. Farmaca met dopaminerge activiteit zouden toepassing kunnen 
vinden bij de ziekte van Parkinson, schizophrenie, endocrinische storingen en 
hypertensie. De op de markt zijnde middelen voor de behandeling van deze ziekte van 
Parkinson, zoals L-DOPA, veroorzaken diverse ongewenste neveneffecten en er bestaat 
dan ook een grote behoefte am nieuwe dopamine agonisten. Van het serotonerge 
systeem is bekend dat het betrokken is bij 0.a. angst, agressie, stress, depressief en 
sexueel gedrag en bij het reguleren van de lichaamstemperatuur. 
De hoofdstukken 1 en 2 geven de noodzakelijke achtergrondinformatie voor de 
hoofdstukken 3 tot en met 9. Hoofdstuk 1 kan opgedeeld worden in drie onderdelen. In 
het eerste deel wordt een inleiding gegeven over de structuur en werking van met G- 
eiwit gekoppelde receptoren. Deze G-eiwitten zijn betrokken bij de signaaloverdracht 
van de receptor naar de "second messengers". De receptoren die met deze G-eiwitten 
gekoppeld zijn blijken alle zeven transmembrane helices te bezitten en blijken vooral in 
deze transmembrane gebieden een opmerkelijke gelijkenis te vertonen wat betreft de 
aminozuurvolgorde. De overeenkomst is het grootst tussen subtypes van eenzelfde 
receptor. De ~ - H T ~ A  receptor vormt echter een uitzondering. Deze receptor heeft een 
grotere gelijkenis met dopaminerge en adrenerge receptoren dan met andere serotonerge 
subtypes. Het tweede deel behandelt dopamine, het dopaminerge systeem, de pathologie 
en geeft een overzicht van de tot nu toe gefsoleerde dopamine receptoren. Het derde 
deel behandelt hetzelfde voor de serotonine receptoren. 
Hoofdstuk 2 geeft een verhandeling over de structuur-activiteit relaties van 
dopamine en serotonine agonisten. Dit overzicht is beperkt tot de Zaminotetralines en 
daaraan gerelateerde verbindingen. Het receptormodel van McDermed, de basis voor de 
ontwikkeling van de meeste in deze dissertatie beschreven verbindingen, wordt 
besproken en vergeleken met andere in de literatuur verschenen receptoxmodellen. 
Hoofdstuk 3 beschrijft de synthese en de farmacologische effecten van mono- en 
di-gehydroxyleerde N-methyl-N-propargylaminotetralines. De verbindingen bezitten 
Samenvatting 14 1 
zowel dopamine agonistische als monoamine oxidase (MAO) inhiberende activiteiten. 
De MA0 remmende activiteiten domineren vooral in de monohydroxy-verbindingen, 
terwijl de catecholen de potentere dopamine agonisten zijn. De 5,6-dihydroxy isomeer 
heeft in verschillende modellen een activiteit vergelijkbaar met apomorfine, een 
dopatnine agonist die herontdekt is en tesamen met de perifeer werkzame dopamine 
antagonist domperidon opnieuw klinisch toegepast wordt in relatie met de ziekte van 
Parkinson. De verbinding is vooral effectief tijdens de "off' perioden. Een andere 
verbinding vooral toegepast bij "nieuwe" Parkinson patienten is de selectieve MAO-B 
remmer seligiline@. Daar bij Parkinson patienten niet alleen het dopamineniveau, maar 
ook de concentraties van andere neurotransmitters zods serotonine en noradrenaline 
verlaagd zijn, kan een verbindmg die tevens de concentraties van deze neurotransmitters 
verhoogt klinisch interessant zijn. Het 5,6-dihydroxy-2-(N-methyl-N-propargyl- 
amino)tetraline combineert zowel dopamine-agonistische en MAO-AIB-remmende 
activiteiten in kdn en hetzelfde molecuul en kan aan deze eigenschappen voldoen. 
In hoofdstuk 4 wordt dit principe van twee activiteiten in een molecuul toegepast 
op een derivaat van het 8-OH-DPAT, het prototype van een ~ - H T ~ A  agonist. Daarvoor 
is het 8-hydroxy-2-(N-methyI-N-propargylamino)te gesynthetiseerd. Met de 
microdialyse-techniek is het effect van deze verbinding in het striatale systeem getest. 
Na i.p. toediening veroorzaakte deze verbinding een verhoging in de afgifte van 
serotonine en in iets mindere mate van dopamine, terwijl de afgifte van de metabolieten 
DOPAC en 5-HIAA sterk b. Dit patroon is vergelijkbaar met dat van de MAO-A 
remmer clorgyline. Er heeft echter een verschuiving plaats gevonden ten gunste van de 
remming van de neurotransmitter serotonine. De verbinding geeft het serotonine 
syndroom en is dus nog steeds een ~ - H T ~ A  agonist. Ook de affi tei t  voor de ~ - H T ~ A  
bindingsplaatsen is hoog (10 nM). De verbinding kan evenals clorgyline van nut zijn in 
studies naar de bruikbaarheid van MAO-remmers tijdens depressies. 
Hoofdstuk 5 beschrijft de 8-staps synthese en de farmacologische evaluatie van 
de tricyclische 4-prowl-hexahydronaftoxazines (PHNO). Deze moleculen bevatten het 
dopamine deel in een stme conformatie. Het 9-OH-PHNO blijkt ken van de potentste 
dopamine D2 agonisten te zijn die ooit gemaakt is. De verbinding is bovendien selectief 
en heeft bijna geen affiniteit voor serotonerge en adrenerge receptoren. 
De resolutie van het 9-OH-PHNO is beschreven in hoofdstuk 6. De resolutie is 
uitgevoerd op het secundaire amine en met het phencyphos en het chlocyphos als 
splitsingsreagentia. Een kristallisatie was voldoende om optisch zuivere producten te 
verkrijgen. Na testen van de beide enantiomeren in het microdialyse-model, bleek de 
(+)-enantiomeer voomamelijk de D2 activiteit te bevatten. Het (+)-PHNO heeft de 
klinische fase bereikt, maar door toxische eigenschappen is het onderzoek in deze fase 
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stopgezet. 
Hoofdstuk 7 beschrijft in de hexahydronaftoxazines de isostere vervanging van 
een methyleengroep door een zuustofatoom. Deze verbindingen, de 
tetrahydrobenzopyranoxazines, vertonen echter een onverwacht lage activiteit. Deze 
lage activiteit was niet verwacht, daar de verbindingen qua structuur namelijk een 
bijzonder grote overeenkomst met het PHNO bezitten. Het meten van de 
verdelingscoefficienten toonde bovendien aan dat de verbindingen voldoende lipofiel 
zijn om de bloed-hersen-barribre te passeren. De gevonden waarden voor de ionisatie- 
constante (pKa) van het stikstofatoom geven aan dat er een correlatie bestaat tussen de 
dopaminerge activiteit en deze pKa waarden. De conclusie van dit onderzoek is dat 
dopaminerge agonisten in de geprotoneerde vorm de receptor activeren. Door de 
verlaagde intrinsieke activiteit is de verbinding echter selectief geworden voor de meer 
gevoelige dopamine-autoreceptoren. Verlaging van de pKa-waarde is dus een bruikbare 
methode om de selectiviteit voor DA autoreceptoren te vergroten. 
In hoofdstuk 8 wordt een bruikbare 1-staps reactie beschreven voor de 
chlorering van 5-hydroxy-2-aminotetralines. Met behulp van het chloreringsreagens 
2,2,3,4,5,6-hexachlorocyclohexadienone wordt selectief de para-isomeer verkregen. 
Hoewel de regioselectiviteit van de reactie erg hoog is, wordt een niet verwachte 
isomeer verkregen. Verder worden de mogelijkheden en de beperkingen van deze 
reactie besproken. Tenslotte wordt er een voorstel gedaan voor het reactiemechanisme 
van deze chlorerings reactie. Het mechanisme is speculatief. Volgens het voorgestelde 
mechanisme verloopt de chlorering via de vonning van een lage steady-state 
concentratie van moleculair chloor. Verder lijkt het polaire oplosmiddel een grote 
invloed te hebben op deze selectiviteit. 
Hoofdstuk 9 beschrijft de farmacologische evaluatie van de para gechloreerde 
dialkylaminotetralines. De invloed van deze kleine veranderingen in de structuur op de 
biologische activiteit is aanzienlijk. De gechloreerde verbindingen vertonen een 
afgenomen affiniteit voor de Dl  en de D2 receptor vergeleken met de niet gechloreerde 
verbindingen. In het hersen-microdialyse-model is vooral het resultaat verkregen met 
het 8-C1-N-0434 opmerkelijk. In dit presynaptische model gedraagt het N-0434 zich als 
een potente D2 agonist terwijl het 8-C1-N-0434 een DA antagonist blijkt te zijn. De 
scheiding van de verbindingen in hun optische antipoden is ook in dit hoofdstuk 
beschreven. Deze enantiomeren zijn getest in het microdialyse-model. We hebben 
gevonden dat het (R)-(+)-8C1-N-0434 de antagonistische activiteit bezit, terwijl de (S)- 
(-)-enantiomeer een lagere agonistische activiteit heeft dan het N-0434 op de DA 
autoreceptoren. Verder zijn de gechloreerde verbindingen en hun enantiomeren getest 
op hun affhiteit voor de ~ - H T ~ A  receptor. De gechloreerde verbindingen blijken alle 
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een aanzienlijke affiniteit te bezitten voor de ~ - H T ~ A  receptor. Het is opmerkelijk dat 
de aftkiteit van de enantiomeren niet sigmficant verschillend is. Alleen in het geval 8- 
C1-N-0434 is er een verschil in affmiteit waargenomen. De verschuiving van affiteit 
voor de dopamine-receptor naar &miteit voor de ~ - H T ~ A  receptor is verrassend. 
Blijkbaar is de aanwezigheid, in de 8-positie van de Zaminotetralines, van een groep 
die een waterstofbrug kan aangaan met bijvoorbeeld een threonine-residu, voldoende 
om affi tei t  voor dit receptor subtype te verkrijgen. De conclusie van dit hoofdstuk is 
dan ook dat er een delicaat evenwicht blijkt te bestaan tussen de affi tei t  van de 
verbindingen voor dopamine D2 receptor en de S-HT~A receptor. Op zich is dit niet 
verwonderlijk gezien de grote gelijkenis tussen deze receptoren wat betreft de structuur 
en de aminozuwvolgorde. 
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